Covid19_DB

Covid19_DB is a curated listing of interventional clinical trials in Covid-19/2019-nCoV produced by the Anticancer Fund. Source data comes from ClinicalTrials.gov, the European Clinical Trials Register and WHO ICTRP. Given our expertise in the area of drug repurposing and the urgent needs presented by the Covid-19 pandemic we feel it is socially responsible that we apply our skills to this very different disease area. The intention is to provide researchers, clinicians and regulators with an easily filtered database of interventional trials. As the number and range of trials has continued to increase we have decided to list only those interventional trials which are testing a drug or blood/cell-based product - this includes drug repurposing, shelved compounds, new molecular entities and immunological interventions using plasma, vaccines, stem cells and so on. By making its database open-access and keeping it up-to-date, the Anticancer Fund wants to help to encourage collaboration and alert researchers to the wide range of hypotheses being explored around the world. Ideally this should result in more collaborations between clinicians investigating similar compounds.

As of 20/08/20 this database is no longer being actively updated. The initial urgency of the situation has passed and there are now a number of other actively managed databases providing similar data and functionality to this one. Good examples are the The COVID19 Clinical Trials Explorer and the Living mapping of Covid-19 studies project. Our preprint, outlining our rationale, methodology and results, has been updated to reflect the data as of the end date of our project.

Cite as: Pan Pantziarka, Liese Vandeborne, Lydie Meheus, Gauthier Bouche (2020).Covid19db -- An online database of trials of medicinal products to prevent or treat COVID-19, with a specific focus on drug repurposing. medrxiv /10.1101/2020.05.27.20114371v1

A machine-readable version of this database can be downloaded here: Covid19db.txt. The ReDO database of repurposing candidates in oncology can be accessed here: ReDO_DB.

Summaries of results for Prevention and Therapeutic trials are listed here.

Important note for patients:

This list includes trials of drugs that, based on their scientific properties, warrant further scientific investigation. In many cases the existing scientific evidence for their effects on coronavirus infection is very limited. Further scientific and clinical research is needed before any statements regarding their therapeutic activity can be made. This list is not intended to be used as a source for possible treatment options for patients.

If you need help exploring further treatment options for your situation, please contact your local medical services at the first instance.

Summary results as of last build on: 20/08/2020 09:45
Total number of interventional trials - including
non-drug trials (i.e. devices, psychological etc)		2354
Total number of interventional drug-based trials,
including vaccines and cell/blood-based products,
included in dataset		1618
Total number of investigational drugs included in trials550
Total number of trials including repurposed drugs1036
Percentage of trials including repurposed drugs64.0%
Total number of prevention trials (vaccines + drugs)202
Percentage of trials for prevention12.5%
Number of countries74
Number of patients included in planned enrollment1064556

Most popular drug candidates - trial counts

Hydroxychloroquine212Favipiravir44Ivermectin39
Azithromycin64Chloroquine43Methylprednisolone31
Tocilizumab58Lopinavir/ritonavir43Ascorbic acid30





Click in header cell to sort table by that column. Hover over header cell for additional text.

Database build date: 20/08/2020 09:45

Number of trials in database: 1618 (Filter not active)

ID Title Country Ctl MA Type Drugs Primary Endpoint Population
NCT04319900 Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia China Y Y Drug Repurposing Favipiravir, Chloroquine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04252885 The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection China Y Y Drug Repurposing Lopinavir/ritonavir, Umifenovir Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04282902 A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection China Y N Drug Repurposing Pirfenidone Efficacy - Oxygen parameters Mild/Moderate Cases
NCT04329520 EPICOS Clinical Trial for the Prevention of Infection in Healthcare Personnel Spain Y Y Drug Repurposing Emtricitabine/tenofovir, Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
2020-00122
4-33		 Randomized controlled trial of hydroxychloroquine versus placebo for the treatment of adult patients with acute coronavirus disease 2019 – COVID-19 Germany Y N Drug Repurposing Hydroxychloroquine Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04343677 Military COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis Study United States Y Y Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
2020-00159
1-15		 Reducing hospital admission of elderly in SARS-CoV-2 pandemic via the induction of trained immunity by bacillus Calmette-Guérin vaccination, a randomized controlled trial. (COVID-19) Netherlands Y N Drug Repurposing BCG Vaccine Efficacy - Other efficacy Other
NCT04380948 A Pilot Study Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Enhance Immune Clearance of SARS-CoV-2 (COVID-19) United States Y N Shelved drug or NME NT-17 Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04308668 Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2 United States Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) General population
NCT04276987 A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia China N N Cell/Blood based ND:Stem cells Safety Severe Cases
2020-00168
4-89		 CATALYST - A randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection. United Kingdom Y N Drug Repurposing Gemtuzumab ozogamicin Efficacy - Oxygen parameters Severe Cases
NCT04380961 A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 United States Y N Shelved drug or NME Sirukumab Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04328467 Pre-exposure Prophylaxis for SARS-Coronavirus-2 United States Y Y Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) General population
NCT04333251 Study Testing Convalescent Plasma vs Best Supportive Care United States Y N Cell/Blood based ND:Convalescent plasma Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04380701 A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults Germany N N Vaccine ND:BNT162 vaccine Safety General population
NCT04367168 Colchicine Twice Daily During 10 Days as an Option for the Treatment of Symptoms Induced by Inflammation in Patients With Mild and Severe Coronavirus Disease Mexico Y N Drug Repurposing Colchicine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04316377 Norwegian Coronavirus Disease 2019 Study Norway Y N Drug Repurposing Hydroxychloroquine Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04276688 Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment Hong Kong Y Y Drug Repurposing Ribavirin, Interferon beta-1b Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT03852537 Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia United States Y N Drug Repurposing Methylprednisolone Other Severe Cases
NCT04404192 PH94B in the Treatment of Adjustment Disorder With Anxiety United States N N Shelved drug or NME PH94B Efficacy - Other efficacy General population
NCT04356833 Nebulised Rt-PA for ARDS Due to COVID-19 United Kingdom N N Shelved drug or NME Nebulised Rt-PA Efficacy - Oxygen parameters Severe Cases
NCT04392219 COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers United States Y N Shelved drug or NME EIDD-2801 Safety General population
NCT04373707 Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19 France Y N Drug Repurposing Enoxaparin Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT03648372 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19) United States N N Shelved drug or NME TAK-981 Safety Other
NCT04393415 Using PRP and Cord Blood in Treatment of Covid -19 Egypt Y N Cell/Blood based ND:Stem cells Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04264533 Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia China Y N Drug Repurposing Ascorbic acid Efficacy - Oxygen parameters Severe Cases
NCT04323527 Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2 Brazil Y N Drug Repurposing Chloroquine Efficacy - Mortality Severe Cases
NCT04322682 Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) Canada Y N Drug Repurposing Colchicine Efficacy - Other efficacy Mild/Moderate Cases
NCT04385836 Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Saudi Arabia Y N Cell/Blood based ND:Alpha-1 antitrypsin Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04275245 Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia China N N Shelved drug or NME Meplazumab Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04341727 Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection United States Y Y Drug Repurposing Hydroxychloroquine, Azithromycin, Chloroquine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04342728 Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation United States Y N Drug Repurposing, Other Ascorbic Acid, ND:Zinc Gluconate Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04404634 Convalescent Plasma To Limit COVID-19 Associated Complications United States Y N Cell/Blood based ND:Convalescent plasma Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04347031 A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19 Russian Federation Y Y Drug Repurposing Mefloquine, Hydroxychloroquine, Azithromycin, Tocilizumab Efficacy - Other efficacy Mild/Moderate Cases
NCT04390152 Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19 Colombia Y N Cell/Blood based ND:Stem cells Efficacy - Mortality Severe Cases
NCT04348370 BCG Vaccine for Health Care Workers as Defense Against COVID 19 United States Y N Vaccine BCG Vaccine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04343729 Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19 Brazil Y N Drug Repurposing Methylprednisolone Efficacy - Mortality Severe Cases
NCT04323800 Convalescent Plasma to Stem Coronavirus (CSSC-001) United States Y N Cell/Blood based ND:Convalescent plasma Efficacy - WHO scale Exposed individuals (family members, HCP)
NCT04376034 Convalescent Plasma Collection and Treatment in Pediatrics and Adults United States Y N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04269525 Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia China N N Cell/Blood based ND:Stem cells Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04261907 Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection China Y N Drug Repurposing, Shelved drug or NME ASC09/ritonavir Efficacy - Oxygen parameters Mild/Moderate Cases
NCT04340557 Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection United States Y N Drug Repurposing Losartan Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04323592 Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome Italy N N Drug Repurposing Methylprednisolone Efficacy - Other efficacy Severe Cases
NCT04345289 Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia Denmark Y Y Drug Repurposing, Cell/Blood based ND:Convalescent plasma, Sarilumab, Baricitinib, Hydroxychloroquine Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04353037 PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine United States Y Y Drug Repurposing Hydroxychloroquine Efficacy - Other efficacy Exposed individuals (family members, HCP), Mild/Moderate Cases, Severe Cases
NCT04280224 NK Cells Treatment for COVID-19 China Y N Cell/Blood based ND:T-cells Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04388826 COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111 United States Y N Shelved drug or NME Veru-111 Efficacy - Other efficacy Severe Cases
NCT04326426 ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection United States Y N Shelved drug or NME Tradipitant Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04299152 Stem Cell Educator Therapy Treat the Viral Inflammation in COVID-19 China Y N Cell/Blood based ND:Stem cells Efficacy - Other efficacy Severe Cases
NCT04306393 Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19 United States Y N Drug Repurposing Nitric oxide Efficacy - Oxygen parameters Severe Cases
NCT04361552 Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection) United States Y N Drug Repurposing Tocilizumab Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04322773 Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure Denmark Y Y Drug Repurposing Tocilizumab, Sarilumab Efficacy - Oxygen parameters Severe Cases
NCT04336410 Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers United States N N Vaccine INO-4800 Safety General population
NCT04338802 Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19 China Y N Drug Repurposing Nintedanib Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04379518 Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients United States N N Drug Repurposing Rintatolimod, Interferon alpha-2b Safety Mild/Moderate Cases
NCT04374539 Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial Spain Y N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04325893 Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease France Y N Drug Repurposing Hydroxychloroquine Efficacy - Mortality Mild/Moderate Cases
NCT04322123 Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19) Brazil Y Y Drug Repurposing Hydroxychloroquine, Azithromycin Efficacy - WHO scale Mild/Moderate Cases
NCT04326036 Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection United States N N Cell/Blood based ND:Stem cells Safety Other
NCT04337918 Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection Canada N N Shelved drug or NME Nitric Oxide Releasing Solution Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP), Mild/Moderate Cases
NCT04346693 An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19 Russian Federation Y N Shelved drug or NME Dalargin Efficacy - Viral load Severe Cases
NCT04322396 Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19 Denmark Y Y Drug Repurposing Azithromycin, Hydroxychloroquine Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04415073 A Phase 2 Study to Evaluate Axatilimab for Hospitalized Patients With Respiratory Involvement Secondary to COVID-19 United States Y N Shelved drug or NME Axatilimab Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04355637 Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia Spain Y N Drug Repurposing Budesonide Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04315480 Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis Italy N N Drug Repurposing Tocilizumab Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04399798 Baricitinib for coRona Virus pnEumonia (COVID-19): a THerapeutic Trial Italy N N Drug Repurposing Baricitinib Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04363437 COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19 United States Y N Drug Repurposing Colchicine Efficacy - Oxygen parameters Severe Cases
NCT04406246 Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide Mexico N N Drug Repurposing Nitazoxanide Efficacy - Other efficacy Exposed individuals (family members, HCP)
NCT04341493 Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19 Mexico Y N Drug Repurposing Nitazoxanide Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04322344 Escin in Patients With Covid-19 Infection Italy Y Y Drug Repurposing Escin Efficacy - Mortality Mild/Moderate Cases
NCT04344041 COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial) France Y N Drug Repurposing Vitamin D3 Efficacy - Mortality Mild/Moderate Cases, Severe Cases, Other
RBR-3cbs3w Randomized, pragmatic, open study evaluating Hydroxychloroquine for prevention of Hospitalization and Respiratory Complications in outpatients with confirmed or presumptive diagnosis of Infection by (COVID-19) Brazil Y Y Drug Repurposing Hydroxychloroquine Efficacy - Other efficacy Mild/Moderate Cases
NCT04384458 COVID-19 Prophylaxis With Hydroxychloroquine Associated With Zinc For High-Risk Healthcare Workers Brazil N N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04403685 Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers Brazil Y N Drug Repurposing Tocilizumab Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04382768 Inhaled Ibuprofen to Treat COVID-19 Argentina N N Drug Repurposing Ibuprofen Efficacy - WHO scale Mild/Moderate Cases
NCT04414631 Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19 Switzerland Y N Drug Repurposing Conestat alfa Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04368377 Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19 Italy N N Drug Repurposing Tirofiban, Clopidogrel, Aspirin, Fondaparinux Efficacy - Oxygen parameters Severe Cases
NCT04365309 Protective Effect of Aspirin on COVID-19 Patients China Y N Drug Repurposing Aspririn Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04312243 NO Prevention of COVID-19 for Healthcare Providers United States Y N Drug Repurposing Nitric oxide Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04406064 Viral Specific T-cells for Treatment of COVID-19 United States N N Cell/Blood based ND:T-cells Other Mild/Moderate Cases, Severe Cases
NCT04357613 IMATINIB IN COVID-19 DISEASE IN AGED PATIENTS. France Y N Drug Repurposing Imatinib Safety Other
NCT04363840 The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations United States Y N Drug Repurposing Aspirin, Vitamin D3 Efficacy - Other efficacy Mild/Moderate Cases
NCT04371523 Hydroxychloroquine to Prevent COVID-19 Disease Amongst Healthcare Workers Canada Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04333654 Hydroxychloroquine in Outpatient Adults With COVID-19 United States Y N Drug Repurposing Hydroxychloroquine Efficacy - Viral load Mild/Moderate Cases
NCT04345887 Spironolactone in Covid-19 Induced ARDS Turkey Y N Drug Repurposing Spironolactone Efficacy - Oxygen parameters Severe Cases
NCT04358783 Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia Mexico Y N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Mild/Moderate Cases
2020-00143
5-27		 Home treatment of elderly patients with symptomatic SARS-CoV-2 infection (COVID-19) : a multiarm, multi-stage (MAMS) randomized trial to assess the efficacy and safety of several experimental treatments to reduce the risk of hospitalization or death (COVERAGE trial) France Y Y Drug Repurposing Favipiravir, Hydroxychloroquine, Imatinib, Telmisartan Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04334629 LIBERATE Trial in COVID-19 United Kingdom Y N Drug Repurposing Ibuprofen Efficacy - Oxygen parameters Severe Cases
NCT04324463 Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial Canada Y N Drug Repurposing Cholchicine, Interferon-beta, Aspirin, Rivaroxaban Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04377672 Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19) United States N N Cell/Blood based ND:Convalescent plasma Safety Other
2020-00244
8-21		 A RANDOMIZED CLINICAL TRIAL FOR ENHANCED TRAINED IMMUNE RESPONSES THROUGH BACILLUS CALMETTE-GUÉRIN VACCINATION TO PREVENT INFECTIONS ?? COVID-19: THE ACTIVATE II TRIAL Greece Y N Vaccine ND:BCG vaccine Efficacy - Infection rate (prevention) General population
NCT04418531 Convalescent Antibodies Infusion in COVID 19 Patients Italy N N Cell/Blood based ND:Immunoglobulin Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04321278 Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II) Brazil Y Y Drug Repurposing Azithromycin, Hydroxychloroquine Efficacy - WHO scale Severe Cases
NCT04345614 A Study of CM4620-Injectable Emulsion (IE) in Patients With Severe COVID-19 Pneumonia United States Y N Shelved drug or NME CM4620 Efficacy - WHO scale Severe Cases
NCT04321174 COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir Canada Y N Drug Repurposing Lopinavir/ritonavir Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04376684 Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease United States Y N Shelved drug or NME Otilimab Efficacy - Mortality Severe Cases
NCT04393792 SINUS WASH Pilot Study in Adults Testing Positive for COVID-19 United Kingdom Y N Shelved drug or NME Povidone-Iodine Efficacy - Viral load Mild/Moderate Cases
NCT02735707 Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia Netherlands Y Y Drug Repurposing Hydrocortisone, Ceftriaxone, Moxifloxacin, Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Oseltamivir, Lopinavir/ritonavir, Hydroxychloroquine, Interferon-beta1a, Anakinra, Tocilizumab, Sarilumab Efficacy - Mortality Severe Cases
NCT04293887 Efficacy and Safety of IFN-a2ß in the Treatment of Novel Coronavirus Patients China Y N Drug Repurposing Interferon alpha-1b Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04327401 COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III Brazil Y N Drug Repurposing Dexamethasone Efficacy - Other efficacy Severe Cases
NCT04342156 Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19 Singapore Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04389385 COVID-19 Specific T Cell Derived Exosomes (CSTC-Exo) Turkey N N Cell/Blood based COVID-19 Specific T Cell derived exosomes Safety Mild/Moderate Cases
NCT04387409 Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic Germany Y N Vaccine ND:VPM1002 vaccine Efficacy - Other efficacy Exposed individuals (family members, HCP)
NCT04371601 Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019 China Y N Cell/Blood based ND:Stem cells Efficacy - Oxygen parameters Severe Cases
NCT04260594 Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus China Y N Drug Repurposing Umifenovir Efficacy - Viral load Mild/Moderate Cases
NCT04336748 HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers Austria Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04383717 Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic Trial Egypt Y N Drug Repurposing Levamisole, Isoprinosine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04429555 Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS United States Y N Drug Repurposing Ibudilast Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04346589 Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients Italy N N Cell/Blood based ND:Convalescent plasma Efficacy - Other efficacy Severe Cases
NCT04340349 Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals Mexico Y N Drug Repurposing Hydroxychloroquine, Bromhexine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04439006 Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization United States Y N Drug Repurposing Ibrutinib Efficacy - Oxygen parameters Other
NCT03042143 Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (COVID-19) United Kingdom Y N Cell/Blood based ND:Stem cells Efficacy - Oxygen parameters Severe Cases
NCT04359810 Plasma Therapy of COVID-19 in Critically Ill Patients United States Y N Cell/Blood based ND:Convalescent plasma Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04252274 Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19 China Y N Drug Repurposing Darunavir, Cobicistat Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04385186 Inactivated Convalescent Plasma as a Therapeutic Alternative in Patients CoViD-19 Colombia Y N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04305457 Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19 United States Y N Drug Repurposing Nitric oxide Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04320277 Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. Italy N N Drug Repurposing Baricitinib Efficacy - Other efficacy Mild/Moderate Cases
NCT04397497 Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19) Italy Y N Shelved drug or NME Mavrilimumab Efficacy - Oxygen parameters Severe Cases
NCT04369794 COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement Brazil Y N Vaccine BCG vaccine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04353128 Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers. Spain Y N Drug Repurposing Melatonin Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04365985 Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19 United States Y Y Drug Repurposing Naltrexone, Ketamine Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04352946 HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial United States Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04331613 Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS China N N Cell/Blood based ND:Stem cells Safety Severe Cases
NCT04334967 Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care United States Y N Drug Repurposing Hydroxychloroquine Efficacy - Other efficacy Mild/Moderate Cases
NCT04363827 Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19) Italy Y Y Drug Repurposing Hydroxychloroquine Efficacy - Other efficacy Mild/Moderate Cases
NCT04340050 COVID-19 Convalescent Plasma United States N N Cell/Blood based ND:Convalescent plasma Other Severe Cases
NCT04363450 Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP) United States Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04335786 Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease Netherlands Y N Drug Repurposing Valsartan Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04446429 Anti-Androgen Treatment for COVID-19 Brazil Y N Drug Repurposing Dutasteride Efficacy - Clinical improvement (except WHO scale) Other
NCT04321616 The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients Norway Y Y Drug Repurposing, Shelved drug or NME Hydroxychloroquine, Remdesivir Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04263402 The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia China N Y Drug Repurposing Methylprednisolone Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04392778 Clinical Use of Stem Cells for the Treatment of Covid-19 Turkey Y N Cell/Blood based ND:Stem cells Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases, Other
NCT04407182 Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19 Ecuador Y N Shelved drug or NME Viusid/Asbrip Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04424134 BromhexIne And Spironolactone For Coron?VirUs Infection Requiring HospiTalization Russian Federation Y N Drug Repurposing Bromhexine, Spironolactone Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04332666 Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial Belgium Y N Drug Repurposing Angiotensin 1-7 Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04332991 Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease United States Y N Drug Repurposing Hydroxychloroquine Efficacy - WHO scale Mild/Moderate Cases
NCT04397692 Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial) United States Y N Drug Repurposing Nitric oxide Efficacy - Other efficacy Mild/Moderate Cases
NCT04433078 RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM United States Y N Drug Repurposing Doxycycline Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04382547 Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells Belarus N N Cell/Blood based ND:Stem cells Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04374565 Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia United States N N Cell/Blood based ND:Convalescent plasma Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04298060 DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19) China Y Y Shelved drug or NME DAS181 Efficacy - Oxygen parameters Severe Cases
NCT04343651 Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19 United States Y N Shelved drug or NME Leronlimab Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04384380 Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19 Taiwan Y N Drug Repurposing Hydroxychloroquine Efficacy - Viral load Mild/Moderate Cases
NCT04381364 Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19) Sweden Y N Drug Repurposing Ciclesonide Efficacy - Oxygen parameters Mild/Moderate Cases
NCT04321096 The Impact of Camostat Mesilate on COVID-19 Infection Denmark Y N Drug Repurposing Camostat Efficacy - WHO scale Mild/Moderate Cases
NCT04355962 Sevoflurane in COVID-19 ARDS (SevCov) Switzerland Y N Drug Repurposing Sevoflurane Efficacy - Mortality Severe Cases
NCT04333368 Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS France Y N Cell/Blood based ND:Stem cells Efficacy - Oxygen parameters Severe Cases
NCT04416399 STerOids in COVID-19 Study United Kingdom Y N Drug Repurposing Budesonide Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04381377 Efficacy and Safety of Polyoxidonium® in Hospitalized Patients With Coronavirus Disease COVID-19 Russian Federation Y N Drug Repurposing Azoximer bromide Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04349228 Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals Tunisia Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04347239 Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19) United States Y N Shelved drug or NME Leronlimab Efficacy - Mortality Severe Cases
NCT04403100 Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: "The Hope Coalition - 1" Brazil Y N Drug Repurposing Hydroxychloroquine, Lopinavir/Ritonavir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04403243 COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial Russian Federation Y Y Drug Repurposing Colchicine, Ruxolitinib, Secukinumab Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04442230 NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19) United States Y N Vaccine ND:NasoVAX Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04361474 Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity France Y N Drug Repurposing Budesonide Other Mild/Moderate Cases
NCT04402957 LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) Canada Y N Shelved drug or NME LSALT peptide Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04448756 M5049 Study in Participants With Coronavirus Disease 2019 (COVID-19) Pneumonia United States Y N Shelved drug or NME M5049 Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04349098 Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection United States Y N Drug Repurposing Selinexor Efficacy - WHO scale Severe Cases
NCT04332380 Convalescent Plasma for Patients With COVID-19: A Pilot Study Colombia N N Cell/Blood based ND:Convalescent plasma Efficacy - Viral load Mild/Moderate Cases
NCT04355676 Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19 United States N N Drug Repurposing Selinexor Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04395716 A Study of ResCure™ to Treat COVID-19 Infection United States N N Shelved drug or NME ResCure Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04419623 A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer United States Y N Shelved drug or NME TL-895 Other Other
NCT04437823 Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients Pakistan Y N Cell/Blood based ND:Stem cells Safety Mild/Moderate Cases, Severe Cases
NCT04402060 A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 United States Y N Shelved drug or NME APL-9 Safety Mild/Moderate Cases
NCT04371978 Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Israel Y N Drug Repurposing Linagliptin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Other
NCT04332835 Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study Colombia Y N Cell/Blood based ND:Convalescent plasma Efficacy - Viral load Mild/Moderate Cases
NCT04312009 Losartan for Patients With COVID-19 Requiring Hospitalization United States Y N Drug Repurposing Losartan Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases, Mild/Moderate Cases, Mild/Moderate Cases
NCT04315948 Trial of Treatments for COVID-19 in Hospitalized Adults France Y Y Drug Repurposing, Shelved drug or NME Remdesivir, Lopinavir/ritonavir, Interferon beta-1a, Hydroxychloroquine Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04311177 Losartan for Patients With COVID-19 Not Requiring Hospitalization United States Y N Drug Repurposing Losartan Efficacy - Other efficacy Mild/Moderate Cases
NCT04402970 Dornase Alfa for ARDS in Patients With SARS-CoV-2 United States N N Drug Repurposing Dornase alfa Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04335084 A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection United States N N Drug Repurposing Hydroxychloroquine, Ascorbic acid, Vitamin D3, Zinc Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04264858 Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients China Y N Cell/Blood based ND:Immunoglobulin Efficacy - WHO scale Severe Cases
NCT04322565 Colchicine Counteracting Inflammation in COVID-19 Pneumonia Italy Y N Drug Repurposing Colchicine Efficacy - WHO scale Mild/Moderate Cases
NCT04341935 Effects of DPP4 Inhibition on COVID-19 United States Y N Drug Repurposing Linagliptin Other Mild/Moderate Cases
NCT04367077 MultiStem Administration for COVID-19 Induced ARDS (MACoVIA) United States Y N Cell/Blood based ND:Stem cells Efficacy - Other efficacy Severe Cases
NCT04365101 Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 (CYNK-001-COVID-19) United States Y N Cell/Blood based ND:CYNK-001 Safety Mild/Moderate Cases
NCT04370834 Tocilizumab for Patients With Cancer and COVID-19 Disease United States N N Drug Repurposing Tocilizumab Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases, Other
NCT04275414 Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia China N N Drug Repurposing Bevacizumab Efficacy - Oxygen parameters Severe Cases
NCT04421664 Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada) United States Y N Drug Repurposing Hydroxychloroquine Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04360096 Inhaled Aviptadil for the Treatment of Moderate and Severe COVID-19 United States Y N Shelved drug or NME, Other Aviptadil, ND:Device Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04342169 University of Utah COVID-19 Hydrochloroquine Trial United States Y N Drug Repurposing Hydroxychloroquine Efficacy - Viral load Mild/Moderate Cases
NCT04320238 Experimental Trial of rhIFNa Nasal Drops to Prevent 2019-nCOV in Medical Staff China N Y Drug Repurposing Interferon alpha, Thymosin alpha Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04327349 Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial Iran N N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04400019 Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM) Spain Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Other
NCT04433546 PB1046, a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS). United States Y N Shelved drug or NME PB1046 Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04357730 Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection United States Y N Drug Repurposing Alteplase Efficacy - Oxygen parameters Severe Cases
NCT04407208 Convalescent Plasma Therapy in Patients With COVID-19 Indonesia N N Cell/Blood based ND:Convalescent plasma Safety Mild/Moderate Cases, Severe Cases
NCT04394377 Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial Brazil Y N Drug Repurposing Rivaroxaban Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04453371 Impact of Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (COVID-19) Russian Federation Y N Drug Repurposing Alteplase Efficacy - Oxygen parameters Severe Cases
NCT04342650 Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection Brazil Y N Drug Repurposing Chloroquine Efficacy - Other efficacy Mild/Moderate Cases
NCT04452565 NA-83, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection United States Y Y Drug Repurposing Atazanavir, Dexamethasone Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04324606 A Study of a Candidate COVID-19 Vaccine (COV001) United Kingdom N Y Vaccine ND:Vaccine, Paracetamol Safety General population
NCT04373733 Early Intervention in COVID-19: Favipiravir Verses Standard Care United Kingdom Y Y Drug Repurposing Favipiravir Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04459702 A Study of Combination Therapies to Treat COVID-19 Infection United States Y Y Drug Repurposing Lopinavir, Ritonavir, Azithromycin, Hydroxychloroquine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04400838 Investigating a Vaccine Against COVID-19 United Kingdom Y Y Vaccine ND:Vaccine Efficacy - Infection rate (prevention) General population
NCT04344379 Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus France Y Y Drug Repurposing Hydroxychloroquine, Azithromycin Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04268537 Immunoregulatory Therapy for 2019-nCoV China Y Y Drug Repurposing Anti-PD-1(NOS), Thymosin alpha Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04355052 Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in SARS CoV 2 Virus Israel Y Y Drug Repurposing Azithromycin, Camostat Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04330495 Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection Spain Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Other
NCT04447781 Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19 Korea, Republic of Y Y Vaccine, Other ND:Vaccine INO-4800, ND:Device Safety Other
NCT04447235 Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection Brazil Y N Drug Repurposing Losartan, Ivermectin Efficacy - Clinical improvement (except WHO scale) Other
NCT04405739 The Safety of EIDD-2801 and Its Effect on Viral Shedding of SARS-CoV-2 (The END-COVID Study) United States Y Y Shelved drug or NME EIDD-2801 Efficacy - Viral load Mild/Moderate Cases
NCT04447404 DUR-928 in Subjects With SARS-CoV-2 With Acute Liver or Kidney Injury United States Y N Shelved drug or NME DUR-928 Efficacy - Mortality Other
NCT04261426 The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia China N N Cell/Blood based ND:Immunoglobulin Efficacy - WHO scale Severe Cases
NCT04386070 Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 United Kingdom Y Y Drug Repurposing Lopinavir-Ritonavir, Hydroxychloroquine Efficacy - Infection rate (prevention) Other
NCT04255017 A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia China Y Y Drug Repurposing Oseltamivir, Lopinavir/ritonavir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04254874 A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia China Y N Drug Repurposing Peg-Interferon alpha-2b Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04408235 High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy Italy Y N Drug Repurposing Enoxaparin Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04261270 A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia China N Y Drug Repurposing, Shelved drug or NME Ritonavir, Oseltamivir, ASC09F Efficacy - Oxygen parameters Mild/Moderate Cases
NCT04350281 Double Therapy With IFN-beta 1b and Hydroxychloroquine Hong Kong Y N Drug Repurposing Interferon beta-1b Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04332042 TOFAcitinib in SARS-CoV2 Pneumonia Italy Y N Drug Repurposing Tofacitinib Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04371393 MSCs in COVID-19 ARDS United States Y N Cell/Blood based ND:Remestemcel-L® Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04467918 CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate Symptoms Brazil Y N Drug Repurposing Cannabidiol Efficacy - Viral load Mild/Moderate Cases
NCT04357366 suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE) Greece N N Drug Repurposing Anakinra, Trimethoprim/sulfamethoxazole Efficacy - Other efficacy Mild/Moderate Cases
NCT04346667 Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds Pakistan Y Y Drug Repurposing Hydroxychloroquine, Chloroquine Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04355429 Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID) France Y N Drug Repurposing Captopril Efficacy - Other efficacy Severe Cases
NCT04420247 Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19 Brazil Y N Drug Repurposing Hydroxychloroquine, Chloroquine Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04356482 CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19 Mexico N N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04311697 Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure United States Y N Shelved drug or NME Aviptadil Efficacy - Mortality Severe Cases
NCT04419025 Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease United States Y N Drug Repurposing N-acetylcysteine Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04407507 Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms Mexico Y N Drug Repurposing Ivermectin Efficacy - Other efficacy Mild/Moderate Cases
NCT04479644 Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-198 China Y N Shelved drug or NME BRII-198 Safety Other
NCT04479631 Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196 China Y N Shelved drug or NME BRII-196 Safety Other
NCT04357782 Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation United States N N Drug Repurposing Ascorbic acid Safety Mild/Moderate Cases, Severe Cases
NCT04400799 Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19 Switzerland Y N Drug Repurposing Enoxaparin Efficacy - Other efficacy Mild/Moderate Cases
NCT04344184 Early Infusion of Vitamin C for Treatment of Novel COVID-19 Acute Lung Injury (EVICT-CORONA-ALI) United States Y N Drug Repurposing Ascorbic acid Efficacy - Other efficacy Severe Cases
NCT04378244 CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19 United States N N Shelved drug or NME DeltaRex-G Safety Mild/Moderate Cases, Severe Cases
NCT04333914 Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection France Y Y Drug Repurposing, Shelved drug or NME GNS651, Nivolumab, Tocilizumab, Avdoralimab, Monalizumab Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04398147 Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada Canada Y Y Vaccine ND:Ad5-nCoV Safety General population
NCT04327206 BCG Vaccination to Protect Healthcare Workers Against COVID-19 Australia Y N Drug Repurposing, Vaccine BCG Vaccine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04466098 Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19) United States Y N Cell/Blood based ND:MSC Safety Severe Cases
NCT04334512 A Study of Quintuple Therapy to Treat COVID-19 Infection United States N N Drug Repurposing Hydroxychloroquine, Azithromycin, Ascorbic acid, Vitamin D3, Zinc Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04328961 Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP) United States Y Y Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) General population
NCT04425733 MK-5475 in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009) United States Y N Shelved drug or NME MK-5475 Safety Mild/Moderate Cases, Severe Cases
NCT04461379 Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers Mexico Y N Vaccine ND:Vaccine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04392232 A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection United States N N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Severe Cases
NCT04339712 Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction Greece N N Drug Repurposing Anakinra, Tocilizumab Efficacy - Other efficacy Severe Cases
NCT04455958 Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year United States Y N Drug Repurposing Lopinavir/Ritonavir Efficacy - Clinical improvement (except WHO scale) Other
NCT04389580 Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus Egypt Y Y Drug Repurposing Isotretinoin, Tamoxifen Efficacy - Other efficacy Severe Cases
NCT04357106 COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma Mexico N N Cell/Blood based ND:Convalescent plasma Efficacy - Other efficacy Severe Cases
NCT04334148 Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine United States Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04333589 Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive China Y N Drug Repurposing Favipiravir Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04310228 Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019 China Y Y Drug Repurposing Favipiravir, Tocilizumab Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04302519 Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells China N N Cell/Blood based ND:Stem cells Efficacy - Other efficacy Severe Cases
NCT04370015 Hydroxychloroquine Chemoprophylaxis for COVID-19 Infection in High-risk Healthcare Workers. Pakistan Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04435015 The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications United States Y N Drug Repurposing Camostat Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04391179 Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19 United States Y N Drug Repurposing Dipyridamole Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04273763 Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) China Y N Drug Repurposing Bromhexine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04393727 Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19 Italy Y N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04490486 Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19 United States Y N Cell/Blood based ND:Stem cells Safety Mild/Moderate Cases, Severe Cases
NCT04354155 COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial United States N N Drug Repurposing Enoxaparin Safety Mild/Moderate Cases, Severe Cases
NCT04435587 Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection Thailand Y N Drug Repurposing Ivermectin Safety Mild/Moderate Cases
NCT04341441 Will Hydroxychloroquine Impede or Prevent COVID-19 United States Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04390217 LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia United States Y N Shelved drug or NME LB1148 Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04445246 Inhaled Iloprost for Suspected COVID-19 Respiratory Failure Qatar N N Drug Repurposing Iloprost Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04348461 BAttLe Against COVID-19 Using MesenchYmal Stromal Cells Spain Y N Cell/Blood based ND:MSC Efficacy - Mortality Severe Cases
NCT04365517 The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients Italy Y N Drug Repurposing Sitagliptin Efficacy - WHO scale Mild/Moderate Cases, Other
NCT04364009 Anakinra for COVID-19 Respiratory Symptoms France Y N Drug Repurposing Anakinra Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04357860 Clinical Trial of Sarilumab in Adults With COVID-19 Spain Y N Drug Repurposing Sarilumab Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04355728 Use of UC-MSCs for COVID-19 Patients United States Y N Cell/Blood based ND:Stem cells Safety Mild/Moderate Cases, Severe Cases
NCT04471519 Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers India Y Y Vaccine BBV152 Vaccine Safety General population
NCT04429529 Safety of TY027, a Treatment for COVID-19, in Humans Singapore Y N Shelved drug or NME TY027 Safety Other
NCT04350086 Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection France N N Drug Repurposing Dexmedetomidine Efficacy - Other efficacy Severe Cases
NCT04361253 Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy United States Y N Cell/Blood based Convalescent plasma Efficacy - WHO scale Severe Cases
NCT04452097 Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS United States N Y Cell/Blood based ND:Stem cells Safety Severe Cases
NCT04380935 Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome Indonesia Y N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Severe Cases
NCT04389450 Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19 Israel Y Y Shelved drug or NME PLX-PAD Efficacy - Other efficacy Severe Cases
NCT04439071 A Study to Evaluate Efficacy and Safety of PTC299 in Hospitalized Participants With Coronavirus (COVID-19) United States Y N Shelved drug or NME PTC299 Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04483973 SPI-1005 Treatment in Severe COVID-19 Patients United States Y N Drug Repurposing Ebselen Safety Severe Cases
NCT04409834 Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial United States Y Y Drug Repurposing Heparin, Enoxaparin, Clopidogrel Efficacy - Mortality Severe Cases
NCT04303507 Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting United Kingdom Y N Drug Repurposing Chloroquine, Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04484025 SPI-1005 Treatment in Moderate COVID-19 Patients United States Y N Drug Repurposing Ebselen Safety Mild/Moderate Cases
NCT04347226 Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19 United States Y N Shelved drug or NME BMS-986253 Efficacy - WHO scale Other
NCT04379492 A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19 United States Y N Drug Repurposing Hydroxychloroquine Efficacy - WHO scale Mild/Moderate Cases
NCT04369469 Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia United States Y N Drug Repurposing Ravulizumab Efficacy - Mortality Severe Cases
NCT04482712 Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS United States Y N Drug Repurposing Sirolimus Efficacy - Mortality Mild/Moderate Cases, Other
NCT04328480 The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients. Argentina Y N Drug Repurposing Colchicine Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04435522 Maraviroc in Patients With Moderate and Severe COVID-19 United States N N Drug Repurposing Maraviroc Safety Mild/Moderate Cases, Severe Cases
NCT04357028 Measles Vaccine in HCW Egypt Y N Drug Repurposing, Vaccine Measles Vaccine Efficacy - Infection rate (prevention) General population
NCT04441918 Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects China Y N Shelved drug or NME JS016 Safety Other
NCT04429854 Donated Antibodies Working Against nCoV Belgium Y N Cell/Blood based ND:Convalescent plasma Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04483375 Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects China Y N Shelved drug or NME SCTA01 Safety Other
NCT04356508 COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1 Hong Kong N N Drug Repurposing Nivolumab Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04458948 Open Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients United States N N Drug Repurposing Hydroxychloroquine, Azithromycin Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04359290 Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS Germany N N Drug Repurposing Ruxolitinib Efficacy - Mortality Severe Cases
NCT04400929 Using GM-CSF as a Host Directed Therapeutic Against COVID-19 Singapore Y Y Drug Repurposing Sargramostim Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04346329 Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19 Colombia Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04335032 EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2) United Kingdom N N Shelved drug or NME Eicosapentaenoic acid Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04401150 Lessening Organ Dysfunction With VITamin C - COVID-19 Canada Y N Drug Repurposing Ascorbic acid Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04365153 Canakinumab in Covid-19 Cardiac Injury (The Three C Study) United States Y Y Drug Repurposing Canakinumab Efficacy - WHO scale Severe Cases
NCT04382846 Novel Regimens in COVID-19 Treatment Egypt Y Y Drug Repurposing Nitazoxanide, Ivermectin, Chloroquine, Azithromycin Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04401527 Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite United States Y N Shelved drug or NME Sodium Nitrite Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04421508 A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19 United States Y N Drug Repurposing Nitric Oxide Efficacy - Other efficacy Mild/Moderate Cases
NCT04453852 Monovalent Recombinant COVID19 Vaccine Australia Y N Vaccine Covax-19 vaccine Safety General population
NCT04405999 Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease Russian Federation Y N Drug Repurposing Bromhexine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04365439 Convalescent Plasma for COVID-19 Italy N N Cell/Blood based ND:Convalescent plasma Efficacy - Viral load Severe Cases
NCT04472585 Efficacy of Subcutaneous Ivermectin With or Without Zinc and Nigella Sativa in COVID-19 Patients Pakistan Y Y Drug Repurposing, Other Ivermectin, Zinc, ND:Nigella sativa Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04324021 Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection. Italy Y Y Drug Repurposing Emapalumab, Anakinra Efficacy - Clinical improvement (except WHO scale) Severe Cases
ChiCTR2000
029939		 A Single-blind, Randomized, Controlled Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19) China Y N Drug Repurposing Chloroquine Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
ChiCTR2000
029935		 A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19) China N N Drug Repurposing Chloroquine Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
ChiCTR2000
029853		 A randomized, open-label, controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19) China Y N Shelved drug or NME Azvudine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
ChiCTR2000
029850		 Effecacy and safty of convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19): a prospective cohort study China N N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Severe Cases
ChiCTR2000
029806		 Optimization of treatment and diagnosis plan for critically ill patients China Y Y Drug Repurposing, Shelved drug or NME Thymosin, Camrelizumab Efficacy - Clinical improvement (except WHO scale) Severe Cases
ChiCTR2000
029776		 A randomized, open-label, blank-controlled, multicenter trial for Polyinosinic-Polycytidylic Acid Injection in the treatment of novel coronavirus pneumonia (COVID-19) China N N Shelved drug or NME Polyinosinic-Polycytidylic Acid Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
ChiCTR2000
029765		 A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Tocilizumab Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
ChiCTR2000
029742		 A randomized, parallel controlled trial for the efficacy and safety of Sodium Aescinate Injection in the treatment of patients with pneumonia (COVID-19) China Y N Shelved drug or NME Sodium Aescinate Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
ChiCTR2000
029741		 Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study China Y N Drug Repurposing Chloroquine Efficacy - Other efficacy Mild/Moderate Cases
ChiCTR2000
029656		 A randomized, open-label study to evaluate the efficacy and safety of low-dose corticosteroids in hospitalized patients with novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Methylprednisolone Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
ChiCTR2000
029636		 Efficacy and safety of aerosol inhalation of vMIP in the treatment of novel coronavirus pneumonia (COVID-19): a single arm clinical trial China N N Shelved drug or NME vMIP Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
029609		 A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in hospitalized patients with novel coronavirus pneumonia (COVID-19) China Y Y Drug Repurposing Chloroquine, Lopinavir/ritonavir Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
029606		 Clinical Study for Human Menstrual Blood-derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19) China Y N Cell/Blood based ND:MSC Efficacy - Mortality Mild/Moderate Cases, Severe Cases
ChiCTR2000
029600		 Clinical study on safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) China Y Y Drug Repurposing Favipiravir, Lopinavir/ritonavir, Interferon alpha Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
029569		 Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled trial China Y N Shelved drug or NME ND:MSC Efficacy - Other efficacy Severe Cases
ChiCTR2000
029559		 Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Hydroxychloroquine Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
029544		 A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy China Y Y Drug Repurposing Baloxavir Marboxil, Favipiravir Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
029542		 A prospective cohort study for the efficacy and safety of chloroquine in hospitalized patients with novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Chloroquine Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
029541		 A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Darunavir, Cobicistat, Lopinavir/ritonavir, Thymosin alpha Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
029539		 A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-Ritonavir in patients with mild novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Lopinavir/ritonavir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
ChiCTR2000
029468		 The early use of lopinavir/litonavir (LPV/r) and emtritabine (FTC)/ Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of the novel coronavirus pneumonia (COVID-19): a real-world study China Y N Drug Repurposing Lopinavir/ritonavir, Emtricitabine, Tenofovir alafenamide Efficacy - Mortality Mild/Moderate Cases, Severe Cases
ChiCTR2000
030179		 Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID-19) China Y N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Mild/Moderate Cases, Severe Cases
ChiCTR2000
030173		 Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration China Y N Cell/Blood based ND:MSC Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
ChiCTR2000
030170		 Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19) China N N Shelved drug or NME Jaktinib Safety Severe Cases
ChiCTR2000
030167		 Clinical Trial for Recombinant Human Interleukin-2 in the Treatment of Novel Coronavirus Pneumonia (COVID-19) China Y N Drug Repurposing recombinant human IL-2 Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
ChiCTR2000
030138		 Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19) China Y N Shelved drug or NME ND:MSC Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
ChiCTR2000
030116		 Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19) China N N Cell/Blood based ND:MSC Efficacy - Clinical improvement (except WHO scale) Severe Cases
ChiCTR2000
030113		 Clinical study for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir China Y N Drug Repurposing Favipiravir Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
ChiCTR2000
030089		 A randomized, open-label, controlled trial for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Adalimumab Efficacy - Clinical improvement (except WHO scale) Severe Cases
ChiCTR2000
030088		 Umbilical cord Wharton's Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19) China Y N Cell/Blood based ND:MSC Efficacy - Viral load Severe Cases
ChiCTR2000
030058		 A multicenter, randomized, double-blind, controlled clinical trial for leflunomide in the treatment of novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Leflunomide Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
030054		 An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of mild and common novel coronavirus pneumonia (COVID-19) China Y Y Drug Repurposing Chloroquine, Hydroxychloroquine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
ChiCTR2000
030046		 A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19) China N N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
ChiCTR2000
030041		 A single-arm, single-center clinical trial for Azivudine tablets in the treatment of adult novel coronavirus pneumonia (COVID-19) China N N Shelved drug or NME Azvudine Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
030039		 Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19) China Y N Cell/Blood based ND:Convalescent plasma Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
030029		 A multi-center study on the efficacy and safety of suramin sodium in adult patients with novel coronavirus pneumonia (COVID-19) China N N Drug Repurposing Suramin Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
ChiCTR2000
030020		 The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19) China N N Shelved drug or NME ND:MSC Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
030016		 Efficacy evaluation of inhalation of mycobacterium vaccae injection for treating Novel coronavirus pneumonia (COVID-19) and the mechanism study of prevention and treatment of respiratory virus infection China Y N Shelved drug or NME ND:Mycobacterium Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
030010		 A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19) China Y N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
ChiCTR2000
030007		 Multicenter randomized controlled trial for rhG-CSF in the treatment of novel coronavirus pneumonia (COVID-19) China Y N Cell/Blood based G-CSF Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
ChiCTR2000
030002		 Clinical study for novel NLRP Inflammasome inhibitor (Tranilast) in the treatment of novel coronavirus (COVID-19) China Y N Drug Repurposing Tranilast Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
ChiCTR2000
030001		 The efficacy and safety of Triazavirin for 2019 novel coronary pneumonia (COVID-19): a multicenter, randomized, double blinded, placebo-controlled trial China Y N Shelved drug or NME Triazavirin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
ChiCTR2000
029996		 A randomized, open-label, controlled trial for the efficacy and safety of Farpiravir Tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Favipiravir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
ChiCTR2000
029990		 Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus (COVID-19) China Y N Shelved drug or NME ND:MSC Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
ChiCTR2000
029989		 A randomized controlled Trial for therapeutic efficacy of Recombinant Human Interferon alpha 1b Eye Drops in the treatment of elderly with novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Interferon alpha 1b Efficacy - Oxygen parameters Other
ChiCTR2000
029988		 Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19) China Y N Drug Repurposing Chloroquine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
ChiCTR2000
029851		 A multicenter, randomized controlled trial for the efficacy and safety of Alpha lipoic acid (iv) in the treatment of patients of severe novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Alpha Lipoic Acid Efficacy - Other efficacy Severe Cases
ChiCTR2000
029803		 A prospective, randomized, open-label, controlled clinical study to evaluate the preventive effect of hydroxychloroquine on close contacts after exposure to the Novel Coronavirus Pneumonia (COVID-19) China Y N Drug Repurposing Hydroxychloroquine, Umifenovir Efficacy - Infection rate (prevention) Mild/Moderate Cases, Severe Cases
ChiCTR2000
029740		 Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus pneumonia (COVID-19) patients(randomized open-label control clinical trial) China Y N Drug Repurposing Hydroxychloroquine Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
ChiCTR2000
030442		 The therapeutic efficacy of combination of Tocilizumab, IVIG and CRRT in sever patients with novel coronavirus pneumonia (COVID-19) China N N Drug Repurposing, Cell/Blood based Tocilizumab Efficacy - Other efficacy Severe Cases
ChiCTR2000
030424		 A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19) China N N Shelved drug or NME Azvudine Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
030398		 A randomized, double-blind, placebo-controlled trial for evaluation of the efficacy and safety of bismuth potassium citrate capsules in the treatment of patients with novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Bismuth potassium citrate Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
030265		 Clinical research program of continuous renal replacement therapy with adsorption filter for the treatment of the novel coronavirus pneumonia (COVID-19) China Y N Cell/Blood based ND:Continuous renal replacement therapy Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
ChiCTR2000
030261		 A study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of novel coronavirus pneumonia (COVID-19) China Y N Cell/Blood based ND:MSC Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
ChiCTR2000
030196		 A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19) China N N Drug Repurposing Tocilizumab Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
ChiCTR2000
030013		 A study on the efficacy and safety of recombinant human interferon alpha 1b spray in preventing novel coronavirus (COVID-19) infection in highly exposed medical staffs. China Y N Drug Repurposing Interferon alpha 1b Safety Exposed individuals (family members, HCP)
ChiCTR2000
029975		 Single arm study for exploration of chloroquine phosphate aerosol inhalation in the treatment of novel coronavirus pneumonia (COVID-19) China N N Drug Repurposing Chloroquine Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
029899		 Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Mild and Commen Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-label, Parallel, Controlled Trial China Y N Drug Repurposing Hydroxychloroquine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
ChiCTR2000
029898		 Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Severe Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-Label, Parallel, Controlled Trial China Y N Drug Repurposing Hydroxychloroquine Efficacy - Clinical improvement (except WHO scale) Severe Cases
ChiCTR2000
029762		 A randomized, open-label, controlled trial for the efficacy and safety of hydroxychloroquine sulfate tablets in the treatment of patients with severe novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Hydroxychloroquine Efficacy - Viral load Severe Cases
ChiCTR2000
029761		 Multicenter, randomized, open clinical study of Hydroxychloroquine Sulfate tablets in the treatment of common patients with novel coronavirus pneumonia (COVID-19) China Y Y Drug Repurposing Hydroxychloroquine Efficacy - Viral load Mild/Moderate Cases
ChiCTR2000
029760		 A randomized controlled study to evaluate the efficacy and safety of hydroxychloroquine for mild and moderate COVID-19 Infectious diseases China Y N Drug Repurposing Hydroxychloroquine, Lopinavir/ritonavir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
ChiCTR2000
029387		 Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia China Y Y Drug Repurposing Ribavirin, Interferon alpha, Lopinavir/ritonavir Efficacy - Viral load Mild/Moderate Cases
ChiCTR2000
029386		 A study on treatment strategies of novel coronavirus pnueumonia patients China Y N Drug Repurposing Methylprednisolone Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
ChiCTR2000
030627		 Study on the application of convalescent plasma therapy in severe COVID-19 China Y N Cell/Blood based ND:Convalescent plasma Efficacy - Viral load Severe Cases
ChiCTR2000
030535		 Multi-Center Clinical Study on the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19) by Ebastine China Y N Drug Repurposing Ebastine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
ChiCTR2000
030487		 A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19) China N N Shelved drug or NME Azvudine Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
030484		 HUMSCs and Exosomes Treating Patients with Lung Injury following Novel Coronavirus Pneumonia (COVID-19) China Y N Cell/Blood based ND:MSC Efficacy - Oxygen parameters Other
ChiCTR2000
030472		 An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing, Shelved drug or NME Danoprevir, Ritonavir Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
ChiCTR2000
030471		 Efficacy and safety of lipoic acid injection in reducing the risk of progression in common patients with novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Alpha Lipoic Acid Efficacy - Other efficacy Mild/Moderate Cases
ChiCTR2000
030312		 A single-center, open-label and single arm trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient China N N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
ChiCTR2000
029757		 Convalescent plasma for the treatment of severe and critical novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial China Y N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Severe Cases
ChiCTR2000
029580		 Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in combination with mesenchymal stem cells: a prospective, single blind, randomized controlled clinical trial China Y N Drug Repurposing, Cell/Blood based Ruxolitinib, ND:MSC Safety Mild/Moderate Cases, Severe Cases
ChiCTR2000
029308		 A randomized, controlled open-label trial to evaluate the efficacy and safety of lopinavir-ritonavir in hospitalized patients with 2019-nCoV infection China Y N Drug Repurposing Lopinavir/ritonavir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
ChiCTR2000
030892		 Efficacy and Safety of Pirfenidone in the Treatment of Severe Post-Novel Coronavirus Pneumonia (COVID-19)) Fibrosis:a prospective exploratory experimental medical study China Y N Drug Repurposing Pirfenidone Efficacy - Other efficacy Severe Cases
ChiCTR2000
030853		 Evaluation of the protective effect of dexmedetomidine on patients with severe new coronavirus pneumonia China N N Drug Repurposing Dexmedetomidine Efficacy - Other efficacy Severe Cases
ChiCTR2000
030841		 Treatment of Acute Severe COVID-19 With Immunoglobulin From Cured COVID-19 Patients China Y N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Severe Cases
ChiCTR2000
030835		 Clinical study on the efficacy of Mesenchymal stem cells (MSC) in the treatment of severe novel coronavirus pneumonia (COVID-19) China Y N Cell/Blood based ND:MSC Efficacy - Other efficacy Severe Cases
ChiCTR2000
030779		 A randomized, open-label, controlled trial for the efficacy and safety of Ulinastatin Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19) China Y N Shelved drug or NME Ulinastatin Efficacy - Oxygen parameters Severe Cases
ChiCTR2000
030718		 Clinical Study of Chloroquine Phosphate in the Treatment of 2019-nCoV Infection China Y N Drug Repurposing Chloroquine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
ChiCTR2000
030703		 A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Ixekizumab Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
ChiCTR2000
030702		 Convalescent plasma for the treatment of common COVID-19: a prospective randomized controlled trial China Y N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
ChiCTR2000
030701		 A randomized, parallel controlled open-label trial to evaluate the efficacy and safety of Prolongin (Enoxaparin Sodium Injection) in adult hospitalized patients with novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Enoxaparin Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
030700		 An evaluative clinical study: efficacy and safety of of Prolongin (Enoxaparin Sodium Injection) in treatment of hospitalized adult patients with common novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Enoxaparin Efficacy - Viral load Mild/Moderate Cases
ChiCTR2000
030580		 Tozumab combined with adamumab(Qletli) in the treatment of severe and critically ill patients with novel coronavirus pneumonia (COVID-19):A prospective, single-center, randomized, parallel controlled trial China Y N Drug Repurposing Adalimumab, Tocilizumab Efficacy - Other efficacy Severe Cases
ChiCTR2000
030509		 Clinical Study of NK Cells in the Treatment of Novel Coronavirus Pneumonia (COVID-19) China Y N Cell/Blood based ND:NK cells Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
030417		 Efficacy and safety of chloroquine phosphate inhalation combined with standard therapy in the treatment of novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Chloroquine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
ChiCTR2000
030381		 A randomized, open-label, controlled and single-center trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient China Y N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
ChiCTR2000
030329		 Clinical trial for umbilical cord blood CIK and NK cells in the treatment of mild and general patients infected with novel coronavirus pneumonia (COVID-19) China Y N Cell/Blood based ND:Umbilical cord NK/CIK cells Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
ChiCTR2000
030187		 Efficacy and safety of Lopinavir and Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Lopinavir/ritonavir Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
ChiCTR2000
030135		 A randomized controlled trial for high-dose Vitamin C in the treatment of severe and critical novel coronavirus pneumonia (COVID-19) patients China Y N Drug Repurposing Ascorbic acid Efficacy - Mortality Severe Cases
ChiCTR2000
030082		 Randomized controlled trial for the efficacy of dihydroartemisinine piperaquine in the treatment of mild/common novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Dihydroartemisinin/piperaquine Efficacy - Viral load Mild/Moderate Cases
ChiCTR2000
030031		 A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Chloroquine Efficacy - Viral load Mild/Moderate Cases
ChiCTR2000
029984		 Study on the effect of human placenta biological preparation on the defense of immune function against novel coronavirus pneumonia (COVID-19) China Y N Cell/Blood based ND:Human placenta extract Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
ChiCTR2000
029895		 Single arm study for the efficacy and safety of GD31 in patients with novel coronavirus pneumonia (COVID-19) China N N Shelved drug or NME GD31 Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
029837		 A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumon (COVID-19)ia China Y N Drug Repurposing Chloroquine Efficacy - Viral load Mild/Moderate Cases
ChiCTR2000
029826		 A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in serious/critically ill patients with novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Chloroquine Efficacy - Mortality Severe Cases
ChiCTR2000
029817		 Clinical Study of Cord Blood NK Cells Combined with Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19) China Y N Cell/Blood based ND:MSC, ND:NK cells Efficacy - Clinical improvement (except WHO scale) Severe Cases
ChiCTR2000
029812		 Clinical Study for Umbilical Cord Blood Mononuclear Cells in the Treatment of Acute Novel Coronavirus Pneumonia (NCP) China Y N Cell/Blood based ND:Cord blood MNC Efficacy - Clinical improvement (except WHO scale) Severe Cases
ChiCTR2000
031139		 Safety and Effectiveness of Human embryonic stem cell-derived M cells (CAStem) for Pulmonary Fibrosis Correlated with novel coronavirus pneumonia(COVID-19) China N N Cell/Blood based ND:MSC Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
ChiCTR2000
031138		 Prospective exploratory clinical research on the efficacy and safety of pirfenidone capsules in the treatment of severe novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Pirfenidone Efficacy - Other efficacy Severe Cases
ChiCTR2000
030987		 Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Chloroquine, Favipiravir Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
ChiCTR2000
030944		 An open, multi-center, control, exploratory clinical study of human NK cells and UC-MSCs transplantation for severe novel coronavirus pneumonia China Y N Cell/Blood based ND:NK cells, ND:MSC Efficacy - Other efficacy Severe Cases
ChiCTR2000
030939		 Preliminary evaluation of the safety and efficacy of oral LL-37 antiviral peptide (CAS001) in the treatment of novel coronavirus pneumonia China N N Shelved drug or NME CSA0001 Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
ChiCTR2000
030929		 A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia (COVID-19) China Y N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Severe Cases
ChiCTR2000
030922		 Prospective, open-label, controlled, multicenter cohort study of long-acting interferon plus ribavirin in patients with COVID-19 infection China Y N Drug Repurposing Interferon alpha 2a Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
030906		 A single-center, open and dose-escalation phase I clinical trial for recombinant novel coronavirus vaccine (adenoviral vector) in healthy adults aged between 18 and 60 years China Y N Vaccine Adenoviral vaccine Safety General population
ChiCTR2000
030539		 Study for the effect of 3% hydrogen peroxide gargle on the Intraoral novel coronavirus of the patients with novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Hydrogen peroxide Efficacy - Viral load Mild/Moderate Cases
ChiCTR2000
030254		 the Efficacy and Safety of Favipiravir for novel coronavirus–infected pneumonia: A multicenter, randomized, open, positive, parallel-controlled clinical study China Y N Drug Repurposing Favipiravir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
ChiCTR2000
030224		 Clinical study of mesenchymal stem cells in treating severe novel coronavirus pneumonia (COVID-19) China Y N Cell/Blood based ND:MSC Efficacy - Oxygen parameters Severe Cases
ChiCTR2000
029868		 Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19): a randomized controlled, open label, multicenter trial China Y N Drug Repurposing Hydroxychloroquine Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
029496		 A randomized, open label, parallel controlled trial for evaluating the efficacy of recombinant cytokine gene-derived protein injection on clearing novel coronavirus in patients with novel coronavirus pneumonia (COVID-19) China Y N Shelved drug or NME Novaferon Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
031204		 A multicenter, single-blind, randomized controlled clinical trial for chloroquine phosphate in the treatment of 2019 novel coronavirus-infected pneumonia China Y N Drug Repurposing Chloroquine Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
031196		 Clinical efficacy of novel coronavirus infection treated by combination of interferon regimen and Ritonavir Tablets China Y N Drug Repurposing Lopinavir/ritonavir, Interferon Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
030028		 Clinical comparative study of PD-1 mAb in the treatment of severe and critical patients with novel coronavirus disease (COVID-19) China Y N Drug Repurposing Anti-PD1 mab (unspecified) Efficacy - Other efficacy Severe Cases
ChiCTR2000
031630		 Clinical study for Celebrex in the treatment of novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Celecoxib Other Mild/Moderate Cases, Severe Cases
ChiCTR2000
031501		 The efficacy of convalescent plasma in patients with critical novel coronavirus pneumonia (COVID-19): a pragmatic, prospective cohort study China Y N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Severe Cases
ChiCTR2000
031494		 Clinical study for stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19) China Y N Cell/Blood based ND:MSC Efficacy - Other efficacy Severe Cases
ChiCTR2000
031454		 Clinical study for prevention and treatment of digestive tract lesions caused by novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Rabeprazole Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
031430		 Evaluation of the safety and efficacy for human umbilical cord mesenchymal stem cells in COVID-19 induced pulmonary fibrosis China Y N Cell/Blood based ND:MSC Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
ACTRN12620
000454976		 High-dose intravenous zinc (HDIVZn) as adjunctive therapy in COVID-19 positive critically ill patients: A pilot randomized controlled trial Australia Y N Drug Repurposing Zinc chloride Efficacy - Oxygen parameters Severe Cases
ChiCTR2000
031781		 A randomized, double-blinded, placebo-controlled phase II clinical trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector) in healthy adults aged above 18 years China Y N Vaccine Adenoviral vaccine Efficacy - Other efficacy General population
ChiCTR2000
031735		 Clinical study for natural killer (NK) cells from umbilical cord blood in the treatment of viral pneumonia include novel coronavirus pneumonia (COVID-19) China Y N Cell/Blood based ND:NK cells Safety Mild/Moderate Cases, Severe Cases
ChiCTR2000
030750		 A clinical study for effectiveness and safety evaluation for recombinant chimeric COVID-19 epitope DC vaccine in the treatment of novel coronavirus pneumonia China Y N Vaccine Chimeric COVID-19 DC vaccine Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
ChiCTR2000
030328		 Clinical application of inhaled acetylcysteine solution in the treatment of novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing N-acetylcysteine Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
ACTRN12620
000473965		 Reducing acute severe respiratory events in health care workers during the Covid-19 pandemic with OM85 Australia Y N Drug Repurposing OM-85 Efficacy - Other efficacy Exposed individuals (family members, HCP)
ACTRN12620
000478910		 Cord Blood Therapy to prevent progression of COVID-19 related pneumonia Australia Y N Cell/Blood based ND:Stem cells Safety Mild/Moderate Cases
ACTRN12620
000480987		 Stress-reduction Using Probiotics to Promote Ongoing Resilience Throughout COVID-19 for Healthcare Workers: A randomised placebo-controlled trial New Zealand Y N Drug Repurposing Lactobacillus rhamnosus HN001 Other Exposed individuals (family members, HCP)
ChiCTR2000
030300		 Umbilical cord mesenchymal stem cells for the treatment of patients at high risk of novel coronavirus pneumonia (COVID-19): a single-center, prospective, open clinical study China N N Cell/Blood based ND:MSC Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT202003
10046736N1		 Comparison of The Therapeutic Effect of Convalescent Plasma and Plasma-derived Immunoglobulin-enriched solution on COVID-19 Patients: A Clinical Trial Study Iran Y Y Cell/Blood based ND:Convalescent plasma Efficacy - Other efficacy Severe Cases
IRCT201002
28003449N30		 Evaluating efficacy and safety of hydroxychloroquine + lopinavir or atazanavir/ritonavir combination in patients with COVID-19 Iran N N Drug Repurposing Hydroxychloroquine, Atazanavir/ritonavir, Lopinavir/ritonavir Efficacy - Other efficacy Mild/Moderate Cases
IRCT201002
28003449N28		 Evaluating efficacy and safety of interferone ß-1a in the treatment COVID-19 infection Iran Y N Drug Repurposing Interferon beta-1a Efficacy - Other efficacy Mild/Moderate Cases
IRCT201002
28003449N27		 Evaluating efficacy and safety of interferone ß-1b (IFN ß-1b) in the treatment of COVID-19 Iran Y N Drug Repurposing Interferon beta-1b Efficacy - Other efficacy Mild/Moderate Cases
IRCT201512
27025726N12		 Evaluting the therapeutic and adverse effects of Interferon beta 1-a subcutaneous administration in patients with novel Coronavirus (COVID-19) Iran N N Drug Repurposing Interferon beta-1a Efficacy - Other efficacy Severe Cases
IRCT201701
17032004N3		 evaluation the effect of vitamin A on respiratory signs and hospitalization in patients with COVID-19 Iran Y N Drug Repurposing Vitamin A Efficacy - Other efficacy Mild/Moderate Cases
IRCT201002
28003449N29		 Evaluating efficacy and safety of sofosbuvir/ ledipasvir in treatment of COVID-19 Iran Y N Drug Repurposing Ledipasvir/sofosbuvir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
IRCT202003
17046797N1		 Effect of Camostate mesylate on clinical improvement and outcome of Coronavirus (COVID-19)-induced pneumonia Iran Y N Drug Repurposing Camostat Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT201606
25028622N1		 The effect of NOSCOVID on pulmonary & other clinical manifestations of COVID-19 patients Iran Y N Drug Repurposing Noscapine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT201208
26010664N6		 Effect of hydroxychloroquine on prevention of covid-19 virus infection among treatment staff in Arash hospital-A double-blind clinical trial Iran Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
IRCT201405
28017891N8		 Evaluation of the efficacy and safety of cord-derived mesenchymal stem cell transplantation in the treatment of COVID-19 Iran N N Cell/Blood based ND:Stem cells Efficacy - Mortality Severe Cases
IRCT202003
21046828N1		 The effect of genetical nanocomposit drug with cell imunity level on human coronavirus (COVID-19) Iran Y Y Shelved drug or NME NOS Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
IRCT201907
27044343N1		 The effect of febuxostat against lung injury induced by COVID-19 virus in infected patients: A clinical trial study Iran Y N Drug Repurposing Febuxostat Efficacy - Other efficacy Mild/Moderate Cases
IRCT201509
14024017N1		 the efficacy of Interferon beta 1 a (ReciGen) in treatment of patients with Covid-19 in Sina Hospital Emergency Department Iran Y N Drug Repurposing Interferon beta-1a Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
IRCT201409
11019125N6		 Study the effect of intravenous injection of dental pulp mesenchymal stem cells in treatment of patients with COVID-19 pneumonia Iran N N Cell/Blood based ND:Stem cells Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT201512
27025726N13		 Evaluation the Efficacy and Safety of Tocilizumab in Patients with Novel Coronavirus (COVID-19) Iran N N Drug Repurposing Tocilizumab, Hydroxychloroquine, Oseltamivir, Lopinavir/Ritonavir, Interferon beta-1a Efficacy - Other efficacy Severe Cases
IRCT201603
10026998N10		 Study of the metformin effect on the survival and recovery rate of COVID-19 patients Iran Y N Drug Repurposing Metformin Efficacy - Mortality Mild/Moderate Cases, Severe Cases
IRCT202003
24046850N5		 Study of the effect of Vitamin C on duration of hospital stay in patients with Covid-19 Iran Y N Drug Repurposing Ascorbic acid Efficacy - Other efficacy Severe Cases
IRCT202003
25046860N1		 Evaluation of Convalescent Plasma as a Potential Therapy for COVID-19 infected patients Iran N N Cell/Blood based ND:Convalescent plasma Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
IRCT202003
17046797N2		 Effect of Fingolimod for treatment of COVID-19-induced cytokine storm Iran Y N Drug Repurposing Fingolimod Efficacy - Clinical improvement (except WHO scale) Severe Cases
IRCT202003
25046860N2		 Mesenchymal stem cell utilization in reducing complications and enhancing pneumonia healing in patients infected with 2019-nCoV (phase I clinical trial) Iran N N Cell/Blood based ND:Stem cells Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT201909
17044805N2		 Effects of High-dose Vitamin C on Treatment, Clinical Symptoms and Laboratory Signs of Iranian COVID-19 Patients: A Double Blind Randomized Clinical Trial Iran Y N Drug Repurposing Ascorbic acid Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT201202
25009124N4		 Efficacy of different methods of administeration of combination regiemn including dexamethasone, IV-IG and Interferone beta for treatment of patients with severe COVID-19: a randomized controlled trial Iran Y Y Drug Repurposing Dexamethasone, Interferon beta, ND:Immunoglobulin Efficacy - Oxygen parameters Severe Cases
IRCT201808
02040678N4		 Evaluation of the effects of Losartan in patients with corona virus disease 2019 Iran Y N Drug Repurposing Losartan Efficacy - Mortality Mild/Moderate Cases, Severe Cases
IRCT201507
04023055N2		 To evaluate the effectiveness of hemoperfusion in patients with severe coronavirus disease 2019 (COVID-19) Iran N N Cell/Blood based ND:Procedure Efficacy - Clinical improvement (except WHO scale) Severe Cases
IRCT202003
19046819N1		 Impact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unit Iran Y N Drug Repurposing, Other Ascorbic acid, ND:Vitamin supplementation Efficacy - Other efficacy Severe Cases
JPRN-Japic
CTI-205238		 Multicenter, Adaptive, Randomized, Placebo-Controlled, Comparative Study to Evaluate the Efficacy and Safety of Favipiravir in Patients with COVID-19 Non-Severe Pneumonia Japan Y N Drug Repurposing Favipiravir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
ACTRN12620
000417987		 Multi-Site, Randomized, Open-Label, Parallel-Group, Placebo-Controlled Study to Assess the Chemoprophylactic Efficacy of Chloroquine Against SARS-CoV-2/COVID-19 in Healthcare Workers at High-Risk of Exposure Australia Y N Drug Repurposing Chloroquine Efficacy - Other efficacy Exposed individuals (family members, HCP)
ACTRN12620
000457943		 A Randomised, Double Blind, Placebo-Controlled Trial of the Efficacy of Hydroxychloroquine for the Community-Based Treatment of Adults With Diagnosed COVID-19 New Zealand Y N Drug Repurposing Hydroxychloroquine Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
ChiCTR2000
032400		 the efficacy and safety of high dose intravenous vitamin C in the treatment of novel coronavirus pneumonia (COVID-19): a prospective, randomize, controlled trial China Y N Drug Repurposing Ascorbic acid Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
ChiCTR2000
032314		 A randomized clinical trial for the efficacy and safety of Aliskiren and Nifedipine in novel coronavirus pneumonia (COVID-19) patients with hypertension China Y Y Drug Repurposing Aliskiren, Nifedipine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases, Other
ChiCTR2000
032242		 A multicenter, randomized, open, controlled trial for the efficacy and safety of oral kolimycin in the treatment of patients with new coronavirus pneumonia (CoVID-19) China Y N Drug Repurposing Colistin Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ACTRN12620
000517976		 A randomised controlled trial of Nebulised Heparin in critically ill mechanically ventilated patients with COVID-19 to assess the effect on the duration of mechanical ventilation. Australia Y N Drug Repurposing Heparin Efficacy - Clinical improvement (except WHO scale) Severe Cases
ChiCTR2000
032487		 Study for using sulfate in the prevention and control of novel coronavirus pneumonia (COVID-19) in high and low prevalence communities China Y N Drug Repurposing Hydroxychloroquine Other General population
ChiCTR2000
032459		 Evaluation of the safety and immunogenicity of inactivated novel coronavirus (2019-CoV) vaccine (Vero cells) in healthy population aged 3 years and above: a randomized, double-blind, placebo parallel-controlled phase I/II clinical trial China Y N Vaccine ND:Vaccine Safety General population
ChiCTR2000
032135		 Efficacy and Safety of ulinastatin in the Treatment of novel coronavirus pneumonia (COVID-19) China Y Y Shelved drug or NME Ulinastatin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
ChiCTR2000
031174		 Effectiveness and safety of hydroxychloroquine sulfate in the preventive treatment of novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Hydroxychloroquine Other General population
ChiCTR2000
032769		 A randomized,double blinded, parallel controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19) China Y N Shelved drug or NME Azvudine Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
032717		 Efficacy and safety of high-dose vitamin C combined with traditional Chinese medicine in the treatment of moderate and severe novel coronavirus pneumonia (COVID-19) China Y Y Drug Repurposing, TCM Ascorbic acid, ND:TCM Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
ChiCTR2000
032716		 High dose intravenous vitamin C might be used as an important rescue therapy for aggravation of severe and critical novel coronavirus pneumonia (COVID-19) patients China N N Drug Repurposing Ascorbic acid Efficacy - Other efficacy Severe Cases
ChiCTR2000
033003		 A safety and immune response study of novel coronavirus pneumonia (COVID-19) s-vax loaded autologous dendritic cells China N N Cell/Blood based ND:Vaccine Safety General population
ChiCTR2000
032915		 A randomized controlled trial for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the mild and common type novel coronavirus pneumonia (COVID-19) patients whose nCoV Nucleic acid did not turn negative after treated by hydroxychloroquine and Abidor China Y N Drug Repurposing Artemisinin-piperaquine Safety Mild/Moderate Cases
ChiCTR2000
030262		 Clinical study of novel coronavirus (SARS-Cov-2) infection treated with aerosol inhalation (IFN-? plus anti-inflammatory factor TFF2) China Y N Shelved drug or NME TFF2 Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
029638		 A Multicenter, Randomized, Controlled trial for Recombinant Super-Compound Interferon (rSIFN-co) in the Treatment of Novel Coronavirus (2019-nCoV) Pneumonia China Y N Shelved drug or NME rSIFN-co Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT202003
14046764N1		 The evaluation of pirfenidone effects on prevention and treatment of pulmonary fibrosis and acute respiratory distress syndrome caused by COVID-19 Iran Y N Drug Repurposing Pirfenidone Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
IRCT201503
03021315N17		 Evaluation of the safety and efficacy of tocilizumab (AryoGen ?Pharmed Co., Iran) in patients with severe COVID-19? Iran N N Drug Repurposing Tocilizumab Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT202003
12046749N1		 Evaluation the efficacy of Tumor Necrosis Factor alpha inhibitor in COVID-19 outcomes: a prospective clinical trial study. Iran N N Drug Repurposing Etanercept biosimilar Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT201907
27044343N2		 Atorvastatin effect in Clinical and Laboratory findings of patiens with COVID-19 admitted RAZI referral hospital in Mazandaran State: A Randomized Clinical Trial Iran Y N Drug Repurposing Atorvastatin Other Mild/Moderate Cases, Severe Cases
IRCT201711
22037571N2		 A single-arm multicenter clinical trial to evaluate the safety and efficacy of Remdesivir in COVID-19 patients with progressive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Iran N N Shelved drug or NME Remdesivir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT202003
24046850N2		 Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19 Patients with Severe Symptoms Iran Y N Drug Repurposing Daclatasvir/sofosbuvir Efficacy - Clinical improvement (except WHO scale) Severe Cases
IRCT201908
04044429N1		 Efficacy and safety evaluation of therapeutic regimen of lopinavir/ritonavir and interferon beta 1b in patients with COVID-19 Iran Y N Drug Repurposing Interferon beta-1b, Hydroxychloroquine, Lopinavir/ritonavir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT202002
04046369N1		 Evaluation of Methylprednisolone Administration as a Therapeutic Option in the 2019 Novel Coronavirus (COVID-19): A Non-Randomized Controlled Study Iran N N Drug Repurposing Methylprednisolone Efficacy - Oxygen parameters Severe Cases
IRCT201308
12014333N145		 Comparative assessment of the efficacy and safety of add ontreatment with “Sofosbuvir plus Velpatasvir†to “standard of care therapeutic regimen†in patients with COVID-19 Iran Y N Drug Repurposing Sofosbuvir/velpatasvir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT202003
25046859N1		 Evaluation of the efficacy of intravenous immunoglobulin (IVIg) in patients with severe COVID-19 (Before intubation phase) who have not responded to treatment with the standard three-drug protocol (hydroxychloroquine / chloroquine + lupinavir / ritonavir + ribavirin) Iran N N Cell/Blood based ND:Immunoglobulin Efficacy - Other efficacy Severe Cases
IRCT201612
04031229N3		 Study of the Efficacy of Teicoplanin on mortality rate of patients with COVID-19 Infection: A randomized clinical trial Iran Y N Drug Repurposing Teicoplanin Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
IRCT201309
17014693N10		 Evaluation the efficacy and safety of Hydroxychloroquine administration for COVID-19 post exposure prophylaxis Iran Y N Drug Repurposing Hydroxychloroquine Efficacy - Other efficacy Exposed individuals (family members, HCP)
IRCT201308
12014333N147		 Comparative assessment of the efficacy and safety of addon treatment with “Sofosbuvir-Daclatasvirâ€, “Lithiumâ€,and “Trifluoprazine†to “standard of care in three groups of patients with COVID-19 Iran Y Y Drug Repurposing Sofosbuvir-Daclatasvir, Lithium, Trifluoperazine, Trihexyphenidyl Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT201312
15015805N2		 Assessment of effect of levamisole on pneumonia caused by COVID-19 Iran Y N Drug Repurposing Levamisole Efficacy - Other efficacy Mild/Moderate Cases
IRCT202004
03046926N1		 The effect of adding SOVODAK (sofosbuvir+daclatasvir) to the treatment protocol of COVID-19 outpatients: A Clinical Trial Study Iran Y N Drug Repurposing Sofosbuvir/daclatasvir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT201512
28025732N53		 Evaluation of the therapeutic effects of Convalescent Plasma (CP) of recovered people from Covid-19 in improving clinical and laboratory symptoms of hospitalized patients Iran N N Cell/Blood based ND:Convalescent plasma Efficacy - Oxygen parameters Severe Cases
IRCT201303
06012728N8		 Prospective post-exposure hydroxycloroquine prophylaxis for Covid 19 (PROSCLOROCOV 19) Iran Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
IRCT201512
27025726N14		 Evaluation the efficacy and safety of Favipiravir made by Shahid Beheshti University of Medical Sciences in comparison with Lopinavir-ritonavir in COVID-19 patients Iran Y N Drug Repurposing Favipiravir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT202004
05046958N1		 Effect of Hydroxychloroquine on Novel Coronavirus Disease (COVID-19) prevention in cancer patients under treatment Iran Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Other
IRCT202003
18046812N2		 Safety and efficacy of “Hydroxychloroquine + Azithromycin + Naproxen + Prednisolone†and “Hydroxychloroquine + Azithromycin + Naproxen†regimens in comparison with “Hydroxychloroquine + kaletra†on the need for intensive care unit treatment in patients with COVID-19; a randomized, multicenter, parallel groups, open label study Iran Y N Drug Repurposing Prednisolone Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
IRCT202003
17046797N4		 Effect of Bromhexine Hydrochloride on clinical improvement and outcome of COVID-19-induced pneumonia Iran Y N Drug Repurposing Bromhexine Efficacy - Other efficacy Mild/Moderate Cases
IRCT202004
04046948N1		 Randomized, parallel-controlled and multi-center clinical study evaluating the efficacy and safety of convalescent plasma, in the treatment of patients with severe SARS-CoV-2 infection (COVID-19) Iran Y N Cell/Blood based ND:Convalescent plasma Efficacy - WHO scale Severe Cases
IRCT201805
20039738N2		 Comparison of the effectiveness of standard treatment with stand treatment plus Vitamin A in treatment in covid19 patients Iran Y N Drug Repurposing Vitamin A Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT200810
19001369N4		 Clinical trial of minocycline against COVID-19 Iran Y N Drug Repurposing Minocycline Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT202004
08046992N1		 Evaluation of the Effect of Trifluoperazin in Treatment of Patients with Confirmed 2019 Novel Coronavirus(COVID- 19): An Open-Label Randomized Clinical Trial Iran Y N Drug Repurposing Trifluoperazine Efficacy - WHO scale Severe Cases
IRCT202004
08046987N1		 Dose-Finding study of Ivermectin treatment on patients infected with Covid-19:A clinical trial Iran Y N Drug Repurposing Ivermectin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT202003
17046797N3		 To evaluate the effectiveness of intravenous immunoglobulin (IVIG) for the treatment of COVID-19-induced cytokine storm Iran Y N Cell/Blood based ND:Immunoglobulin Efficacy - Clinical improvement (except WHO scale) Severe Cases
IRCT202004
06046968N1		 The effect of IL-6 inhibitor (Tocilizumab) on the prognosis of covid-19 patients with acute respiratory failure Iran N N Drug Repurposing Tocilizumab Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT201508
08023559N20		 Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in hospitalized patients with COVID-19 Iran Y N Drug Repurposing Favipiravir Efficacy - Mortality Severe Cases
IRCT202004
10047009N1		 Evaluation of the role of naproxen as adjunctive therapy with standard therapies and its efficacy in the early improvement and reduced mortality rate of COVID-19 patients Iran Y N Drug Repurposing Naproxen Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT202004
09047007N1		 The effect of plasma administration of COVID-19 survivors in patients with acute respiratory distress syndrome due to COVID-19 Iran Y N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Mild/Moderate Cases, Other
IRCT202002
17046526N2		 Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection: A Phase 2-3 Clinical Trial Iran Y N Cell/Blood based ND:Stem cells Safety Mild/Moderate Cases, Severe Cases
IRCT202004
11047025N1		 Evaluation of effectiveness? of Intravenous vitamin c in Patients with COVID-19 Referred to Imam ?Khomeini Hospital: a clinical trial ? Iran Y N Drug Repurposing Ascorbic acid Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
IRCT200809
01001165N46		 Investigating the efficacy and safety of Umifenovir in controlling the symptoms of patients with COVID-19 Iran Y N Drug Repurposing Umifenovir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT202004
06046963N1		 Evaluation of the efficacy and safety of methylprednisolone pulse therapy in treatment of Covid-19 patients with ARDS Iran Y N Drug Repurposing Methylprednisolone Efficacy - Mortality Severe Cases
IRCT201901
22042450N4		 Prevention of COVID-19 disease after contact with an infected patient with coronavirus after taking hydroxychloroquine in the community Iran Y N Drug Repurposing Hydroxychloroquine Efficacy - Other efficacy Exposed individuals (family members, HCP)
IRCT202004
11047030N1		 Evaluation of adding melatonin to routine treatment on outcomes and quality of sleep in COVID-19 patients Iran N N Drug Repurposing Melatonin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT201907
17044241N2		 Cell therapy in patients with coronavirus19 using mesenchymal stem cells Iran N N Cell/Blood based ND:Stem cells Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT202004
06046968N2		 Efficacy of convalescent plasma transfusion of COVID-19 survivors on the treatment of respiratory failure of these patients Iran N N Cell/Blood based ND:Convalescent plasma Efficacy - Viral load Severe Cases
IRCT201702
07032444N3		 The efficacy and safety of Thalidomide in severe Covid19 pneumonia: Arandomized controlled clinical trial Iran Y N Drug Repurposing Thalidomide Efficacy - Clinical improvement (except WHO scale) Severe Cases
IRCT200810
19001369N5		 Clinical trial of lithium in improving the clinical and laboratory symptoms of patients with COVID-19 Iran Y N Drug Repurposing Lithium Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT202004
08046988N1		 Evaluation of the efficacy of melatonin tablets as auxiliary medication in accelerating the improvement of the COVID-19 symptoms and clinical findings: A double-blind randomized and placebo controlled trial Iran Y N Drug Repurposing Melatonin Efficacy - Viral load Mild/Moderate Cases, Severe Cases
IRCT202004
13047062N1		 Evaluating the efficacy of Atorvastatin in clinical improvement, prognosis and hospitalization course in patients with COVID-19 infection Iran Y N Drug Repurposing Atorvastatin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT202004
06046968N3		 effect of Interfron-beta1(zifron) on clinical improvement and prognosis of COVID-19 in Tabriz Imam-Reza hospital Iran Y N Drug Repurposing Interferon beta-1b Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
IRCT202004
13047063N1		 Placental Mesenchymal Stem cells for treatment of ARDS in Coronavirus infection, Phase 1 and 2 Clinical Trials Iran Y N Cell/Blood based ND:Stem cells Safety Mild/Moderate Cases, Severe Cases
IRCT202004
14047070N1		 Determining the effect of skin test purified protein derivative (PPD) on the recovery process of patients with COVID 19 in patients with this disease Iran Y N Cell/Blood based ND:Purified protein derivative Efficacy - Viral load Mild/Moderate Cases, Severe Cases
IRCT201702
10032478N3		 The efficacy of inhaled formoterol on symptom improvement in covid 19 patients Iran Y N Drug Repurposing Formoterol Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT202004
13047056N1		 Comparison between the efficacy of intravenous immunoglobulin and convalescent plasma in improving the condition of patients with COVID-19: A randomized clinical trial Iran Y N Cell/Blood based ND:Immunoglobulin, ND:Convalescent plasma Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
IRCT202004
18047116N1		 Effect of Intravenous immunoglobulin (IVIG) versus Kaletra (lopinavir and ritonavir) tablets in patients with acute respiratory infection (COVID-19): A clinical trial studies Iran N N Cell/Blood based ND:Immunoglobulin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT202004
15047092N1		 Safety and Effectiveness of azithromycin in Patients with COVID-19 Referred to zeiaeian Hospital : A clinical trial study Iran Y N Drug Repurposing Azithromycin Efficacy - Other efficacy Severe Cases
IRCT202004
17047113N1		 Evaluating the safety and efficacy of allogeneic NK cells on COVID-19 induced pneumonia, double blind, randomized clinical trial Iran Y Y Cell/Blood based ND:NK-cells Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT202004
19047128N1		 Assessment of the effect of Tranilast on the efficacy of antiviral drug regimens in the treatment of patients with severe COVID19 Iran Y N Drug Repurposing Tranilast Efficacy - Clinical improvement (except WHO scale) Severe Cases
IRCT202004
16047099N1		 Use of convalescent plasma in the treatment of patients with severe COVID-19 pneumonia Iran N N Cell/Blood based ND:Convalescent plasma Efficacy - Other efficacy Severe Cases
IRCT202004
18047122N1		 Evaluation of the protective effect of a combination drug including Apocynin, Niacin, and Tannin on prevention of cardiovascular and respiratory morbidities and mortality in COVID-19 infection: A Clinical Trial Iran Y N Drug Repurposing Niacin-Tannin, Apocynin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
IRCT202004
18047121N2		 Investigation the adipose and placenta-derived mesenchymal stem cells effect on the respiratory distress syndrome in patients with COVID-19: a pilot study Iran N N Cell/Blood based ND:Stem cells Efficacy - Infection rate (prevention) Mild/Moderate Cases
IRCT202003
29046892N1		 Evaluation of Trifluoperazine Effectiveness in Treatment Process, Survival rate and Cure rate of COVID-19 Patients Iran Y N Drug Repurposing Trifluoperazine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT201512
22025660N2		 The prophylactic effect of Hydroxychloroquine on Novel Corona virus (COVID-19) in health care providers Iran Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
IRCT202004
20047147N1		 Evaluation the efficacy and safety of Sitagliptin administration in patients with COVID-19 Iran Y N Drug Repurposing Sitagliptin Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
IRCT202004
21047155N1		 Therapeutic Effect of Tenofovir and hydroxychloroquine combination therapy compared to chloroquine alone in patients with COVID-19 Iran Y N Drug Repurposing Tenofovir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT202004
22047168N1		 Comparison of the Effectiveness of Tenofovir antiviral drug beside (Kaletra and Chloroquine) with routine drug regime (Kaletra and Chloroquine) in COVID-19 patients Iran Y N Drug Repurposing Tenofovir Efficacy - Mortality Mild/Moderate Cases, Severe Cases
IRCT202004
08046990N2		 Evaluation of colchicine tablet efficacy as an adjuvant treatment for patients with mild to moderate COVID-19 in Qaem Hospital, Mashhad: A triple-blind randomized placebo controlled clinical trial Iran Y N Drug Repurposing Colchicine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
IRCT201801
14038350N3		 Investigating the effect of Deferiprone on the improvement of symptoms of Coronavirus 2019 (COVID 19) Iran Y N Drug Repurposing Deferiprone Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT201202
15009014N353		 Effect of plasma of patients recovered from covid-19 versus control group on treatment of covid-19: a randomized clinical trial Iran Y N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT201403
05016852N4		 Comparison of three methods of treatment in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with and without coronavirus positive test (Kovid-19) Iran Y N Drug Repurposing Ascorbic acid, Vitamin D3 Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT201804
25039414N2		 The effect of zinc on the treatment and clinical course of patients with SARS-cov2 (COVID-19) Iran Y N Drug Repurposing Zinc Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT202004
27047215N1		 Efficacy and safety of oral indomethacin for treatment of covid 19 induced pneumonia Iran Y N Drug Repurposing Indomethacin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT200809
01001165N50		 Investigating the efficacy and safety of Azithromycin inhaled spray in controlling the symptoms of patients with COVID-19 Iran Y N Drug Repurposing Azithromycin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
IRCT200809
01001165N51		 Investigating the efficacy and safety of Hydroxychloroquine nasal spray in controlling the symptoms of patients with COVID-19 Iran Y N Drug Repurposing Hydroxychloroquine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
IRCT202004
18047121N1		 Study of the effectiveness of concomitant use of vitamin C, metformin, azithromycin and doxycycline on improving patients with COVID-19 Iran Y N Drug Repurposing Azithromycin, Doxycycline, Ascorbic acid, Metformin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT201508
08023559N21		 The Effect of Convalescent Plasma Therapy on the Outcomes of Patients with 19-COVID Iran N N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Mild/Moderate Cases, Severe Cases
IRCT202005
01047258N1		 Investigation of the effects of COVID-19 convalescent plasma in acute respiratory distress syndrome due to COVID-19 Iran Y N Cell/Blood based ND:Convalescent plasma Efficacy - Infection rate (prevention) Mild/Moderate Cases, Severe Cases
IRCT200809
01001165N52		 Investigating the efficacy of high dose of glucocorticoid in patients with moderate to severe pneumonia related to COVID-19 Iran Y N Drug Repurposing Methylprednisolone, Prednisolone Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
IRCT202005
08047346N1		 Evaluation of the efficacy and safety of Rabbit polyclonal antibody (CoviGlobulin) in patients with coronavirus COVID-19 virus moderate to severe Iran Y N Cell/Blood based ND:CoviGlobulin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT201202
15009014N354		 Evaluating the effect of intravenous hydrocortisone, methylprednisolone, and dexamethasone in treatment of patients with moderate to severe acute respiratory distress syndrome caused by COVID-19: A double blind randomized clinical trial Iran Y Y Drug Repurposing Hydrocortisone, Methylprednisolone, Dexamethasone Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
KCT0005003 Treatment effect of Nafamostat mesilate in patients with COVID-19 pneumonia: open labelled randomized controlled clinical trial Korea, Republic of Y N Drug Repurposing Nafamostat Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
ACTRN12620
000445976		 Australasian COVID-19 Trial (ASCOT). A multi-centre randomised clinical trial to assess clinical, virological and immunological outcomes in patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care Australia Y N Drug Repurposing Hydroxychloroquine, Lopinavir/ritonavir Efficacy - Mortality Mild/Moderate Cases, Severe Cases
ACTRN12620
000580976		 Tocilizumab for the treatment of COVID-19 in intensive care patients: effect on days free of ventilatory support. Australia N N Drug Repurposing Tocilizumab Efficacy - Mortality Severe Cases
ISRCTN8521
6856		 Investigating the use of convalescent plasma from patients who have recovered from COVID-19 in the management of Ecuadorian patients infected with SARS-CoV-2 with clinical deterioration: IMPACT Ecuador Y N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Mild/Moderate Cases, Severe Cases
ChiCTR2000
033056		 Convalescent Plasma in the treatment of 6 COVID-19 Patients China N N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
ChiCTR2000
033049		 A clinical study for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the untreated mild or common type novel coronavirus pneumonia (COVID-19) patients China N N Drug Repurposing Artemisinin-piperaquine Efficacy - Viral load Mild/Moderate Cases
ChiCTR2000
033372		 Efficacy and safety of leflunomide for Refractory novel coronavirus pneumonia (COVID-19): A non-Randomized Controlled Study China N N Drug Repurposing Leflunomide Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
033323		 Severe Reluctant COVID-19 Patients Responding to Convalescent Plasma; A case series Iraq N N Cell/Blood based ND:Convalescent plasma Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
033627		 In vivo use of ivermectin (IVR) for treatment for corona virus infected patients: a randomized controlled trial Iraq Y N Drug Repurposing Ivermectin Efficacy - Viral load Mild/Moderate Cases
ChiCTR2000
033491		 The Single Oral Favipiravir for Patients with Delayed SARS-Cov-2 viral RNA Clearance China N N Drug Repurposing Favipiravir Efficacy - Viral load Mild/Moderate Cases
ChiCTR2000
033774		 Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets in Treating Pediatric novel coronavirus pneumonia (COVID-19) China Y N Drug Repurposing Bromhexine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Other
IRCT202001
28046294N2		 A prospective randomized controlled trial comparing Sovodak (Sofosbuvir plus Daclatasvir) in participants with moderate to severe Coronavirus disease (COVID-19) compared to standard of care treatment Iran Y N Drug Repurposing Daclatasvir/sofosbuvir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT202003
14046774N1		 Assessment of vitamin A effectiveness on COVID-19 patients and treatment outcomes referred to health centers of Qom province Iran Y N Drug Repurposing Vitamin A Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
IRCT202003
24046850N3		 The effect of naproxen on the healing process of patients with COVID-19 Iran Y N Drug Repurposing Naproxen Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
IRCT202003
24046850N1		 Comparison of vitamin D3 and N-acetylcysteine prescription in COVID19 patients and their effect on recovery process Iran Y Y Drug Repurposing Vitamin D3, N-acetylcysteine Efficacy - Other efficacy Severe Cases
IRCT202003
18046812N1		 Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra on the need for intensive care unit treatment in patients with COVID-19; a randomized, multicenter, parallel groups, open label study Iran Y N Drug Repurposing Favipiravir, Lopinavir/Ritonavir Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
IRCT201908
10044500N5		 Investigation of the efficacy and safety of colchicine In combination with standard treatment on covid-19 patients: A clinical trial Iran Y N Drug Repurposing Colchicine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT202004
01046909N1		 The efficacy of oral 25-hydroxyvitamin D3 on COVID-19 treatment in adults: A Randomized, Controlled Double-Blind Clinical Trial. Iran Y N Drug Repurposing Vitamin D3 Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
IRCT201807
25040596N2		 Evaluation of the effect of Arbidol drug in the treatment of hospitalized patients with COVID-19 Iran Y N Drug Repurposing Umifenovir, Lopinavir/ritonavir Efficacy - Clinical improvement (except WHO scale) Severe Cases
IRCT202004
04046947N1		 Study of Methylprednisolone effects on treatment and clinical symptoms and laboratory signs of Iranian ?COVID-19 patients: a clinical trial study Iran Y N Drug Repurposing Methylprednisolone Efficacy - Clinical improvement (except WHO scale) Severe Cases
IRCT201512
28025732N52		 A study on melatonin and Vitamin C and zinc efficacy in patients with COVID19 hospitalized in intensive care unit of Semnan Kowsar Hopsital Iran Y N Drug Repurposing, Other ND:Zinc, Ascorbic acid Efficacy - Oxygen parameters Severe Cases
IRCT200810
27001411N3		 Study of Prednisolone effects on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a clinical trial study Iran Y N Drug Repurposing Methylprednisolone Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
IRCT200912
01002804N12		 The effect of surfactant on clinical outcome of patients with COVID-19 under mechanical ventilation Iran Y N Drug Repurposing Beractant Efficacy - Oxygen parameters Severe Cases
IRCT202004
01046909N2		 Investigating preventive effects of oral 25-hydroxyvitamin D3 on COVID-19 in adults: A Randomized, Controlled Double-Blind Clinical Trial. Iran Y N Drug Repurposing Vitamin D3 Efficacy - Infection rate (prevention) General population
IRCT202002
17046526N1		 Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection : A Phase 1 and 2 clinical trial Iran N N Cell/Blood based ND:Stem cells Safety Mild/Moderate Cases, Severe Cases
IRCT201907
27044343N3		 Evaluation of ANIF1 antiviral drug in COVID-19 patients: A Randomized Clinical Trial Iran Y N Shelved drug or NME ANIF1 Efficacy - Viral load Mild/Moderate Cases, Severe Cases
IRCT200810
19001369N6		 Evaluation of the effect of trans sodium crocetinate in respiratory distress caused by COVID-19 Iran Y N Shelved drug or NME Trans sodium crocetinate Efficacy - Mortality Mild/Moderate Cases, Severe Cases
IRCT200910
12002582N21		 Effect of intratracheal Injection of Processed Autologous Serum Derived from Patients with covid-19 in oxygenation parameters and pulmonary Complications Iran Y N Cell/Blood based ND:Convalescent plasma Efficacy - Oxygen parameters Severe Cases
IRCT202003
25046859N2		 evaluation of the effects of the 2-drug diet (hydroxychloroquine + umifenovir(Arbidol)) compared with Hydroxy chlorquine on the of mortality rate in patients with moderate symptoms of COVID-19 infections: A randomized interventional study in Imam Reza Hospital, Mashhad. Iran N N Drug Repurposing Umifenovir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
IRCT202004
11047019N1		 Investigating the Effect of BCG Vaccine on Preventing COVID-19 Infection in Healthcare Staff Exposed to SARS-CoV-2 Iran Y N Vaccine BCG Vaccine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
IRCT201503
03021315N19		 The evaluation of safety and efficacy of Pembrolizumab (CinnaGen Co, Iran) in patients with COVID-19 Iran N N Drug Repurposing Pembrolizumab Efficacy - Mortality Mild/Moderate Cases
IRCT202005
01047259N1		 Intravenous immunoglubolin (IVIG) effect on improvement of severe pulmonary damage in COVID 19 disease Iran Y N Cell/Blood based ND:Immunoglobulin Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
IRCT202005
02047268N1		 Evaluation of the effect of GCSF injection in treatment of COVID-19 patients with lymphopenia (less than 1000) Iran Y N Drug Repurposing Granulocyte colony-stimulating factor Efficacy - Other efficacy Other
IRCT202004
18047126N1		 Evaluation of the therapeutic effect of colchicine plus chloroquine in comparison with chloroquine in patients with COVID-19 Iran Y N Drug Repurposing Colchicine Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
IRCT202004
05046951N1		 The effect of supplementation with vitamin A on improvement of symptoms of acute respiratory syndrome in patients with COVID-19: A randomized clinical trial Iran Y N Drug Repurposing Vitamin A Efficacy - Oxygen parameters Severe Cases
IRCT202004
21047150N1		 Assessment of safety, efficacy and effective dose determination of human umbilical cord Wharton’s jelly mesenchymal stem cell transplantation on treatment of COVID-19 (coronavirus) pneumonia and complications in humans Iran Y N Cell/Blood based ND:Stem cells Efficacy - Mortality Mild/Moderate Cases, Severe Cases
IRCT201404
28017469N1		 Short-term Protection for COVID-19 by Oral Polio Vaccine Iran N N Vaccine ND:Polio vaccine Efficacy - Infection rate (prevention) General population, Other
IRCT201512
27025726N15		 Evaluation the efficacy and safety of Umifenovir (Arbidol) Administration in comparison with Lopinavir-ritonavir (Kaletra) in COVID-19 patients Iran Y N Drug Repurposing Umifenovir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
IRCT201507
16023235N15		 The use of sex hormones in the control of coronavirus inflammation Iran Y N Drug Repurposing Testosterone, Progesterone Efficacy - Clinical improvement (except WHO scale) Other
IRCT202005
10047383N1		 Evaluation of the effect of Tocilizumab on outcomes of the severe COVID-19, determining indications within the paradigm of host-directed therapy Iran Y N Drug Repurposing Tocilizumab Efficacy - Mortality Severe Cases
IRCT201202
15009014N355		 Evaluating the effect of intravenous N-acetyl cysteine versus placebo in the treatment of patients with mild and moderate acute respiratory distress syndrome caused by COVID-19: A double-blind randomized clinical trial Iran Y N Drug Repurposing N-acetylcysteine Efficacy - Mortality Mild/Moderate Cases
IRCT201707
31035423N2		 Effect of the combination of BCc1 & Hep-S on the improvement of clinical & laboratory symptoms of hospitalized COVID-19 patients in a randomized, double-blind, clinical trial Iran Y N Shelved drug or NME BCc1 nanomedicine, Hep-s Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
IRCT200809
01001165N55		 Investigating the efficacy and safety of N-Acetyl Cysteine (NAC) inhalation spray in controlling the symptoms of patients with COVID-19 Iran Y N Drug Repurposing N-acetylcysteine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT200809
01001165N53		 Investigating the efficacy and safety of Interferon Beta1a nasal spray in controlling the symptoms of patients with COVID-19 Iran Y N Drug Repurposing Interferon Beta-1A Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT201512
27025726N17		 Evolution of the efficacy and safety of Dexamethasone administration in patients with mild to moderate COVID-19 acute respiratory disease syndrome Iran Y N Drug Repurposing Dexamethasone Efficacy - Oxygen parameters Mild/Moderate Cases
IRCT202005
16047468N1		 Interventional study of intravenous vitamin C in definitive patients with covid 19 and its effect on changes in lung CT scan and clinical and laboratory symptoms of patients Iran Y N Drug Repurposing Ascorbic acid Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
IRCT201501
07020592N23		 Plasmapheresis and plasma exchanges;usefulness in covid-19 critically ill patients Iran N N Cell/Blood based ND:Convalescent plasma Efficacy - Oxygen parameters Severe Cases
IRCT201608
09029275N1		 Evolution of Allogenic Mesenchymal stem cell- derived Umbilical cord transplantation for ARDS patients infected with COVID19. Iran Y N Cell/Blood based ND:Stem cells Efficacy - Oxygen parameters Severe Cases
IRCT202005
17047485N1		 Evaluation of the efficacy and side effects of combination therapy of Kaletra and Hydroxychloroquine in comparison with Atazanavir / Ritonavir and Hydroxychloroquine in the treatment of patients with COVID-19 Iran Y N Drug Repurposing Atazanavir/ritonavir, Lopinavir/ritonavir Efficacy - Oxygen parameters Mild/Moderate Cases
IRCT201501
07020592N22		 Cyclosporin for the Prevention and Treatment of COVID-19 Disease Iran N N Drug Repurposing Cyclosporine Efficacy - Other efficacy Severe Cases
IRCT201512
27025726N18		 The effect of pentaglobin in the treatment of critically ill patients with COVID-19 Iran Y N Cell/Blood based ND:Immunoglobulin Efficacy - Oxygen parameters Severe Cases
IRCT201612
06031256N3		 Evaluation and comparison of the effect of two interferon alpha and beta antiviral drugs on the prognosis of patients with COVID 19 Iran Y Y Drug Repurposing Interferon alpha, Interferon beta Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
IRCT202004
22047168N2		 A randomized clinical trial study, comparison of the therapeutic effects of Ivermectin, Kaletra and Chloroquine with Kaletra and Chloroquine in the treatment of patients with coronavirus 2019 (COVID-19) Iran Y N Drug Repurposing Ivermectin Efficacy - Mortality Mild/Moderate Cases, Severe Cases
IRCT202005
23047550N1		 Evaluating effectiveness and safety of Umifenovir in the treatment (COVID-19)infection In patients referred to Tehran Imam Khomeini Hospital Complex Iran N N Drug Repurposing Umifenovir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT201601
18026097N3		 Evaluation of interferon treatment in high-risk covid19 patients in Qom Iran Y N Drug Repurposing Interferon beta-1b Efficacy - Mortality Mild/Moderate Cases, Severe Cases
IRCT201207
03010178N20		 ?Evaluation of Safety and efficacy of anakinra utilization in COVID-19, a randomized controlled clinical trial Iran Y N Drug Repurposing Anakinra Efficacy - Mortality Mild/Moderate Cases, Severe Cases
IRCT202004
12047042N1		 Evaluation the effect of raltegravir, and raltegravir/interferon beta combination on covid 19 patients admitted in Peymanieh hospital of Jahrom in 2020 Iran Y Y Drug Repurposing Raltagravir, Interferon beta Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
JPRN-Japic
CTI-205270		 A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia in Japan Japan N N Drug Repurposing Tocilizumab Safety Severe Cases
JPRN-jRCTs
031190227		 A prospective multi-center open trial to evaluate the safety and efficacy of triple combination therapy of lopinavir , ritonavir and hydroxychloroquine sulfate in patients infected with COVID-19. Japan N N Drug Repurposing Hydroxychloroquine, Lopinavir/ritonavir Efficacy - Other efficacy Mild/Moderate Cases
JPRN-jRCTs
041190120		 Multicenter, open-label, randomized trial of favipiravir in asymptomatic and minimally symptomatic patients infected with SARS-CoV2 to evaluate viral load reduction Japan Y N Drug Repurposing Favipiravir Efficacy - Viral load Mild/Moderate Cases
JPRN-jRCTs
061200002		 Randomized controlled trial of teprenone for preventing aggravation of COVID-19 Japan Y N Drug Repurposing Teprenone Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
ACTRN12620
000501943		 Effectiveness of Prophylactic Hydroxychloroquine on incidence of COVID-19 infection in Front-line Health and Allied Health Care Workers: The COVID-SHIELD Trial Australia Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
ACTRN12620
000676910		 Allogeneic Amniotic Epithelial Cells for the Treatment of COVID-19 related respiratory failure, a pilot feasibility randomised controlled trial Australia Y N Cell/Blood based ND:Amniotic epithelial cells Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
ISRCTN3357
8935		 Rationale and investigational study for the treatment of COVID-19 with severe viral pneumonia with isolated, placental, mesenchymal stem cell exosomes Germany Y N Cell/Blood based ND:Stem cell exosomes Safety Severe Cases
ISRCTN4030
2986		 A double-blind clinical trial to repurpose and assess the efficacy and safety of ivermectin in COVID-19 Nigeria Y N Drug Repurposing Ivermectin Efficacy - Viral load Mild/Moderate Cases, Severe Cases
ChiCTR2000
034112		 A Phase I clinical trial to evaluate the safety, tolerance and preliminary immunogenicity of different doses of a SARS-CoV-2 mRNA vaccine in population aged 18-59 years and 60 years and above China Y Y Vaccine ND:Vaccine Safety Other
ChiCTR2000
034076		 A safety and immune response trial of novel coronavirus pneumonia (COVID-19) S-Vax loaded autologous dendritic cells China N N Vaccine ND:Vaccine Safety Other
ACTRN12620
000707965		 A Multicenter, Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of the recombinant BCG VPM1002 on the Incidence or Disease Severity of SARS-COV-2/COVID-19 Among High-Risk Participants in Australia Australia Y N Vaccine ND: VPM1002 vaccine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
ACTRN12620
000612910		 A pilot, open-label, randomised controlled clinical trial to investigate early efficacy of CYP-001 in adults admitted to intensive care with COVID-19 Australia Y N Cell/Blood based ND:Stem cells Efficacy - Oxygen parameters Severe Cases
SLCTR/2020
/011		 Hydroxychloroquine for Post-Exposure Prophylaxis of COVID-19 among naval personnel: a placebo-controlled, randomized, clinical trial Sri Lanka Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
IRCT201511
13025025N3		 Clinical Trial of renin-angiotensin-aldosterone system inhibitors with halting their administration and the effect on clinical outcomes of patients with coronavirus disease-2019 (COVID-19) referring to Sina and Imam-Khomeini Hospitals in 2020 Iran N N Drug Repurposing, Other Efficacy - Mortality Mild/Moderate Cases, Severe Cases
IRCT202004
16047099N2		 Plasma exchange in patients with COVID-19 to reduce viral load and inflammatory molecules Iran N N Cell/Blood based ND:Plasma exchange Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
IRCT202004
28047232N1		 Effectiveness and safety of thalidomide in moderate COVID-19 pneumonia: A randomized clinical trial Iran Y N Drug Repurposing Thalidomide Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
IRCT201711
05037262N4		 Evaluation of adalimumab effect on clinical symptoms including respiratory distress, oxygen saturation and lung involvement of patients with COVID-19 Iran Y N Drug Repurposing Adalimumab Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT202005
11047396N1		 Efficacy evaluation of inhalation therapy (nasal spray) of Interferon Beta-1a in hospitalized Covid-19 patients Iran Y N Drug Repurposing Interferon Beta-1a Efficacy - Other efficacy Mild/Moderate Cases
IRCT201804
25039414N3		 The effect of vitamin C and E in the treatment and clinical course of patients with SARS-cov2 (COVID-19) Iran Y N Drug Repurposing Ascorbic acid, Vitamin E Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT202005
10047385N1		 Effect of stromal vascular fraction (SVF), blood and condition medium derived exosomes on treatment of covid-19 patients with Acute Respiratory Distress Syndrome(ARDS)/ clinical Trial Iran Y Y Cell/Blood based ND:Convalescent plasma Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
IRCT202005
13047426N1		 The prophylactic effect of oral hydroxy-chloroquine in close contacts of COVID-19 patients Iran Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
IRCT201107
26007117N11		 Effect of vitamin D supplementation in diagnosed cases of 2019 Novel Coronavirus; a randomized clinical trial Iran Y N Drug Repurposing Vitamin D3 Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
IRCT202001
12046089N1		 Evaluation of the effect of Resveratrol on the effectiveness of antiviral drug regimen in patients with COVID-19 Iran Y N Shelved drug or NME Resveratrol Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT200810
27001411N4		 Study of Tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ?crinical trial study Iran Y N Drug Repurposing Tocilizumab Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
IRCT202005
25047562N1		 Immediate uses of convalescent covid-19 plasma in the treatment of new infected patients at the first day of hospitalization in a clinical trail Iran N N Cell/Blood based ND:Convalescent plasma Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
IRCT202003
17046797N6		 Effect of edaravone on clinical improvement and outcome of patients with respiratory distress syndrome caused by COVID-19 Iran Y N Drug Repurposing Edaravone Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
IRCT202005
04047298N1		 Evaluation of Atazanavir/Ritonavir effect on COViD-19 patients treatment in comparison with Lopinavir / Ritonavir Iran Y N Drug Repurposing Atazanavir, Ritonavir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT202006
08047686N1		 Evaluation of therapeutic effects of Metronidazole In Inpatients with Pneuomonia Due to COVID-19 Iran Y N Drug Repurposing Metronidazole Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
IRCT201501
07020592N26		 Favipiravir effectiveness in patients undergoing COVID19 Acute respiratory distress syndrome (ARDS) Iran N N Drug Repurposing Favipiravir Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
IRCT202006
09047707N1		 Effective of Elman tablet on illness severity and length of hospital stay in the patients with COVID-19 infection Iran Y N Shelved drug or NME Elman Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT201501
07020592N27		 The effect of pentaglobin in the treatment of critically ill patients with COVID-19 Iran N N Shelved drug or NME Pentaglobin Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
IRCT202005
15047456N1		 Evaluation of Tissue Plasminogen Activator (tPA) in comparition of anticoagulation for treatment of critical COVID 19 patient Iran Y N Drug Repurposing Alteplase Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
IRCT201501
07020592N30		 Favipiravir prophylactic to reduce the involvement of health care workers in the COVID-19 epidemic Iran N N Drug Repurposing Favipiravir Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
IRCT201507
25023332N3		 The effect of Bromelain and Montelukast on Clinical and non-Clinical parameters in Covid-19 patients Iran Y Y Drug Repurposing, Other Montelukast, ND:Bromelain Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
IRCT201901
21042444N3		 Considering the administration of Desferral supplementary and Vitamin C on the ferritin levels of Quid 19 patients Iran Y N Drug Repurposing Deferoxamine, Ascorbic acid Efficacy - Other efficacy Mild/Moderate Cases
IRCT201112
24008507N3		 Effectiveness of Ivermectin in the Treatment of Coronavirus Infection in Patients admitted to Educational Hospitals of Mazandaran in 2020 Iran Y N Drug Repurposing Ivermectin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT202006
24047908N1		 Evaluation of the effect of sofosbuvir/daclatasvir in COVID-19 patients: A randomized double-blind clinical trial Iran Y N Drug Repurposing Sofosbuvir/Daclatasvir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
IRCT202004
26047206N2		 Clinical trial of efficacy and safety of mesenchymal stem cell transplantation in patients with COVID-19 pneumonia Iran Y N Drug Repurposing ND:Stem cells Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
JPRN-jRCT2
031200035		 A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Adaptive COVID-19 Treatment Trial (ACTT-2) Japan Y N Drug Repurposing, Shelved drug or NME Baricitinib, Remdesivir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
JPRN-jRCTs
031190226		 A prospective multi-center open trial to evaluate the safety and efficacy of favipiravir in patients infected with COVID-19. Japan N N Drug Repurposing Favipiravir Efficacy - Other efficacy Mild/Moderate Cases
JPRN-jRCTs
031200026		 Multicenter, Single blinded Randomized Controlled, Comparative Study to Evaluate the Efficacy and Safety of Favipiravir and Nafamostat Mesilate in Patients with COVID-19 Pneumonia Japan Y N Drug Repurposing Favipiravir, Nafamostat Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
JPRN-jRCTs
041200025		 Japanese, multicenter, phase II trial of combination therapy with favipiravir and corticosteroids for coronavirus disease 2019 (COVID-19) patients with mild respiratory failure - J-CRITICAL trial Japan N N Drug Repurposing Favipiravir, Methylprednisolone Efficacy - Other efficacy Mild/Moderate Cases
PACTR20200
4801273802		 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of Chloroquine Phosphate, Hydroxychloroquine sulphate and Lopinavir/Ritonavir for the Treatment of COVID-19 in Lagos State. Nigeria Y Y Drug Repurposing Chloroquine, Hydroxychloroquine, Lopinavir/Ritonavir Efficacy - WHO scale Severe Cases
PACTR20200
5599385499		 The host Epigenetic methylation repair in COVID-19 using Folic acid: A new suggested prevention and treatment. Egypt N N Drug Repurposing Folic acid Efficacy - Viral load Mild/Moderate Cases
PACTR20200
4893013257		 PROTECT-Surg Ghana Y Y Drug Repurposing Hydroxychloroquine, Lopinavir/Ritonavir Efficacy - Other efficacy Other
PACTR20200
5681895696		 A phase Ib/II single-blinded, randomised, controlled study to determine safety, immunogenicity and efficacy of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults in Kenya Kenya Y N Vaccine ND: Vaccine ChAdOx1 Safety General population
PACTR20200
5622389003		 Efficacy and safety of Hydroxychloroquine, Azythromycine and Zinc for the treatment of patients with SARS-Cov2 infection in Senegal: a dose ranging randomised trial. COVID-19 Senegal Y N Drug Repurposing Hydrochloroquine, Azythromycine, Zinc Efficacy - Viral load Mild/Moderate Cases, Severe Cases
PACTR20200
6899597082		 Randomized clinical trial, phase 2, to evaluate the efficacy of Artesunate IV alone or combined with vitamin C IV for the treatment of COVID-19 Madagascar Y Y Drug Repurposing Artesunate, Ascorbic acid Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
PACTR20200
6537901307		 An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild/moderate cases of COVID-19 Switzerland Y N Drug Repurposing Lopinavir/Ritonavir, Hydroxychloroquine Efficacy - Oxygen parameters Mild/Moderate Cases
PACTR20200
7606032743		 Nebulized heparin in patients with mainly moderate coronavirus disease 2019: Randomized controlled trial. COVID-19 Egypt Y N Drug Repurposing Heparin Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
PACTR20200
6922165132		 COVID-19: An Adaptive Phase I/II Randomized Placebo-controlled Trial to Determine Safety, Immunogenicity and Efficacy of Non-replicating ChAdOx1 SARSCoV-2 Vaccine in South African Adults Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV. South Africa Y Y Vaccine ND:ChAdOx1 vaccine Safety General population, Other
PACTR20200
6760881890		 A Multi-Center, Randomized, Double-Blind, Placebo- Controlled Clinical Trial of the Safety and Efficacy of Convalescent Plasma for the Treatment of COVID-19 in Hospitalized Patients in Lagos State Nigeria Y N Cell/Blood based ND:Convalescent plasma Efficacy - Viral load Severe Cases, Other
PACTR20200
6883882711		 Effectiveness of Measles, Mumps and Rubella Vaccine in Health Care Professionals for COVID-19 Egypt Y N Drug Repurposing, Vaccine ND: MMR vaccine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
RBR-8969zg Clinical Trial using N-acetylcysteine for treatment of 2019-nCoV Pneumonia Brazil Y N Drug Repurposing N-acetylcysteine Efficacy - Mortality Severe Cases
RBR-3k4wxb Evaluation of the use of Hydroxychlorochine in patients with discrete form of Covid-19: randomized clinical trial Brazil Y Y Drug Repurposing Hydroxychloroquine, Azithromycin Efficacy - Viral load Mild/Moderate Cases, Severe Cases
RBR-4vm3yy Use of convalescent plasma submitted to pathogen inactivation for the treatment of patients with severe COVID-19 Brazil N N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Severe Cases
RBR-949z6v Full versus prophylactic heparinization for the treatment of severe forms of SARS-Covid-19: clinical, randomized, open and controlled study - HeSAcovid trial Brazil Y N Drug Repurposing Enoxaparin Efficacy - Oxygen parameters Severe Cases
RBR-876qb5 Eculizumab for the treatment of Covid-19 severe cases - : Eculizumabe for COVID Brazil N N Drug Repurposing Eculizumab Efficacy - Mortality Severe Cases
RBR-3zdynp Clinical Characterisation Protocol for Severe Emerging Infections ISARIC/WHO: COVID-19 Brazil Y N Drug Repurposing Tocilizumab Efficacy - Mortality Mild/Moderate Cases, Severe Cases
RBR-7jqpnw Therapeutic effectiveness of COVID-19 convalescent plasma produced by HEMOPE: a multicenter, randomized and controlled clinical trial - PLAVID-TRIAL: Covid convalescent plasma - Clinical Trial Brazil Y N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Mild/Moderate Cases, Severe Cases
RBR-5vpyh4 Use of Anti-IL-17 in patients with the severe acute respiratory syndrome (SARS) associated with Covid-19 Brazil Y N Drug Repurposing Secuquinumab Efficacy - Other efficacy Severe Cases
RBR-3rywwg A phase IIb, double-blind, randomized controlled trial to evaluate the efficacy and safety of Naproxen compared to placebo in combination with Azithromycin or Levofloxacin in patients with Severe Acute Respiratory Syndrome during the Covid-19 pandemic Brazil Y N Drug Repurposing Naproxen Efficacy - Mortality Severe Cases
TCTR202005
14001		 An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients without Pneumonia â?? An open-label randomized controlled study â?? Thailand Y N Drug Repurposing Favipiravir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
TCTR202004
04004		 Comparative effectiveness of chloroquine and vitamin C prophylaxis in household contacts of confirmed COVID-19 patients Thailand Y N Drug Repurposing Chloroquine, Ascorbic acid Efficacy - Viral load Mild/Moderate Cases
PER-013-20 CONVALESCENT PLASMA USE AS TREATMENT FOR HOSPITALIZED PATIENTS WITH COVID-19 IN ESSALUD Peru Y N Cell/Blood based ND:Convalescent plasma Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
PER-016-20 PERUCONPLASMA: RANDOMIZED CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF THE USE OF CONVALESCENT PLASMA IN HOSPITALIZED PATIENTS WITH COVID-19 Peru Y N Cell/Blood based ND:Convalescent plasma Safety Mild/Moderate Cases, Severe Cases
CTRI/2020/
03/024402		 Hydroxy Chloroquine, in open labelled, Randomised intervention for prevention of new infection and adverse outcomes following COVID-19 infection- A Tertiary Hospital based study - CORONA study India N N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
CTRI/2020/
04/024479		 Open labelled Randomised controlled trial to study the effect of Chloroquine in addition to standard therapy in COVID-19 patients India Y N Drug Repurposing Chloroquine Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
CTRI/2020/
04/024729		 Topical Chloroquine Nasal Drops in Early Stage Covid 19- Impact on Viral load and cure rates India Y N Drug Repurposing Chloroquine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
CTRI/2020/
04/024775		 A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications in Moderate Disease. - PLACID India Y N Cell/Blood based ND:Convalescent plasma Efficacy - Other efficacy Mild/Moderate Cases
CTRI/2020/
04/024749		 A Multicenter, Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of Recombinant BCG VPM1002 in Reducing Infection Incidence and Disease Severity of SARS-COV-2/COVID-19 Among High-Risk Subjects India Y N Drug Repurposing BCG Vaccine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
CTRI/2020/
04/024806		 Efficacy of Imatinib in mild SARS CoV2 infection: A randomized study India Y N Drug Repurposing Imatinib Efficacy - Viral load Mild/Moderate Cases
CTRI/2020/
04/024804		 Open Label, parallel arm, phase I/II clinical trial to evaluate Safety and efficacy of Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease India N N Cell/Blood based ND:Convalescent plasma Safety Mild/Moderate Cases, Severe Cases
CTRI/2020/
04/024833		 Effect of BCG-Denmark (Green Signal) on prevention of COVID 19 infection in health care workers â?? a double blind randomized controlled trial India Y N Drug Repurposing BCG Vaccine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
CTRI/2020/
04/024846		 A clinical trial to evaluate the safety and efficacy of Mycobacterium W in critically ill patients suffering from COVID 19 infection India Y N Shelved drug or NME ND:Mycobacterium Efficacy - Other efficacy Severe Cases
CTRI/2020/
04/024904		 Randomised Controlled Trial to compare efficacy of hydroxychloroquine alone and in combination with azithromycin in treatment of COVID-19 - HAZES India Y Y Drug Repurposing Hydroxychloroquine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
CTRI/2020/
04/024948		 EFFICACY OF HYDROXYCHLOROQUINE, CICLESONIDE AND IVERMECTIN IN TREATMENT OF MODERATE COVID-19 ILLNESS: AN OPEN-LABEL RANDOMISED CONTROLLED STUDY - EHYCIVER-COVID India Y N Drug Repurposing Hydroxychloroquine, Ciclesonide, Ivermectin Efficacy - Viral load Mild/Moderate Cases
CTRI/2020/
04/024949		 EFFICACY OF ORAL NICLOSAMIDE IN TREATMENT OF MILD AND VERY MILD COVID-19 CASES: AN OPEN-LABEL RANDOMIZED CONTROLLED TRIAL - EONIC-COVID India Y N Drug Repurposing Niclosamide Efficacy - Viral load Mild/Moderate Cases
CTRI/2020/
05/024967		 A Prospective, Open label observational clinical study to evaluate the efficacy and safety of MyVir tablets to improve immunity in quarantine patients of COVID-19 India N N Shelved drug or NME MyVir Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
CTRI/2020/
05/024959		 A Multi-Centre, Open label, Two Arm Randomized, Pivotal Phase 2 Trial to Study the Efficacy and Safety of Itolizumab in COVID-19 Complications India Y N Drug Repurposing Itolizumab Efficacy - Mortality Mild/Moderate Cases, Severe Cases
CTRI/2020/
05/024962		 Effectiveness of topical povidone iodine (PVP-I) oropharyngeal and intranasal application during the current coronavirus pandemic amongst COVID-19 positive patients in Andhra Pradesh, India India Y N Shelved drug or NME Povidone-Iodine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
CTRI/2020/
05/025013		 Phase 2 Clinical Trial for the Evaluation of BCG as potential therapy for CoVID-I9 - COVID-19 BCG India Y N Drug Repurposing BCG Vaccine Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
CTRI/2020/
05/025022		 An open label randomised controlled trial to assess the efficacy of Hydroxychloroquine in patients with mild COVID -19 illness with risk factors for severe disease. India Y N Drug Repurposing Hydroxychloroquine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
CTRI/2020/
05/025067		 A randomized controlled trial of hydroxychloroquine prophylaxis for Healthcare Workers exposed to COVID-19 India Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
CTRI/2020/
05/025068		 A Phase IIB open label randomized controlled trial to evaluate the efficacy and safety of Ivermectin in reducing viral loads in patients with hematological disorders who are admitted with COVID 19 infection - Not applicable India Y N Drug Repurposing Ivermectin Efficacy - Viral load Other
CTRI/2020/
05/025114		 A Randomized, Open-label, multicenter study to evaluate the efficacy and safety of Favipiravir combined with STANDARD supportive care in adult Indian patients with mild to moderate COVID-19 India Y N Drug Repurposing Favipiravir Efficacy - Viral load Mild/Moderate Cases
CTRI/2020/
05/025167		 Evaluation of Efficacy and Safety of Thymoquinone compared to Best supportive care in Patients with COVID-19. India Y N Shelved drug or NME Thymoquinone Efficacy - Viral load Mild/Moderate Cases, Severe Cases
CTRI/2020/
05/025209		 AN OPEN LABEL RANDOMISED CONTROL TRIAL ON PASSIVE IMMUNIZATION WITH CONVALESCENT PLASMA IN SEVERE COVID-19 DISEASE - PICP19 India Y N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Severe Cases
CTRI/2020/
05/025224		 Interventional study to assess the efficacy of Ivermectin with standard of care treatment versus standard of care in patients of COVID-19 at R D Gardi Medical College, Ujjain, India India Y N Drug Repurposing Ivermectin Efficacy - Viral load Mild/Moderate Cases, Severe Cases
CTRI/2020/
05/025242		 Population pharmacokinetics of hydroxychloroquine sulphate in healthcare workers given for prophylaxis against Corona Virus Disease 2019 (COVID 19) pandemic in India India N N Drug Repurposing Hydroxychloroquine Other Exposed individuals (family members, HCP)
CTRI/2020/
05/025271		 A Randomized, Double-blind, Two arm, controlled clinical trial to compare the Efficacy and Safety of Mycobacterium w (Mw) administered along with Standard of care versus Placebo administered along with Standard of care, in adult, COVID 19 positive patients hospitalized but not critically ill. India Y N Shelved drug or NME Mycobacterium Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
CTRI/2020/
05/025277		 A Randomized, Double-blind, Two arm, Placebo Controlled Clinical Trial to Evaluate the Efficacy and Safety of Mycobacterium w in preventing COVID-19 in subjects at risk of getting infected with COVID-19. India Y N Shelved drug or NME Mycobacterium Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
CTRI/2020/
05/025299		 Convalescent Plasma to Limit Coronavirus Associated Complications: An Open label Clinical Study of Anti-SARS-CoV-2 Plasma in Hospitalized Patients with COVID-19 India Y N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
CTRI/2020/
05/025319		 Angiotensin Receptor Blocker Losartan for prevention of COVID 19 complications: a randomized placebo controlled trial - LICCI India Y N Drug Repurposing Losartan Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
CTRI/2020/
05/025328		 To Assess the Safety and Efficacy of Convalescent Plasma on outcome of COVID-19 Associated Complications - COVID PLASMA STUDY India Y N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Severe Cases
CTRI/2020/
05/025346		 A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma in Severe Covid-19 patients. India Y N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Severe Cases
CTRI/2020/
05/025369		 A Multi-center, Randomized Controlled, Phase III Study to evaluate the Clinical Outcomes and Safety of Tocilizumab along with Standard of Care in Patients with Cytokine Release Syndrome associated with COVID-19 infection - None India Y N Drug Repurposing Tocilizumab Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
CTRI/2020/
06/025575		 Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised control trial - SEV-Covid Trial India Y Y Drug Repurposing Oseltamivir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
CTRI/2020/
06/025613		 Melatonin For COVID 19 pre exposure prophylaxis in High Risk population . (MELATONIN IMMUNE BOOST COVID 19 STUDY ) India Y N Drug Repurposing Melatonin Efficacy - Infection rate (prevention) Other
CTRI/2020/
06/025704		 A Phase 3, Prospective, Randomized, Open Label, Comparative, Clinical Study To Evaluate Efficacy And Safety Of Ulinastatin Plus Standard-Of-Care Compared To Standard-Of-Care In Treatment Of Acute Respiratory Distress Syndrome (ARDS) In Hospitalized COVID-19 Infection Patient India Y N Shelved drug or NME Ulinastatin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
CTRI/2020/
06/025760		 Efficacy of Sofosbuvir in the management of hospitalized COVID 19 patients. India N N Drug Repurposing Sofosbuvir Efficacy - Mortality Mild/Moderate Cases, Severe Cases
CTRI/2020/
06/025799		 A Randomized, Open Label, Prospective, Comparative, Parallel Group, Multicentre Study To Evaluate Efficacy And Safety Of Favipiravir With Supportive Care Versus Supportive Care Alone In Subjects With Mild To Moderate Coronavirus Disease (COVID-19). - NA India Y N Drug Repurposing Favipiravir Efficacy - Other efficacy Mild/Moderate Cases
CTRI/2020/
06/025803		 Efficacy of Convalescent Plasma Therapy in Patients With COVID-19: A Randomized Control Trial India Y N Cell/Blood based ND:Convalescent plasma Efficacy - WHO scale Severe Cases
CTRI/2020/
06/025849		 A Randomized, Open Label, 2-Treatment Groups Clinical Trial Evaluating the Safety and Efficacy of a Combination of Nitazoxanide and Hydroxychloroquine Versus Hydroxychloroquine Alone in the Acute Treatment of Moderate COVID-19 Patients India Y N Drug Repurposing Nitazoxanide Efficacy - Viral load Mild/Moderate Cases
CTRI/2020/
06/025854		 Study to Evaluate the Effectiveness of BCG vaccine in Reducing Morbidity and Mortality in Elderly individuals in COVID-19 Hotspots in India - BCG for COVID-19 India N N Vaccine Vaccine Efficacy - WHO scale Other
CTRI/2020/
06/025928		 Povidone Iodine Gargle and Intranasal application: A Quasi-Experimental study to reduce the spread of coronavirus infection in community with Covid-19 positive clusters. India N N Shelved drug or NME Povidone-Iodine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
CTRI/2020/
06/025957		 A Randomized Open-Label Study To Evaluate The Efficacy And Safety Of Favipiravir And Umifenovir As Compared To Favipiravir Alone In Moderate Hospitalized Adult Indian COVID-19 Patients. India Y N Drug Repurposing Umifenovir Efficacy - WHO scale Mild/Moderate Cases
CTRI/2020/
06/026001		 Randomised Controlled Trial of Ivermectin in hospitalised patients with COVID19 - RIVET-COV India Y N Drug Repurposing Ivermectin Efficacy - Viral load Mild/Moderate Cases, Severe Cases
CTRI/2020/
06/026087		 A phase II, randomized, controlled, open-label study to evaluate the efficacy and safety of Pegylated IFN alfa-2b in the treatment of adult patients diagnosed with SARS-CoV2 (COVID-19). India Y N Drug Repurposing Interferon alpha-2b Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
CTRI/2020/
06/026123		 A phase II, Open label, randomized controlled trial to assess the safety and efficacy of convalescent plasma in severe COVID-19. - PLATINA TRIAL. India Y N Cell/Blood based ND:Convalescent plasma Efficacy - WHO scale Severe Cases
CTRI/2020/
06/026187		 Phase II, open label, randomized controlled trial to evaluate Safety and Efficacy of ACT12 Tablet and ACT 13 dry syrup as an immunomodulator in adult Covid 19 positive patients - Nil India Y N Shelved drug or NME ACT12, ACT13 Efficacy - Other efficacy Mild/Moderate Cases
CTRI/2020/
06/026189		 Randomized, Double Blind, Parallel Group Study of Vitamin D3 & Magnesium in Covid 19 Infection - Covid India Y N Drug Repurposing Vitamin D, Magnesium Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
CTRI/2020/
06/026191		 Randomized, Double Blind, Comparative, Parallel group study of Vitamin D3 ( Cholecalciferol ) Vitamin K2-7 & magnesium in prophylaxis of COVID-19 infection in health care professionals - Covid19 India Y N Drug Repurposing Vitamin K, Magnesium Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
CTRI/2020/
06/026192		 A randomised, double-blind, placebo-controlled, phase 2 trial investigating the safety and efficacy of C21 in hospitalised subjects with COVID-19 infection not requiring mechanical ventilation - The ATTRACT Trial India Y N Shelved drug or NME C21 Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
CTRI/2020/
06/026193		 A randomized control study to evaluate the therapeutic effects of Lithium in Covid-19 patients India Y N Drug Repurposing Lithium Efficacy - Mortality Mild/Moderate Cases, Severe Cases
CTRI/2020/
06/026222		 A Phase II Safety and Efficacy Study on prognosis of Moderate Pneumonia in COVID-19 patients with Regular Intravenous Immunoglobulin Therapy India Y N Cell/Blood based Immunoglobulin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
CTRI/2020/
06/026220		 An Open Label, Randomized, Multicenter, Controlled Clinical Study to Evaluate the Efficacy and Safety of Nafamostat Mesilate in the Treatment of Moderate COVID-19 Disease India Y N Drug Repurposing Nafamostat Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
CTRI/2020/
06/026232		 A Clinical Trial to Study the Efficacy of â??Ivermectinâ?? in the prevention of Covid-19. .A Single Arm Study. â?? India N N Drug Repurposing Ivermectin Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
CTRI/2020/
07/026340		 Prospective study to assess therapeutic role of Zinc in COVID-19 patients India Y N Drug Repurposing Zinc Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
CTRI/2020/
07/026352		 A prospective, randomized, adaptive, phase I/II clinical study to evaluate the safety and immunogenicity of Novel Corona Virus -2019-nCov vaccine candidate of M/s Cadila Healthcare Limited by intradermal route in healthy subjects India Y N Vaccine Safety Other
ACTRN12620
000731998		 Safety and efficacy of a pharmacological strategy using Losartan in hospital patients with COVID-19 Australia N N Drug Repurposing Losartan Safety Mild/Moderate Cases, Severe Cases
ChiCTR2000
034796		 the efficacy and safety of heparin in the treatment of novel coronavirus pneumonia (COVID-19): a prospective, randomized, controlled trial China N N Drug Repurposing LMWH Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
ChiCTR2000
034780		 Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Safety and Protective Efficacy of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 18 Years and above United Arab Emirates Y Y Vaccine ND:Vero cell vaccine Efficacy - Infection rate (prevention) General population
ChiCTR2000
034825		 Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects: A Phase I, Randomized, Placebo-controlled, Observer-blind Study China N N Shelved drug or NME BNT162b1 Safety Other
ACTRN12620
000588998		 The safety and efficacy of STC3141 in patient with COVID-19 ARDS require intensive care Australia Y N Shelved drug or NME STC3141 Efficacy - Oxygen parameters Severe Cases
ACTRN12620
000566932		 BEAT COVID-19: A Bayesian adaptive randomised controlled trial platform to evaluate the efficacy of interventions for high risk older patients with COVID-19 in reducing the risk of hospital admission or death. Australia Y N Drug Repurposing Efficacy - Other efficacy Mild/Moderate Cases
ACTRN12620
000674932		 A Phase 1 Randomised, Double-Blind, Placebo-Controlled, Dosage-Escalation, Single Centre Study To Evaluate The Safety And Immunogenicity Of An Adjuvanted SARS-CoV-2 Sclamp Protein Subunit Vaccine (COVID-19 vaccine) In Healthy Adults Aged 18 To 55 Years Old Australia Y N Shelved drug or NME SARS-CoV-2 Sclamp Protein Subunit Vaccine Safety Other
ISRCTN1432
6006		 Protecting frontline health care workers from COVID-19 with hydroxychloroquine pre-exposure prophylaxis: a randomized, placebo-controlled multi-site trial in Toronto, Canada Canada Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
ISRCTN4873
4830		 RAAS blockagE in SARS COV-2 Critically ill patiEnts– a Randomized controlled trial Sweden Y N Drug Repurposing Losartan Efficacy - Other efficacy Severe Cases
ISRCTN8995
1424		 A phase III randomized controlled trial to determine safety, efficacy, and immunogenicity of the non-replicating ChAdOx1 nCoV-19 vaccine United Kingdom Y N Vaccine ND:ChAdOx1 vaccine Efficacy - Infection rate (prevention) Other
ISRCTN5904
8638		 Sulodexide in the treatment of early stages of COVID-19 Mexico Y N Drug Repurposing Sulodexide Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
ISRCTN1707
2692		 A first-in-human clinical trial to assess the safety and immunogenicity of a self-amplifying ribonucleic acid (saRNA) vaccine encoding the S glycoprotein of SARS-CoV-2, the causative agent of COVID-19 United Kingdom Y N Vaccine ND:Vaccine Safety General population
ISRCTN8397
1151		 An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care Switzerland Y Y Drug Repurposing Remdesivir, Chloroquine, Hydroxychloroquine, Lopinavir/ritonavir, Interferon beta Efficacy - WHO scale General population, Severe Cases
NL8523 Volatile agents for sedation in patients with COVID-19-associated acute respiratory distress syndrome – a pilot study Netherlands N N Drug Repurposing Isoflurane Efficacy - Oxygen parameters Severe Cases
NL8578 Alkaline phosphatase for reducing systemic inflammatory response syndrome (SIRS) in patients with Sars-CoV-2 infection and acute respiratory insufficiency (COVID 19) Netherlands N N Drug Repurposing Alkaline phosphatase Efficacy - Oxygen parameters Severe Cases
NL8609 Enhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine: a possible preventive approach against COVID-19 (BCG-PLUS) Netherlands Y N Drug Repurposing, Vaccine ND:BCG vaccine, Bisphosphonate, ND:MMR vaccine Efficacy - Other efficacy General population
NL8633 Convalescent plasma compared to standard plasma for treatment of hospitalized non-ICU patients with COVID-19 infections Netherlands Y N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NL8726 Randomized, placebo-controlled multiple dose study to evaluate the effect of hydroxychloroquine on the general immuno-competence in young and elderly healthy male volunteers Netherlands N N Drug Repurposing Hydroxychloroquine Other Other
NL8490 An open label randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19 Netherlands Y Y Drug Repurposing Chloroquine, Hydroxychloroquine Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
DRKS000215
73		 Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Covid-19 - K724_HCQ-PPI Germany Y N Drug Repurposing Pantoprazole Other General population
DRKS000212
14		 Improvement of the nutritional status regarding nicotinamide (vitamin B3) and the course of COVID-19 disease - COVit Germany Y N Drug Repurposing Nicotinamide Efficacy - Other efficacy Mild/Moderate Cases
DRKS000222
03		 Efficacy & Safety of Sofosbuvir/Daclatasvir treatment in COVID-19: A randomized, controlled study Egypt Y Y Drug Repurposing Sofosbuvir, Daclatasvir, Hydroxychloroquine Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
RPCEC00000
306		 Randomized control clinical trial of CIGB 2020 in contacts and SARS-CoV-2 infection suspects (COVID-19) Cuba Y N Shelved drug or NME CIGB 2020 vaccine Efficacy - Other efficacy Exposed individuals (family members, HCP)
RPCEC00000
307		 Evaluation of the effect and safety of HeberFERON versus Heberon alfa in patients infected with the SARS-CoV-2 coronavirus (COVID-19). Cuba Y N Drug Repurposing Interferon Alpha Gamma Efficacy - Viral load Mild/Moderate Cases, Severe Cases
RPCEC00000
308		 Pharmacodynamics and safety of recombinant interferon alfa 2b, by different routes of administration, in healthy volunteers (COVID-19). Cuba Y Y Drug Repurposing Interferon alpha-2b Other General population
RPCEC00000
309		 Evaluation of the effect of 0.002% sodium chloride saline (activated) administered intravenously and / or mists in patients with covid-19. (COVID-19) - TX-COVID19 Mexico Y N Drug Repurposing Sodium chloride Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
RPCEC00000
311		 Treatment of patients with severe SARS-CoV-2 pneumonia with the anti-CD6 monoclonal antibody itolizumab. (COVID-19) - VICTORIA Cuba N N Drug Repurposing Itolizumab Efficacy - Clinical improvement (except WHO scale) Severe Cases
RPCEC00000
313		 Administration of the CIGB-258 peptide in patients with COVID-19 under intensive therapy regimen (COVID-19) Cuba N N Shelved drug or NME CIGB-258 Efficacy - Mortality Mild/Moderate Cases, Severe Cases
RPCEC00000
314		 Population impact of intervention based on the administration of a single dose of the Outer Membrane Vesicle (OMV) complex contained in VA-MENGOC-BC to stimulate the innate response against SARS-CoV-2 (COVID-19) - VME-CORONA Cuba N N Vaccine ND:Vaccine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
RPCEC00000
315		 Evaluation of the synergistic effect of sequential administration of two immunostimulant products: Immuno-1 and Immuno-2 for the stimulation of the immune response in older adults. Exploratory study (COVID-19) - InmunoCorona Cuba Y N Shelved drug or NME Immuno-1, Immuno-2 Other Other
RPCEC00000
316		 Evaluation of the effect and safety of BIOMODULIN T(R) for the stimulation of the immune response in patients with Stage 5 Chronic Kidney Disease under an iterated hemodialysis regimen. Exploratory study. (COVID-19) Cuba Y N Shelved drug or NME Biomodulin T Efficacy - Other efficacy Other
RPCEC00000
317		 Application of the CIGB 300 as Antiviral in the treatment of patients with a diagnosis of Covid 19. (COVID-19) Cuba Y N Shelved drug or NME CIGB 300 Efficacy - Viral load Mild/Moderate Cases, Severe Cases
RPCEC00000
321		 Expanded clinical use of CIGB-258 in the treatment of serious or critically ill patients by COVID-19 (COVID-19) Cuba N N Shelved drug or NME CIGB-258 Efficacy - Oxygen parameters Severe Cases
JPRN-jRCTs
031190269		 A multicenter, open-label, randomized controlled phase II study to evaluate the efficacy and safety of inhaled ciclesonide for asymptomatic and mild patients with COVID-19 - RACCO trial Japan Y N Drug Repurposing Ciclesonide Efficacy - Other efficacy Mild/Moderate Cases
2020-00178
3-28		 REDUCING ABSENCE FROM WORK OF HEALTHCARE WORKERS DUE TO COVID-19 INFECTION BY BCG (BACILLUS CALMETTE-GUÉRIN) VACCINATION Hungary Y N Vaccine BCG vaccine Efficacy - Other efficacy Exposed individuals (family members, HCP)
2020-00145
9-42		 Ruxolitinib Treatment in Patients with Severe COVID-19 Infection. A Danish Safety and Efficacy Study. Denmark N N Drug Repurposing Ruxolitinib Efficacy - Mortality Severe Cases
2020-00119
4-69		 Pilot study to evaluate the efficacy and safety of mefloquine as prophylaxis in people exposed to the disease caused by the SARS-CoV-2 coronavirus (COVID-19) Spain Y N Drug Repurposing Mefloquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
2020-00212
3-11		 RANDOMIZED CLINICAL TRIAL OF PARALLEL GROUPS TO COMPARE THE EFFICACY OF HYDROXYCHLOROQUINE VS. CYCLOSPORINE - HYDROXYCHLOROQUINE IN THE TREATMENT OF COVID-19 PNEUMONIA. Spain Y N Drug Repurposing Cyclosporine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
2020-00167
8-31		 Randomized controlled trial evaluating the efficacy of vaccination with Bacillus Calmette and Guérin (BCG) in the Prevention of COVID-19 via the strengthening of innate immunity in Health Care Workers.” COVID-BCG France Y N Vaccine BCG Vaccine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
2020-00152
7-14		 COVID-19: addition of azithromycin to chloroquine treatment Netherlands Y N Drug Repurposing Azithromycin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
2020-00188
8-90		 Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic. A randomised controlled multi-center trial. Denmark Y N Vaccine BCG vaccine Efficacy - Other efficacy Exposed individuals (family members, HCP)
2020-00142
1-31		 Clinical trial randomized, unblinded and controled for evaluation of efficacy and safety of hydroxychloroquine chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals. Spain Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
2020-00154
6-19		 A First-in-Human Study in Adult Subjects Hospitalized with Covid-19 to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Efficacy of ARGX-117 Belgium N N Shelved drug or NME ARGX-117 Safety Mild/Moderate Cases, Severe Cases
2020-00202
7-10		 A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19) Sweden Y N Drug Repurposing Enzalutamide Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
2020-00169
7-30		 PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE IN SANITARIES HIGHLY EXPOSED TO COVID-19. (COVIDNA) Spain Y N Drug Repurposing Hydroxychloroquine Efficacy - Other efficacy Exposed individuals (family members, HCP)
2020-00168
6-36		 A double-blind, randomized study versus placebo of avdoralimab (IPH5401), an anti-C5aR antibody, in patients with COVID-19 induced pneumonia France Y N Shelved drug or NME Avdoralimab Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
2020-00141
7-21		 An open label single center randomized controlled trial to evaluate the effect of hydroxychloroquine on viral shedding in mild COVID-19 Belgium Y N Drug Repurposing Hydroxychloroquine Efficacy - Viral load Mild/Moderate Cases
2020-00144
0-26		 Pilot, double-blind clinical trial to evaluate the efficacy and safety of pre-exposure use of hydroxychloroquine versus placebo in the prevention of SARS-CoV-2 (COVID-19) infection in healthcare personnel. Spain Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
2020-00198
7-28		 PRECOV: a randomized controlled clinical trial on the effects of hydroxychloroquine in the prevention of COVID-19 in healthcare workers at risk Italy Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
2020-00244
9-41		 Pilot trial on early treatment with hydroxychloroquine in patients with COVID-19 who do not have hospital admission at diagnosis. Spain Y N Drug Repurposing Hydroxychloroquine Efficacy - Other efficacy Mild/Moderate Cases
2020-00132
7-13		 A SINGLE-BLINDED RANDOMIZED, PLACEBO-CONTROLLED PHASE II TRIAL OF PROPHYLACTIC TREATMENT WITH ORAL AZITHROMYCIN VERSUS PLACEBO IN CANCER PATIENTS UNDERGOING ANTINEOPLASTIC TREATMENT DURING THE COVID-19 PANDEMIC Austria N N Drug Repurposing Azithromycin Efficacy - Infection rate (prevention) Other
2020-00199
4-66		 Ramdomised clinical trial of ivermectin for treatment and prophylaxis of COVID-19 Spain Y N Drug Repurposing Ivermectin Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP), Mild/Moderate Cases
2020-00223
3-15		 A randomized, single blind, placebo-controlled, parallel-arm study to investigate the safety and preliminary efficacy of Niclosamide and Camostat alone and in combination to treat Covid-19 (“NICCAM”) Germany Y Y Drug Repurposing Niclosamide, Camostat Safety Mild/Moderate Cases
2020-00177
7-71		 Ruxolitinib therapy to Avoid Ventilation and improve outcome for deteriorating COVID-19 patiENts - RAVEN United Kingdom N N Drug Repurposing Ruxolitinib Efficacy - Other efficacy Severe Cases
2020-00174
0-26		 A multi-centre open-label two-arm randomised superiority clinical trial of Azithromycin versus usual care In Ambulatory COVID-19 (ATOMIC2) United Kingdom Y N Drug Repurposing Azithromycin Efficacy - Other efficacy Mild/Moderate Cases
2020-00180
3-17		 A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants from Birth to < 18 Years of Age with COVID-19 United Kingdom N N Shelved drug or NME Remdesivir Safety Mild/Moderate Cases, Severe Cases, Other
2020-00161
8-39		 A Phase II, randomized, open–label study to evaluate the efficacy and tolerability of treatment with vafidemstat in combination with standard of care treatment to prevent Acute Respiratory Distress Syndrome (ARDS) in adult severely ill patients with COVID-19. Spain Y N Drug Repurposing Vafidemstat Efficacy - Clinical improvement (except WHO scale) Severe Cases
2020-00209
1-12		 Multicenter, randomized, double-blind, placebo-controlled study investigating efficacy, safety and tolerability of ivermectin HUVE-19 in patients with proven SARS-CoV-2 infection (COVID-19) and manifested clinical symptoms. Bulgaria Y N Drug Repurposing Ivermectin Efficacy - Viral load Mild/Moderate Cases, Severe Cases
2020-00221
1-21		 A Phase II, randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in diabetic patients hospitalised with suspected or confirmed COVID-19. The ARCADIA Trial United Kingdom Y N Shelved drug or NME AZD1656 Efficacy - WHO scale Other
2020-00144
8-24		 Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 United Kingdom Y Y Drug Repurposing Hydroxychloroquine, Ritonavir/lopinavir Efficacy - Other efficacy General population
2020-00175
0-22		 MATIS: Phase 2/3, Randomised, Open-Label, Single-Site, Multi-Arm Trial of Ruxolitinib Plus Best Supportive Treatment (BST) versus Fostamatinib Plus BST versus BST for COVID-19 pneumonia United Kingdom Y Y Drug Repurposing Ruxolitinib, Fostamatinib Efficacy - Other efficacy Mild/Moderate Cases
2020-00172
1-31		 Can a sinus rinse and mouth wash reduce viral load in COVID-19 positive individuals? United Kingdom Y N Shelved drug or NME iodonated Povidone Efficacy - Viral load Mild/Moderate Cases, Severe Cases
2020-00129
6-33		 Efficacy and safety of 72-hour infusion of Prostacyclin (1 ng/kg/min) in patients with COVID-19 induced respiratory failure – a multicentre randomized, placebo-controlled, blinded, investigator-initiated trial Denmark Y N Drug Repurposing Iloprost Efficacy - Oxygen parameters Severe Cases
2020-00167
1-32		 A multi-center, open-label, randomized parallel controlled evaluation on the efficacy and safety of BDB-001 injection in the treatment of progressive severe COVID-19 in phase II Spain Y N Shelved drug or NME BDB-001 Efficacy - Oxygen parameters Severe Cases
2020-00160
5-23		 Effectiveness of the combined treatment with hydroxycloroquine and azithromycin vs lopinavir/ritonavir + hydroxycloroquine in hospitalized patients with confirmed COVID-19 infection Spain Y N Drug Repurposing Hydroxychloroquine, Azithromycin Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
2020-00247
2-12		 Lanadelumab for treatment of COVID-19 disease Netherlands Y N Drug Repurposing Lanadelumab Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
2020-00192
1-30		 Steroids and unfractionated heparin in critically-ill patients with pneumonia from COVID-19 infection. A multicenter, interventional, randomized, three arms study design. Italy Y N Drug Repurposing Methylprednisolone Efficacy - Mortality Severe Cases
2020-00192
9-31		 Controlled, randomized, non-blind trial on the usefulness of pioglitazone treatment in patients with type 2 diabetes mellitus and COVID-19. Spain Y N Drug Repurposing Pioglitazone Efficacy - Clinical improvement (except WHO scale) Other
2020-00130
8-40		 Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19 Italy N N Drug Repurposing Enoxaparin Efficacy - Mortality Mild/Moderate Cases, Severe Cases
2020-00158
7-29		 Hydroxychloroquine efficacy in preventing SARS-CoV-2 infection and CoVid-19 disease severity during pregnancy Spain Y N Drug Repurposing Hydroxychloroquine Efficacy - Viral load Exposed individuals (family members, HCP), Mild/Moderate Cases
2020-00199
5-13		 A multicentre, open-label clinical trial to evaluate the effectiveness and safety of intravenous tocilizumab for treating patients with COVID-19 pneumonia: the BREATH-19 Study Spain Y N Drug Repurposing Tocilizumab Efficacy - Mortality Mild/Moderate Cases, Severe Cases
2020-00212
0-37		 An open-label, adaptive randomized, controlled multicenter study to evaluate the efficacy and safety of RESP301 plus standard of care (SOC) compared to SOC alone in hospitalized participants with COVID-19 requiring supplemental oxygen (NOCoV2) United Kingdom Y N Shelved drug or NME RESP301 Efficacy - WHO scale Severe Cases
2020-00190
4-41		 Glasgow Early Treatment Arm FavIpiravir? : A randomized controlled study of favipiravir as an early treatment arm in COVID-19 patients United Kingdom Y N Drug Repurposing Favipiravir Efficacy - WHO scale Mild/Moderate Cases
2020-00176
5-37		 Pragmatic clinical trial to evaluate the efficacy of hydroxychloroquine in the treatment of COVID-19 infection in two cohorts: patients with oncohaematological disease and SARS-CoV-2 positive without radiological alteration and sars-cov-2 positive professionals without radiological alteration Spain N N Drug Repurposing Hydroxychloroquine Efficacy - Clinical improvement (except WHO scale) Other
2020-00163
5-27		 A Phase 2, Randomized, Open-label Clinical Trial comparing the Safety and Efficacy of Hydroxychloroquine, and Standard of Care to a Combination of Masitinib, Isoquercetin, and Standard of Care for the Treatment of Hospitalized Moderate and Severe COVID-19 Patients. France Y N Drug Repurposing Masitinib, Isoquercetin Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
2020-00153
6-98		 Prophylaxis of COVID-19 infection with hydroxychloroquine in healthcare personnel with high risk of infection. Spain N N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
2020-00127
0-29		 An adaptive Phase 2/3, randomized, open-label study assessing efficacy and safety of hydroxychloroquine for hospitalized patients with moderate to severe COVID-19 United Kingdom Y N Drug Repurposing Hydroxychloroquine Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
2020-00138
6-37		 Uno studio randomizzato multicentrico in aperto per valutare l’efficacia della somministrazione precoce del Tocilizumab (TCZ) in pazienti affetti da polmonite da COVID-19. Italy Y N Drug Repurposing Tocilizumab Efficacy - Clinical improvement (except WHO scale) Severe Cases
2020-00160
3-16		 A RANDOMIZATION, MULTICENTRIC, OPEN-LABEL, CONTROLLED, CLINICAL TRIAL TO INVESTIGATE THE EFFECTIVENESS OF EARLY CHOLCHICINE ADMINISTRATION IN PATIENTS OVER 70 YEARS OF AGE WITH HIGH RISK OF DEVELOPING SEVERE PULMONARY COMPLICATIONS ASSOCIATED WITH CORONAVIRUS SARS-CoV2 PNEUMONIA (COVID-19) Spain Y N Drug Repurposing Colchicine Efficacy - Mortality Mild/Moderate Cases, Severe Cases
2020-00150
2-38		 A randomised, double blind, placebo controlled, Phase 2 trial investigating the safety and efficacy of C21 in hospitalised subjects with COVID-19 infection not requiring mechanical ventilation United Kingdom Y N Shelved drug or NME C21 Other Mild/Moderate Cases
2020-00170
4-42		 Controlled and randomised trial to assess the safety and efficacy of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in hospital healthcare personnel (Sanitarios sin COVID-19 -SANsinCOVID-19). Spain Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
2020-00184
1-38		 Colchicine for the Treatment of Hyperinflammation associated with Pneumonia due to COVID-19 Spain Y N Drug Repurposing Colchicine Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
2020-00149
2-33		 Interest in the administration of Dornase alpha aerosol in ARDS secondary to respiratory infection by the coronavirus SRASCoV-2 / COVID-19 France Y N Drug Repurposing Dornase alfa Efficacy - Oxygen parameters Severe Cases
2020-00176
6-11		 Losartan and spironolactone treatment for COVID-19 patients with acute respiratory failure in intensive care unit France Y N Drug Repurposing Losartan, Spironolactone Efficacy - Other efficacy Severe Cases
2020-00180
8-42		 PHASE II CLINICAL TRIAL, SINGLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED TO EXPLORE THE EFFECTIVENESS AND SAFETY OF MELATONIN I.V. IN PATIENTS WITH COVID-19 ENTERED INTO THE ICU (MELCOVID STUDY) Spain Y N Drug Repurposing Melatonin Efficacy - Mortality Severe Cases
2020-00120
9-22		 Platform Randomised trial of INterventions against COVID-19 In older peoPLE United Kingdom Y N Drug Repurposing Hydroxychloroquine, Azithromycin Efficacy - Other efficacy General population
2020-00144
5-39		 PRAGMATIC, CONTROLLED, OPEN, SINGLE CENTER, RANDOMIZED, PHASE II CLINICAL TRIAL TO EVALUATE METHYLPREDNISOLONE PULSES AND TACROLIMUS IN HOSPITALIZED PATIENTS WITH SEVERE PNEUMONIA SECONDARY TO COVID-19 (TACROVID) Spain Y N Drug Repurposing Methylprednisolone, Tacrolimus Efficacy - Clinical improvement (except WHO scale) Severe Cases
2020-00180
7-18		 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-center Study of an Inhaled Pan-Janus Kinase Inhibitor, TD-0903, to Treat Symptomatic Acute Lung Injury Associated with COVID-19 United Kingdom Y N Shelved drug or NME TD-0903 Safety Severe Cases
2020-00168
2-36		 Double-blind, placebo-controlled phase I/II clinical trial to evaluate the safety and efficacy of allogeneic mesenchymal stem cells (MSV®-allo) in acute respiratory failure in patients with COVID-19 pneumonia. Spain Y N Cell/Blood based ND:Stem cells Efficacy - Other efficacy Severe Cases
2020-00136
7-88		 Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia. A double-blinded, randomized, multi-stage, 6-armed placebo-controlled trial in the framework of an adaptive trial platform Denmark Y Y Drug Repurposing, Cell/Blood based Hydroxychloroquine, Baricitinib, Sarilumab, ND:Convalescent plasma Efficacy - Mortality Mild/Moderate Cases, Severe Cases
2020-00203
2-69		 Single-center, randomized, open-label clinical trial on the efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 Spain Y N Drug Repurposing Tocilizumab Efficacy - Other efficacy Mild/Moderate Cases
2020-00164
0-26		 A pilot, open label, phase II clinical trial of nebulised recombinant tissue-Plasminogen Activator (rtPA)in patients with COVID-19 ARDS: The Plasminogen Activator COVID-19 ARDS (PACA) trial United Kingdom N N Drug Repurposing Alteplase Efficacy - Oxygen parameters Severe Cases
2020-00211
1-22		 A multi-centre, randomised, double-blind, placebo-controlled phase III study assessing the impact of BCG vaccination on the incidence and course of SARS-CoV-2 infection among healthcare workers in Poland during the COVID-19 pandemic. Poland Y N Vaccine ND:Vaccine Efficacy - Mortality Exposed individuals (family members, HCP)
2020-00218
6-34		 Efficacy of the early use of corticotherapy in CoV-2 infection to prevent the progression of acute respiratory distress syndrome (ARDS) in COVID-19 Spain N N Drug Repurposing Methylprednisolone Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
2020-00247
6-13		 A study to assess the safety and efficacy of Clazakizumab in patients with COVID-19 and kidney disease. United Kingdom N N Shelved drug or NME Clazakizumab Efficacy - Other efficacy Other
2020-00146
9-35		 A multicenter, open, randomized, non-commercial study to evaluate the efficacy and safety of chloroquine phosphate in the outpatient treatment of COVID-19 in combination with telemedicine care for patients with SARS-CoV-2 infection with the risk of developing complications to reduce the risk of COVID-19-related hospitalization and death. Poland Y N Drug Repurposing Chloroquine Efficacy - Other efficacy Mild/Moderate Cases
2020-00180
5-21		 Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination with Oseltamivir, in Adults with Coronavirus Disease COVID-19 United Kingdom Y N Shelved drug or NME IMU-838 Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
2020-00125
0-21		 COVID-19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease upon Hydroxychloroquine and Azithromycin Therapy in French Cancer patients France N N Drug Repurposing Hydroxychloroquine, Azithromycin Efficacy - Clinical improvement (except WHO scale) Other
2020-00143
7-12		 Random, controlled, open, one-site clinical trial in adult patients with COVID-19 severe pneumonia treated with immunomodulatory drugs Spain Y Y Drug Repurposing Cyclosporine, Tocilizumab Efficacy - Mortality Severe Cases
2020-00165
9-42		 Pilot study of antithrombin as prophylaxis of acute respiratory distress syndrome in patients with COVID-19 Spain Y N Cell/Blood based ND:Human antithrombin Efficacy - Clinical improvement (except WHO scale) Severe Cases
2020-00188
2-36		 ANTI-INFLAMMATORY CLARITHROMYCIN TO IMPROVE SARS-CoV-2 (COVID-19) INFECTION EARLY: THE ACHIEVE OPEN-LABEL NON-RANDOMIZED CLINICAL TRIAL Greece N N Drug Repurposing Clarithromycin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
2020-00147
4-29		 Pilot study to evaluate the potential of ivermectin to reduce COVID-19 transmission Spain Y N Drug Repurposing Ivermectin Efficacy - Viral load Mild/Moderate Cases
2020-00164
3-13		 A randomised double-blind placebo-controlled trial of Brensocatib (INS1007) in patients with severe COVID-19 United Kingdom Y N Shelved drug or NME Brensocatib Efficacy - WHO scale Severe Cases
2020-00182
5-29		 CLINICAL TRIAL OF THE USE OF ANAKINRA (ANTI IL-1) IN CYTOKINE STORM SYNDROME (CSS) SECONDARY TO COVID-19 Spain Y N Drug Repurposing Anakinra Efficacy - Oxygen parameters Severe Cases
2020-00160
6-33		 Randomized clinical trial to evaluate the efficacy of hydroxychloroquine associated or not with azithromycin as a treatment for COVID-19 infection. Spain Y N Drug Repurposing Hydroxychloroquine, Azithromycin Efficacy - Viral load Mild/Moderate Cases
2020-00124
3-15		 Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2. Belgium Y N Drug Repurposing Itraconazole Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
2020-00137
5-32		 Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial Netherlands Y N Drug Repurposing Tocilizumab Efficacy - Mortality Mild/Moderate Cases, Severe Cases
2020-00189
0-56		 Double-blind randomized placebo-controlled clinical trial to evaluate the efficacy and safety of the use of intravenous gammaglobulins in the treatment of patients with COVID-19 Spain Y N Cell/Blood based ND:Gamma globulin Efficacy - Mortality Mild/Moderate Cases, Severe Cases
2020-00123
6-10		 COUNTER-COVID - Oral imatinib to prevent pulmonary vascular leak in COVID-19 – a randomized, single-blind, placebo controlled, clinical trial in patients with severe COVID-19 disease Netherlands Y N Drug Repurposing Imatinib Efficacy - Other efficacy Severe Cases
2020-00182
3-15		 Evaluation of the concentration-effect relationship of enoxaparin for thromboembolic prevention in COVID-19 resuscitation patients. COV-ENOX study France N N Drug Repurposing Enoxaparin Efficacy - Other efficacy Severe Cases
2020-00195
3-36		 A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of Prolastin® plus Standard Medical Treatment (SMT) versus SMT alone in Hospitalized Subjects with COVID-19. Spain Y N Drug Repurposing Prolastin Efficacy - Other efficacy Severe Cases
2020-00169
6-32		 A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) plus Standard Medical Treatment (SMT) versus SMT alone in Hospitalized Subjects with COVID-19 Spain Y N Cell/Blood based ND:Human normal immunoglobulin Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
2020-00149
3-29		 Charité trial of Cenicriviroc (CVC) treatment for COVID-19 patients Germany Y N Shelved drug or NME Cenicriviroc Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
2020-00227
4-28		 Usefulness of vitamin D on morbidity and mortality of SARS-COV-2 virus infection (Covid-19) at the Central University Hospital of Asturias Spain Y N Drug Repurposing Cholecalciferol Efficacy - Viral load Mild/Moderate Cases, Severe Cases
2020-00196
0-28		 Efficacy of vitamin D treatment in patients diagnosed with pneumonia who require hospital admission and have vitamin D deficiency and a positive diagnosis for SARS-Cov-2 (COVID-19) Spain Y N Drug Repurposing Vitamin D3 Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
2020-00184
9-39		 Aerosolized DNase I for the treatment of severe respiratory failure in COVID-19 - a phase 2, randomized controlled trial Sweden Y N Drug Repurposing Dornase alfa Efficacy - Oxygen parameters Severe Cases
2020-00193
4-37		 USE OF CORTICOSTEROIDS IN PATIENTS WITH SARS-COV2 CORONAVIRUS INFECTION (GLUCOCOVID). Pragmatic trial inserted in real practice during a pandemic COVID-19 Spain Y N Drug Repurposing Methylprednisolone Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
2020-00229
3-28		 Resolving inflammatory storm in COVID-19 patients by Omega-3 polyunsaturated fatty acids. - A single-blind, randomized, placebo-controlled feasibility study Sweden Y N Drug Repurposing Omegaven Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
2020-00155
8-23		 Hydroxychloroquine sulfate early administration in symptomatic out of hospital COVID-19 positive patients. Hydro-Stop-COVID19 Trial Italy Y N Drug Repurposing Hydroxychloroquine Efficacy - Viral load Mild/Moderate Cases
2020-00245
6-21		 Enhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine: a possible preventive approach against COVID-19 (BCG-PLUS) Netherlands Y Y Drug Repurposing, Vaccine MMR Vaccine, Alendronic acid Other General population
2020-00174
7-21		 Impact of Montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): an investigator-initiated open labelled randomized controlled pragmatic trial Portugal Y N Drug Repurposing Montelukast Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
2020-00216
6-13		 Randomized, open, multicenter phase II clinical trial, proof of concept, to evaluate efficacy and safety of Icatibant in hospitalized patients with SARS-COV-2 (COVID-19) without assisted ventilation compared with standard care Spain Y N Drug Repurposing Icatibant Safety Mild/Moderate Cases, Severe Cases
2020-00231
0-41		 Intravenous Metoprolol in Respiratory Distress Due to COVID-19: Pilot Study "MADRID-COVID" Spain N N Drug Repurposing Metoprolol Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
2020-00177
0-30		 COVID 19: Experimental use of tocilizumab (Roactemra®) in severe SARS-CoV-2 related pneumonia. Belgium Y N Drug Repurposing Tocilizumab Efficacy - WHO scale Severe Cases
2020-00133
3-13		 Dexamethasone associated with hydroxychloroquine vs. hydroxychloroquine alone for the early treatment of severe ARDS caused by COVID-19 : a randomized controlled trial France Y N Drug Repurposing Dexamethasone Efficacy - Mortality Severe Cases
2020-00210
6-68		 Favipiravir, lopinavir/ritonavir or combination therapy: a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19 United Kingdom Y Y Drug Repurposing Favipiravir, Lopinavir/ritonavir Efficacy - Viral load Mild/Moderate Cases
2020-00185
4-23		 Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 Italy Y Y Drug Repurposing Siltuximab, Tocilizumab, Canakinumab, Baricitinib, Methylprednisolone, Sarilumab Efficacy - Oxygen parameters Mild/Moderate Cases
2020-00140
8-41		 A prospective, randomized, double blinded placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia Germany Y N Drug Repurposing Tocilizumab Efficacy - Other efficacy Severe Cases
2020-00248
2-34		 Efficacy and safety of Octagam 10% therapy in COVID-19 patients with severe disease progression United States Y N Cell/Blood based ND:Octagam Efficacy - WHO scale Severe Cases
2020-00130
6-35		 Protective role of inhaled steroids for COVID-19 infection France Y N Drug Repurposing Budesonide, Formoterol Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
2020-00102
3-14		 A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFNß-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection (COVID-19) United Kingdom Y N Drug Repurposing Interferon beta-1a Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
2020-00154
1-39		 Pilot study of single-dose bevacizumab as a treatment for acute respiratory distress syndrome in patients with COVID-19 Spain N N Drug Repurposing Bevacizumab Efficacy - Mortality Severe Cases
2020-00136
3-85		 COVID-19 Prophylaxis with hydroxychloroquine, Vitamin D, and Zinc supplementation in Danish nursing home residents – a randomized controlled trial Denmark Y N Drug Repurposing Hydroxychloroquine, Zinc, Vitamin D3 Efficacy - Infection rate (prevention) General population
2020-00163
6-95		 Subcutaneous and Intravenous anakinra in COVID-19 Infection - Feasibility & Pharmacokinetics/ Pharmacodynamics study United Kingdom Y N Drug Repurposing Anakinra Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
2020-00176
7-86		 An open-label, multi-centre, randomised trial comparing different doses of single-dose tocilizumab in adults with severe, non-critical, PCR-confirmed COVID-19 infection with evidence of progressive decline in respiratory function and evolving systemic inflammation on time to intubation, non-invasive ventilation and/or all-cause mortality Ireland Y N Drug Repurposing Tocilizumab Efficacy - Clinical improvement (except WHO scale) Severe Cases
2020-00139
1-15		 A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness. Ireland N N Cell/Blood based ND:Alpha-1 antitrypsin Efficacy - Other efficacy Severe Cases
2020-00136
4-29		 Phase I/II clinical trial to evaluate the safety and efficacy of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded in patients with severe COVID-19 pneumonia Spain Y N Cell/Blood based ND:Stem cells Safety Severe Cases
2020-00178
6-36		 Recombinant InterLeukin-7 (CYT107) to Improve clinical outcomes in lymphopenic pAtients with COVID-19 infection “ILIAD 7 trial” France Y N Drug Repurposing CYT107 Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
2020-00231
2-43		 Clinical trial, PHASE III, randomized, open-label, to evaluate the efficacy of administering high-dose cholecalciferol orally alongside standard therapy in patients with COVID-19 pneumonia (COVID-19 HUSO). Spain Y N Drug Repurposing Vitamin D3 Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
2020-00197
2-13		 Randomised controlled trial comparing efficacy and safety of high versus low low-molecular weight heparin dosages in hospitalised patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD) Italy Y N Drug Repurposing Enoxaparin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
2020-00149
8-63		 Adaptive design phase 2 to 3, randomized, double- blind, multicenter, to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BIO101 in the prevention of the respiratory deterioration in hospitalized patients with COVID-19 pneumonia (severe stage) France Y N Shelved drug or NME BIO101 Efficacy - Other efficacy Severe Cases
2020-00186
0-27		 AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment United Kingdom Y N Shelved drug or NME Nomacopan Safety Mild/Moderate Cases, Severe Cases
2020-00128
1-11		 Evaluation of the concentration/viral effect relationship of hydroxychloroquine in COVID-19 patients in the intensive care unit. France N N Drug Repurposing Hydroxychloroquine Other Severe Cases
2020-00189
1-14		 Impact of the use of low molecular weight heparins (LMWH), at prophylactic versus intermediate doses, on SARS-CoV2 infection (COVID-19) Spain Y N Drug Repurposing Enoxaparin Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
2020-00159
8-66		 Preliminary randomized controlled trial of poractant alfa (Curosurf®) by fiberoptic bronchoscopy-directed endobronchial administration in acute respiratory distress syndrome (ARDS) due to COVID-19 viral pneumonia. France Y N Drug Repurposing Poractant alfa Efficacy - Oxygen parameters Severe Cases
2020-00143
1-27		 Treatment of Sars-CoV2 infections (COVID-19) with valsartan vs placebo, a three-armed randomized, partly blinded trial Germany Y N Drug Repurposing Valsartan Efficacy - WHO scale Mild/Moderate Cases, Other
2020-00144
2-19		 Pilot, randomized, multicenter, open-label clinical trial of combined use of hydroxychloroquine, azithromycin, and tocilizumab for the treatment of SARS-CoV-2 infection (COVID-19) Spain Y N Drug Repurposing Tocilizumab Efficacy - Mortality Mild/Moderate Cases
2020-00162
2-64		 OUTPATIENT TREATMENT OF COVID-19 WITH EARLY PULMONARY CORTICOSTEROIDS AS AN OPPORTUNITY TO MODIFY THE COURSE OF THE DISEASE Spain Y N Drug Repurposing Prednisone Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
2020-00182
7-15		 EARLY TREATMENT OF PNEUMONIA COVID-19 WITH GLUCOCORTICOIDS. RANDOMIZED CONTROLLED CLINICAL TRIAL Spain Y N Drug Repurposing Methylprednisolone Efficacy - Mortality Mild/Moderate Cases, Severe Cases
2020-00103
1-27		 Treatment of non-severe confirmed cases of COVID-19 and chemoprophylaxis of their contacts as prevention strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study) Spain Y N Drug Repurposing Darunavir Efficacy - Infection rate (prevention) Mild/Moderate Cases
2020-00175
4-21		 An open prospective randomized therapeutic trial using ANAKINRA or TOCILIZUMAB alone or in combination with RUXOLITINIB in severe stage 2b and 3 COVID-19 disease France Y N Drug Repurposing Anakinra, Tocilizumab, Ruxolitinib Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
2020-00111
3-21		 Randomised Evaluation of COVID-19 Therapy (RECOVERY) United Kingdom Y Y Drug Repurposing Lopinavir/ritonavir, Dexamethasone, Azithromycin, Tocilizumab Efficacy - Mortality Mild/Moderate Cases, Severe Cases
2020-00145
0-22		 Phase II Clinical Trial to explore the efficacy of allogeneic mesenchymal cells from umbilical cord tissue in patients with severe pulmonary involvement by COVID-19. Spain Y N Cell/Blood based ND:Stem cells Efficacy - Mortality Severe Cases
2020-00089
0-25		 Treatment of Coronavirus SARS-Cov2 Respiratory Infections with Hydroxychloroquine France N N Drug Repurposing Hydroxychloroquine Efficacy - Viral load Mild/Moderate Cases, Severe Cases
2020-00170
9-21		 Effectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolism in coronavirus disease 2019 (COVID-19) hospitalized patients : The randomized multicentric controlled open-label trial COVI-DOSE France Y N Drug Repurposing Enoxaparin, Tinzaparin, Nadroparin Other Mild/Moderate Cases
2020-00125
5-40		 Sarilumab Treatment In cytoKinE storm caused by infection with COVID-19. Spain N N Drug Repurposing Sarilumab Efficacy - Clinical improvement (except WHO scale) Severe Cases
2020-00172
2-66		 Plasma turnover in patients with COVID-19 disease and invasive mechanical ventilation: a randomized study Spain Y N Drug Repurposing Albumin Efficacy - Mortality Severe Cases
2020-00161
4-38		 Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2. Belgium Y N Drug Repurposing Azithromycin Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
2020-00132
1-31		 Prospective, phase II, randomized, open-label, parallel group study to evaluate the efficacy of hydroxychloroquine together with baricitinib, imatinib or early lopinavir / ritonavir in patients with SARS Cov2 pneumonia (COVID-19 HUF) Spain Y Y Drug Repurposing Hydroxychloroquine, Baricitinib, Imatinib, Lopinavir/ritonavir Efficacy - Clinical improvement (except WHO scale) Severe Cases
2020-00153
1-27		 Clinical trial of Sarilumab in adults hospitalized with COVID-19 presenting cytokine release syndrome Spain Y N Drug Repurposing Sarilumab Efficacy - Oxygen parameters Severe Cases
2020-00142
0-34		 Senicapoc in COVID-19 Patients with Severe Respiratory Insufficiency – A Randomized, Open-Label, Phase II Trial Denmark Y N Shelved drug or NME Senicapoc Efficacy - Oxygen parameters Severe Cases
2020-00124
6-18		 Cohort Multiple randomized controlled trials open-label of immune modulatory drugs and other treatments in COVID-19 patients France Y N Drug Repurposing Sarilumab, Tocilizumab, Nivolumab, Bevacizumab, Tinzaparin, Hydroxychloroquine, Eculizumab, Baricitinib, Secukinumab Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
2020-00124
4-26		 COVID-19: Efficacy of solnatide to treat pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS - a pilot-trial. Austria Y N Shelved drug or NME Solnatide Efficacy - Other efficacy Severe Cases
2020-00139
0-76		 A phase 3, randomized, open-labeled, multi-center study comparing clinical efficacy and safety of intravenous sarilumab plus standard of care compared to standard of care, in the treatment of patients with severe COVID-19 pneumonia Italy Y N Drug Repurposing Sarilumab Efficacy - Clinical improvement (except WHO scale) Severe Cases
2020-00131
0-38		 A randomized, prospective, open label clinical trial on the use of convalescent plasma compared to best supportive care in patients with severe COVID-19 Germany Y N Cell/Blood based ND:Convalescent plasma Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
2020-00271
3-17		 A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MSTT1041A OR UTTR1147A IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA Spain Y Y Shelved drug or NME MSTT1041A, UTTR1147A Efficacy - WHO scale Severe Cases
2020-00140
9-21		 A prospective, multicenter, randomized, parallel, double-blind, placebo-controlled phase IIb clinical trial to evaluate intravenous infusion of Defibrotide in the prevention and treatment of respiratory distress and cytokine release syndrome in patients with COVID-19. Spain Y N Drug Repurposing Defibrotide Efficacy - Mortality Severe Cases
2020-00173
2-10		 Ruxolitinib for treatment of Covid-19 induced lung injury ARDS (RuXoCoil) A single-arm, open-label, proof of concept study Germany N N Drug Repurposing Ruxolitinib Efficacy - Mortality Severe Cases
2020-00163
2-10		 A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease Germany Y N Cell/Blood based ND:Convalescent plasma Efficacy - WHO scale Severe Cases
2020-00219
3-27		 Double-blind, randomized, controlled, clinical trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 Spain Y N Cell/Blood based ND:Stem cells Efficacy - Oxygen parameters Severe Cases
2020-00115
6-18		 Randomized clinical trial to evaluate the efficacy of different treatments in patients with COVID-19 who require hospitalization Spain Y Y Drug Repurposing Lopinavir/ritonavir, Hydroxychloroquine, Azithromycin Efficacy - Mortality Severe Cases
2019-00268
8-89		 Phase 1/2 clinical study to assess the feasibility, safety, tolerability and preliminary efficacy of the administration of HCR040, a drug whose active substance is HC016, allogeneic adipose-derived adult mesenchymal stem cells expanded and pulsed with H2O2, in patients with acute respiratory distress syndrome. (included patients COVID-19) Spain Y N Cell/Blood based ND:Stem cells Safety Severe Cases
2020-00176
8-27		 "STUDY OF THE EFFICIENCY OF NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE" GERONIMO 19 France N N Cell/Blood based Immunoglobulin Efficacy - Mortality Severe Cases
2020-00131
9-26		 Multicenter, randomized, controlled, open-label clinical trial to assess the prognostic implications of rosuvastatin treatment in patients discharged after hospitalization for COVID-19 Positive. Spain Y N Drug Repurposing Rosuvastatin Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
2020-00137
9-34		 Sedation with sevoflurane versus propofol in patients with Acute Respiratory Distress Syndrome caused by COVID-19 infection Spain Y N Drug Repurposing Sevoflurane Efficacy - Oxygen parameters Severe Cases
2020-00125
7-51		 The Danish Pre-HCQ Dialysis Study: Hydroxychloroquine for prevention of COVID-19 in dialysis-treated patients with end-stage renal disease - A multicenter parallel-group open randomized clinical trial Denmark Y N Drug Repurposing Hydroxychloroquine Other Other
2020-00197
1-33		 Pragmatic study "CORIVER": Ivermectin as antiviral treatment for patients infected by SARS-COV2 (COVID-19) Spain Y N Drug Repurposing Ivermectin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
2020-00126
6-11		 Two-center, randomized, controlled clinical trial with two treatment arms to evaluate the safety and efficacy of intravenous administration of expanded allogeneic adipose tissue adult mesenchymal cells in critically ill patients COVID-19. Spain Y N Cell/Blood based ND:MSC Efficacy - Mortality Severe Cases
2020-00171
7-20		 Prevention and treatment with Calcifediol of Coronavirus COVID-19-induced acute respiratory syndrome (SARS) Spain Y N Drug Repurposing Calcifediol Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
2020-00157
3-78		 Recombinant InterLeukin-7 (CYT107) to Improve clinical outcomes in lymphopenic pAtients with COVID-19 infection United States Y N Shelved drug or NME CYT-107 Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
2020-00130
3-16		 Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on Survival in Elderly Hospitalized Patients with VIDOC-19 : A Randomized, Multi-Centre, Adaptive, Blinded Study France Y Y Drug Repurposing Hydroxychloroquine, Telmisartan, Azithromycin Efficacy - Mortality Severe Cases, Other
2020-00151
1-25		 Randomized open-blind controlled trial to study the benefit of Colchicine in Patients with COVID-19 Spain Y N Drug Repurposing Colchicine Efficacy - WHO scale Severe Cases
2020-00140
6-27		 Randomized open label trial assessing efficacy and safety of hydroxychloroquine plus azithromycin versus hydroxychloroquine for hospitalized patients with COVID-19 France Y N Drug Repurposing Azithromycin Efficacy - WHO scale Severe Cases
2020-00190
3-17		 A randomized clinical trial (IIIb) of eficacy of a single dose of Tocilizumab or a combination of Tocilizumab plus Vitamin D (single i.m. dose) for the treatment of the COVID-19 hyperimmune complication. Assessment of IL-6. Spain Y Y Drug Repurposing Tocilizumab, Vitamin D3 Efficacy - Mortality Severe Cases
2020-00126
5-36		 A multicentre, prospective, randomised trial comparing standard of care (SOC) alone, SOC plus hydroxychloroquine monotherapy or SOC plus a combination of hydroxychloroquine and azithromycin in the treatment of non-critical, SARS-CoV-2 PCR-positive population not requiring immediate resuscitation or ventilation but who have evidence of clinical decline. Ireland Y Y Drug Repurposing Azithromycin, Hydroxychloroquine Efficacy - Other efficacy Mild/Moderate Cases
2020-00103
8-36		 A Multi-site Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults Germany N N Vaccine BNT162 vaccine Safety General population
2020-00203
7-15		 Multicenter, randomized, open-label study to evaluate the efficacy and safety of SOC + Sarilumab versus Standard of Care for the Early Treatment of COVID-19-pneumonia in Hospitalized Patients Spain Y N Drug Repurposing Sarilumab Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
2020-00295
2-18		 Targeting de novo Pyrimidine Biosynthesis by leflunomide as a Novel Concept for the Treatment of Corona Virus Disease 2019 (COVID-19) United Kingdom Y N Drug Repurposing Leflunomide Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
2020-00173
9-28		 A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19. Belgium Y N Drug Repurposing Aprotinin, Anakinra Efficacy - Viral load Mild/Moderate Cases, Severe Cases
2020-00130
7-16		 Efficacy and Safety of corticoids in patients with adult respiratory distress syndrome (ARDS) secondary to COVID-19. Spain Y N Drug Repurposing Methylprednisolone Efficacy - Mortality Severe Cases
2020-00173
6-95		 ACCORD 2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients United Kingdom Y N Drug Repurposing, Shelved drug or NME Bemcentinib, MEDI3506, Acalabrutinib, Zilucoplan Efficacy - WHO scale Severe Cases
2020-00126
2-11		 Randomized, controlled, blinded clinical trial for the evaluator, to evaluate the efficacy and safety of treatment with cyclosporine A (CsA) associated with standard treatment versus standard treatment only in hospitalized patients with confirmed infection by COVID-19 Spain Y N Drug Repurposing Cyclosporine Efficacy - Clinical improvement (except WHO scale) Severe Cases
2020-00150
5-22		 Double-blind, randomized, parallel, placebo-controlled pilot clinical trial, nested in a prospective cohort observational study, for the evaluation of the efficacy and safetyof two doses of WJ-MSC in patients with acute respiratory distress syndrome secondary to infection by COVID-19 Spain Y N Cell/Blood based ND:Stem cells Efficacy - Mortality Mild/Moderate Cases, Severe Cases
2020-00129
0-74		 Efficacy and safety of sarilumab in the early treament of hospitalized patients with mild-moderate neumonia and COVID19 infection versus standard of care Spain Y N Drug Repurposing Sarilumab Efficacy - WHO scale Mild/Moderate Cases
2020-00141
3-20		 Phase 2, randomized, open-label study to compare the efficacy and safety of siltuximab vs. corticosteroids in hospitalized patients with COVID19 pneumonia Spain Y N Drug Repurposing Siltuximab, Methylprednisolone Efficacy - Other efficacy Severe Cases
2020-00170
7-16		 PHASE III RANDOMIZED, UNICENTRIC, OPEN, CONTROLLED CLINICAL TRIAL TO DEMONSTRATE THE EFFECTIVENESS OF TOCILIZUMAB AGAINST SYSTEMIC CORTICOTHERAPY IN PATIENTS ENTERED BY COVID-19 WITH BILATERAL PNEUMONIA AND BAD EVOLUTION Spain Y N Drug Repurposing Tocilizumab Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
2020-00263
2-75		 Multicenter, open-label, randomised trial to assess the efficacy and tolerability of poractant alfa (porcine surfactant, Curosurf®) in hospitalized patients with SARS-COV-19 acute respiratory distress syndrome (ARDS) United States Y N Drug Repurposing Poractant alfa Efficacy - Oxygen parameters Severe Cases
2020-00140
5-23		 Randomized phase II clinical trial of ruxolitinib plus simvastatin in the prevention and treatment of respiratory failure of COVID-19.Ruxo-Sim-20 clinical trial. Spain Y N Drug Repurposing Ruxolitinib, Simvastatin Efficacy - WHO scale Severe Cases
NCT04372602 Duvelisib to Combat COVID-19 United States N N Drug Repurposing Duvelisib Efficacy - Mortality Severe Cases
NCT04482621 Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial United States Y N Drug Repurposing Decitabine Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04425538 A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19). United States N N Drug Repurposing Infliximab Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04454307 Safety and Efficacy of Tramadol in COVID-19 Egyptian Patients Egypt Y N Drug Repurposing Tramadol Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04333550 Application of Desferal to Treat COVID-19 Iran Y N Drug Repurposing Deferoxamine Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04432987 Dornase Alpha for the Treatment of COVID-19 Turkey Y N Drug Repurposing Dornase alfa Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04336904 Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19 Italy Y N Drug Repurposing Favipiravir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04359095 Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia Colombia Y Y Drug Repurposing Hydroxychloroquine, Lopinavir/ritonavir, Azithromycin Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04354831 A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection United States N N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04445285 Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure United States Y N Drug Repurposing Dornase alfa Efficacy - Mortality Severe Cases
NCT04345445 Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression Malaysia Y N Drug Repurposing Tocilizumab, Methylprednisolone Efficacy - Oxygen parameters Severe Cases
NCT04476888 Convalescent Plasma Treatment in COVID-19 Pakistan N N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04366739 Repurposing of Chlorpromazine in Covid-19 Treatment France Y N Drug Repurposing Chlorpromazine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04366960 Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients Italy Y Y Drug Repurposing Enoxaparin Efficacy - Infection rate (prevention) Mild/Moderate Cases, Severe Cases
NCT04361422 Isotretinoin in Treatment of COVID-19 Egypt Y N Drug Repurposing Isotretinoin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04405310 Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial Mexico Y Y Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Severe Cases
NCT04328272 Effectiveness of Hydroxychloroquine in Covid-19 Patients Pakistan Y N Drug Repurposing Hydroxychloroquine, Azithromycin Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04345679 Anti COVID-19 Convalescent Plasma Therapy Hungary N N Cell/Blood based ND:Convalescent plasma Efficacy - Viral load Severe Cases
NCT04461340 Efficacy and Safety of Sirolimus in COVID-19 Infection Egypt Y N Drug Repurposing Sirolimus Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04428801 Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19 United States Y N Cell/Blood based ND:Stem cells Safety Other
NCT04321421 Hyperimmune Plasma for Critical Patients With COVID-19 Italy N N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Severe Cases
NCT04370288 Clinical Application of Methylene Blue for Treatment of Covid-19 Patients Iran Y N Drug Repurposing Methylene blue, Ascorbic acid, N-acetylcysteine Efficacy - Oxygen parameters Severe Cases
NCT04347915 The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19 Korea, Republic of Y N Drug Repurposing Clevudine Efficacy - Other efficacy Mild/Moderate Cases
NCT04333407 Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial. United Kingdom Y Y Drug Repurposing Aspirin, Clopidogrel, Rivaroxaban, Atorvastatin, Omeprazole Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04473690 KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers United States Y N Vaccine KBP-201 Vaccine Safety General population
NCT04470622 Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1) United States Y N Drug Repurposing Aprepitant Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04401423 TXA COVID-19 Clinical Trial United States Y N Shelved drug or NME TXA127 Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04412486 COVID-19 Convalescent Plasma (CCP) Transfusion United States N N Cell/Blood based ND:Convalescent plasma Efficacy - Oxygen parameters Severe Cases
NCT04452669 VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation United States N N Drug Repurposing Epoprostenol Efficacy - Oxygen parameters Severe Cases
NCT04406389 Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial) United States Y Y Drug Repurposing Enoxaparin, Heparin, Fondaparinux, Argatroban Efficacy - Mortality Severe Cases
NCT04463472 Study of COVID-19 DNA Vaccine (AG0301-COVID19) Japan N N Vaccine AG0301 Vaccine Safety General population
NCT04474483 Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19 United States Y N Drug Repurposing Melatonin Safety Mild/Moderate Cases
NCT04393038 ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19 France Y N Shelved drug or NME ABX464 Efficacy - Other efficacy Mild/Moderate Cases
NCT04434248 An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19 Russian Federation Y N Drug Repurposing Favipiravir Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04466657 Antioxidant Therapy for COVID-19 Study Nigeria Y N Drug Repurposing, Other ND:Antioxidant supplements, N-acetylcysteine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04363346 Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia United States N N Shelved drug or NME FT516 Efficacy - Other efficacy Severe Cases
NCT04372979 Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients. France Y N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04456413 Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection United States Y N Cell/Blood based ND:Convalescent plasma Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04333420 Open-label, Randomized Study of IFX-1 in Patients With Severe COVID-19 Pneumonia Netherlands Y N Shelved drug or NME IFX-1 Efficacy - Oxygen parameters Severe Cases
NCT04467151 Administration of Anti-SARS-CoV-2 Convalescent Plasma in Hospitalized, Non-ICU Patients With COVID-19 United States Y N Cell/Blood based ND:Convalescent plasma Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04479358 Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19 United States Y N Drug Repurposing Tocilizumab Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04343755 Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection United States N N Cell/Blood based ND:Convalescent plasma Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04464395 Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients United States N N Shelved drug or NME CPI-006 Safety Mild/Moderate Cases, Severe Cases
NCT04324489 DAS181 for Severe COVID-19: Compassionate Use China N N Shelved drug or NME DAS181 Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04432298 Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Patients With Acute COVID-19 Disease United States Y N Shelved drug or NME Pamrevlumab Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04449965 Povidone-Iodine Rinses in the Management of COVID-19 Canada Y N Shelved drug or NME Povidone-iodine Efficacy - Viral load Mild/Moderate Cases
NCT04392141 Colchicine Plus Phenolic Monoterpenes to Treat COVID-19 Iran Y N Drug Repurposing, Other Colchicine, ND:Dietary supplement Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04370262 Multi-site Adaptive Trials for COVID-19 United States Y N Drug Repurposing Famotidine Efficacy - Mortality Severe Cases
NCT04382586 Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants United States Y N Drug Repurposing Zanubrutinib Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04459286 The Nitazoxanide Plus Atazanavir for COVID-19 Study Nigeria Y N Drug Repurposing Nitazoxanide, Atazanavir/ritonavir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04329611 ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease Canada Y N Drug Repurposing Hydroxychloroquine Efficacy - Other efficacy Mild/Moderate Cases
NCT04335123 Study of Open Label Losartan in COVID-19 United States N N Drug Repurposing Losartan Safety Severe Cases
NCT04321993 Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients Canada Y Y Drug Repurposing Baricitinib Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04376788 Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19 Egypt Y Y Drug Repurposing, Cell/Blood based Methylene blue, ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04360356 Ivermectin and Nitazoxanide Combination Therapy for COVID-19 Egypt Y N Drug Repurposing Ivermectin, Nitazoxanide Efficacy - Viral load Mild/Moderate Cases
NCT04350593 Dapagliflozin in Respiratory Failure in Patients With COVID-19 United States Y N Drug Repurposing Dapagliflozin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04361318 Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19 Egypt Y N Drug Repurposing Hydroxychloroquine, Nitazoxanide Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04375046 Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2 Egypt Y N Shelved drug or NME rbACE2 Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04420299 Clinical Trial on the Efficacy and Safety of Bemiparin in Patients Hospitalized Because of COVID-19 Spain Y N Drug Repurposing Bemiparin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04425629 Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult Patients With COVID-19 United States Y N Shelved drug or NME REGN10987, REGN10933 Safety Mild/Moderate Cases
NCT04352933 PROLIFIC ChemoprophylaxisTrial (COVID-19) United Kingdom Y Y Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04364022 Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland Switzerland Y Y Drug Repurposing Hydroxychloroquine, Lopinavir/ritonavir Efficacy - Other efficacy Exposed individuals (family members, HCP)
NCT04347889 Preventing COVID-19 in Healthcare Workers With HCQ: A RCT United States Y N Drug Repurposing Hydroxychloroquine, Ascorbic acid Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04405102 COVID-19 Ozanimod Intervention Study Canada Y N Drug Repurposing Ozanimod Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04358081 Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease United States Y Y Drug Repurposing Hydroxychloroquine, Azithromycin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04381052 Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection United States N N Shelved drug or NME Clazakizumab Safety Severe Cases
NCT04325633 Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection France Y N Drug Repurposing Naproxen Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04486001 Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19 United States N N Cell/Blood based ND:Stem cells Safety Mild/Moderate Cases, Severe Cases
NCT04464408 Favipiravir Therapy in Adults With Mild COVID-19 Saudi Arabia Y N Drug Repurposing Favipiravir Efficacy - Viral load Mild/Moderate Cases
NCT04382066 Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19 Spain Y Y Shelved drug or NME Plitidepsin Safety Mild/Moderate Cases, Severe Cases
NCT04408456 Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 India Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04380532 Tableted COVID-19 Therapeutic Vaccine Canada N N Shelved drug or NME ND:Convalescent plasma Safety General population
NCT04432103 Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma Mexico N N Cell/Blood based ND:Convalescent plasma Efficacy - Other efficacy Severe Cases
NCT04390178 Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19) Sweden N N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04415086 Treatment of Patients With COVID-19 With Convalescent Plasma Brazil Y N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04485130 DISulfiram for COvid-19 (DISCO) Trial United States Y N Drug Repurposing Disulfiram Safety Mild/Moderate Cases, Severe Cases
NCT04385043 Hyperimmune Plasma in Patients With COVID-19 Severe Infection Italy Y N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Severe Cases
NCT04317092 Tocilizumab in COVID-19 Pneumonia (TOCIVID-19) Italy N N Drug Repurposing Tocilizumab Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04375202 Colchicine in COVID-19: a Pilot Study Italy Y N Drug Repurposing Colchicine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04339660 Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia China Y N Shelved drug or NME ND:Stem cells Other Severe Cases
NCT04465695 Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19 Hong Kong Y Y Drug Repurposing Interferon beta-1b, Clofazimine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04348071 Safety and Efficacy of Ruxolitinib for COVID-19 United States N N Drug Repurposing Ruxolitinib Safety Severe Cases
NCT04340232 Safety and Efficacy of Baricitinib for COVID-19 United States N N Drug Repurposing Baricitinib Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04329832 Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 United States Y N Drug Repurposing Hydroxychloroquine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04388410 Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19 Mexico Y N Cell/Blood based Convalescent plasma Efficacy - Mortality Severe Cases
NCT04489446 Sildenafil in COVID-19 Chile Y N Drug Repurposing Sildenafil Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04426695 Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19 United States Y N Shelved drug or NME REGN10987, REGN10933 Safety Severe Cases
NCT04467047 Safety and Feasibility of Allogenic MSC in the Treatment of COVID-19 Brazil N N Cell/Blood based ND:Stem cells Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04480632 Therapeutic Plasmapheresis in Critically Ill Adult Patients With COVID-19 Confirmed Diagnosis Colombia N N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Severe Cases
NCT04443270 Chloroquine Phosphate Prophylactic Use in Health Personnel Exposed to COVID-19 Patients Mexico N N Drug Repurposing Chloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04324996 A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19 China N Y Cell/Blood based ND:T-cells Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04384497 Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study Sweden N N Cell/Blood based ND:Convalescent plasma Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04354597 Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients Jordan Y N Drug Repurposing Hydroxychloroquine, Azithromycin Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04410354 Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19 United States Y N Shelved drug or NME Merimepodib Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04371406 Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients France Y N Drug Repurposing Azithromycin, Hydroxychloroquine Efficacy - Other efficacy Mild/Moderate Cases
NCT04380688 Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. United States Y N Drug Repurposing Acalabrutinib Safety Mild/Moderate Cases, Severe Cases
NCT04449588 Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS China Y N Shelved drug or NME BDB-001 Efficacy - Oxygen parameters Severe Cases
NCT04346199 Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. United States Y N Drug Repurposing Acalabrutinib Efficacy - Other efficacy Severe Cases
NCT04359615 Favipiravir in Hospitalized COVID-19 Patients Iran Y N Drug Repurposing Favipiravir Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04333355 Safety in Convalescent Plasma Transfusion to COVID-19 Mexico N N Cell/Blood based ND:Convalescent plasma Safety Severe Cases
NCT04421404 Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients United States Y N Cell/Blood based ND:Convalescent plasma Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04359316 Azithromycin in Hospitalized COVID-19 Patients Iran Y N Drug Repurposing Azithromycin Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04381884 Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19 United States Y N Drug Repurposing Ivermectin Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04352400 Efficacy of Nafamostat in Covid-19 Patients (RACONA Study) Italy Y N Drug Repurposing Nafamostat Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04364815 The University of the Philippines Hydroxychloroquine PEP Against COVID-19 Trial Philippines Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04343768 An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial Iran Y Y Drug Repurposing Hydroxychloroquine, Lopinavir/ritonavir, Interferon Beta-1A, Interferon Beta-1B Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04365231 Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial France Y N Drug Repurposing Hydroxychloroquine, Azithromycin Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04428008 Thymosin Alpha 1 to Prevent COVID-19 Infection in Elderly Renal Dialysis Patients United States Y N Drug Repurposing Thymalfasin Efficacy - Infection rate (prevention) Other
NCT04355936 Telmisartan for Treatment of COVID-19 Patients Argentina Y N Drug Repurposing Telmisartan Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04252118 Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19 China Y N Shelved drug or NME ND:Stem cells Efficacy - Other efficacy Mild/Moderate Cases
NCT04466670 Hemostasis in COVID-19: an Adaptive Clinical Trial Brazil Y Y Drug Repurposing Heparin, Aspirin, Enoxaparin Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04492475 Adaptive COVID-19 Treatment Trial 3 (ACTT-3) United States Y N Drug Repurposing, Shelved drug or NME Interferon beta-1a Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04438980 Glucocorticoids in COVID-19 (CORTIVID) Spain Y N Drug Repurposing Methylprednisolone Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04280705 Adaptive COVID-19 Treatment Trial (ACTT) United States Y N Shelved drug or NME Remdesivir Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04401579 Adaptive COVID-19 Treatment Trial 2 (ACTT-2) United States Y N Drug Repurposing Baricitinib Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04348656 CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1) Canada Y N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Severe Cases
NCT04475107 The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients Korea, Republic of Y N Drug Repurposing Pyronaridine/Artesunate Efficacy - Viral load Mild/Moderate Cases
NCT04343976 Pegylated Interferon Lambda Treatment for COVID-19 United States Y N Shelved drug or NME Peg-Interferon lambda Efficacy - Viral load Mild/Moderate Cases
NCT04357808 Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID) Spain Y N Drug Repurposing Sarilumab Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04441385 Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19). Spain Y N Drug Repurposing Maraviroc Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04397328 COVID-19 PEP- High-risk Individuals in Long-term and Specialized Care - Canada Canada Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04330586 A Trial of Ciclesonide in Adults With Mild COVID-19 Korea, Republic of Y Y Drug Repurposing Ciclesonide, Hydroxychloroquine Efficacy - Viral load General population
NCT04414098 Ruxolitinib in the Treatment of Covid-19 Argentina N N Drug Repurposing Ruxolitinib Efficacy - Oxygen parameters Severe Cases
NCT04345523 Convalescent Plasma Therapy vs. SOC for the Treatment of COVID19 in Hospitalized Patients Spain Y N Cell/Blood based ND:Convalescent plasma Efficacy - WHO scale Severe Cases
NCT04374279 Trial to Promote Recovery From COVID-19 With Endocrine Therapy United States Y N Drug Repurposing Bicalutamide Efficacy - WHO scale Mild/Moderate Cases
NCT04349592 Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19 Qatar Y N Drug Repurposing Hydoxychloroquine, Azithromycin Efficacy - Viral load Mild/Moderate Cases
NCT04350671 Interferon Beta 1a in Hospitalized COVID-19 Patients Iran Y N Drug Repurposing Interferon beta-1A Efficacy - WHO scale Severe Cases
NCT04425252 Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19 United States Y N Drug Repurposing Brequinar Safety Mild/Moderate Cases, Severe Cases
NCT04365257 Prazosin to Prevent COVID-19 (PREVENT-COVID Trial) United States Y N Drug Repurposing Prazosin Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04379479 Clinical Effect of Dialyzable Leukocyte Extract in Suspected or Confirmed Cases of COVID-19 (FUTURE-T) Mexico Y N Shelved drug or NME Dialyzable Leukocyte Extract Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04466540 Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19) Brazil Y N Drug Repurposing Hydroxychloroquine Efficacy - Other efficacy Mild/Moderate Cases
NCT04350684 Umifenovir in Hospitalized COVID-19 Patients Iran Y N Drug Repurposing Umifenovir Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04328285 Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers France Y Y Drug Repurposing Hydroxychloroquine, Lopinavir/ritonavir Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04299724 Safety and Immunity of Covid-19 aAPC Vaccine China N N Vaccine ND:Covid-19 aAPC vaccine Safety General population, Mild/Moderate Cases
NCT04456153 Atovaquone for Treatment of COVID-19 United States Y N Drug Repurposing Atovaquone Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04416048 Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19 Germany Y N Drug Repurposing Rivaroxaban Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04315298 Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 United States Y Y Drug Repurposing Sarilumab Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04389359 PROphylaxis for paTiEnts at Risk of COVID-19 infecTion United Kingdom Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04418518 A Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness United States Y N Cell/Blood based ND:Convalescent plasma Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04366232 Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation (JAKINCOV) France Y N Drug Repurposing Ruxolitinib, Anakinra Efficacy - Other efficacy Severe Cases
NCT04363372 A Study for Efficacy and Safety of Live Biotherapeutic MRx4DP0004 to Treat COVID-19 United Kingdom Y N Shelved drug or NME MRx-4DP0004 Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04355897 CoVID-19 Plasma in Treatment of COVID-19 Patients United States N N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04377620 Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) United States Y N Drug Repurposing Ruxolitinib Efficacy - Mortality Severe Cases
NCT04475991 Safety and Efficacy of Maraviroc and/or Favipiravir vs Currently Used Therapy in Severe COVID-19 Adults Mexico Y Y Drug Repurposing Maraviroc, Favipiravir Efficacy - Other efficacy Severe Cases
NCT04435184 Crizanlizumab for Treating COVID-19 Vasculopathy United States Y N Drug Repurposing Crizanlizumab Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04377750 The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation Israel Y N Drug Repurposing Tocilizumab Efficacy - Mortality Severe Cases
NCT04448119 Control of COVID-19 Outbreaks in Long Term Care Canada Y N Drug Repurposing Favipiravir Efficacy - Infection rate (prevention) Other
NCT04353180 Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 (Randomized) Egypt Y Y Drug Repurposing Retinoic acid Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04371965 Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19 France Y N Shelved drug or NME Povidone-Iodine Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04363866 A Pilot Study to Assess Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19) United States Y N Drug Repurposing Hydroxychloroquine Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04330638 Treatment of COVID-19 Patients With Anti-interleukin Drugs Belgium Y Y Drug Repurposing Anakinra, Siltuximab, Tocilizumab Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04394442 Hydroxychloroquine in COVID-19 Patients Saudi Arabia Y N Drug Repurposing Hydroxychloroquine Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04485429 Efficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia Brazil Y Y Drug Repurposing Methylprednisolone, Heparin Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04382625 Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial United States Y N Drug Repurposing Hydroxychloroquine Efficacy - Oxygen parameters Mild/Moderate Cases
NCT04353206 Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure United States N N Cell/Blood based ND:Convalescent plasma Other Severe Cases
NCT04488081 I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients United States Y Y Drug Repurposing Cenicriviroc, Icatibant, Razuprotafib, Apremilast Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04473053 Rapid Experimental Medicine for COVID-19 United Kingdom Y Y Drug Repurposing, Shelved drug or NME TD139, Nafamostat Safety Mild/Moderate Cases, Severe Cases
NCT04400890 Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of Resveratrol for COVID-19 United States Y N Drug Repurposing Resveratrol Efficacy - Other efficacy Mild/Moderate Cases
NCT04425837 Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19 Colombia Y N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04452474 Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). United States Y N Shelved drug or NME Olokizumab Efficacy - WHO scale Severe Cases
NCT04361214 Leflunomide in Mild COVID-19 Patients United States N N Drug Repurposing Leflunomide Safety Mild/Moderate Cases
NCT04380519 Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19) Russian Federation Y N Shelved drug or NME Olokizumab, RPH-104 Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04483635 Preventing COVID-19 With High-dose Vitamin D Supplements Canada Y N Drug Repurposing Vitamin D Efficacy - Infection rate (prevention) General population
NCT04313322 Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells Jordan N N Cell/Blood based ND:Stem cells Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04369742 Treating COVID-19 With Hydroxychloroquine (TEACH) United States Y N Drug Repurposing Hydroxychloroquine Safety Severe Cases
NCT04394117 Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease Australia Y N Drug Repurposing Angiotensin Receptor Blockers Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04389411 The COvid-19 Symptom MOntelukast Trial Canada Y N Drug Repurposing Montelukast Efficacy - Other efficacy Mild/Moderate Cases
NCT04398303 ACT-20 in Patients With Severe COVID-19 Pneumonia United States Y Y Cell/Blood based ND:Stem cells Efficacy - Mortality Severe Cases
NCT04435795 Inhaled Ciclesonide for Outpatients With COVID19 United States Y N Drug Repurposing Ciclesonide Efficacy - Oxygen parameters Mild/Moderate Cases
NCT04425707 Ivermectin In Treatment of COVID 19 Patients Egypt Y N Drug Repurposing Ivermectin Efficacy - Other efficacy Mild/Moderate Cases
NCT04355767 Convalescent Plasma in Outpatients With COVID-19 United States Y N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04326920 Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC) Belgium Y N Drug Repurposing Sargramostim Efficacy - Oxygen parameters Mild/Moderate Cases
NCT04446377 A Study of LAM-002A for the Prevention of Progression of COVID-19 United States Y N Shelved drug or NME Apilimod dimesylate Efficacy - Viral load Mild/Moderate Cases
NCT04304313 A Pilot Study of Sildenafil in COVID-19 China N N Drug Repurposing Sildenafil Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04390503 Convalescent Plasma for COVID-19 Close Contacts United States Y N Cell/Blood based ND:Convalescent plasma Efficacy - Other efficacy Exposed individuals (family members, HCP), Mild/Moderate Cases
NCT04382755 Zilucoplan® in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure Belgium Y N Shelved drug or NME Zilucoplan Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04365699 Cardiovascular Effects of COVID-19 United States N N Shelved drug or NME AT-001 Efficacy - Other efficacy Other
NCT04458298 A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients United States Y N Shelved drug or NME OP-101 Safety Severe Cases
NCT04351243 A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) United States Y N Shelved drug or NME Gimsilumab Efficacy - Mortality Severe Cases
NCT04355247 Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm United States N N Drug Repurposing Methylprednisolone Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04405908 SCB-2019 as COVID-19 Vaccine China Y Y Vaccine ND:Vaccine Safety General population
NCT04353284 Camostat Mesylate in COVID-19 Outpatients United States Y N Drug Repurposing Camostat Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04389710 Convalescent Plasma for the Treatment of COVID-19 United States N N Cell/Blood based ND:Convalescent plasma Other Severe Cases
NCT04494399 IFN Beta-1b and Ribavirin for Covid-19 Hong Kong Y N Drug Repurposing Interferon beta-1b, Ribavirin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04380402 Atorvastatin as Adjunctive Therapy in COVID-19 United States Y N Drug Repurposing Atorvastatin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04374903 Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients Jordan Y N Drug Repurposing Azithromycin, Sirolimus Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04386239 Study on the Use of Sarilumab in Patients With COVID-19 Infection Italy N N Drug Repurposing Sarilumab Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04354805 Administration of Chlorpromazine as a Treatment for COVID-19 Egypt Y N Drug Repurposing Chlorpromazine Other Mild/Moderate Cases, Severe Cases
NCT04351763 Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms Poland Y Y Drug Repurposing Amiodarone, Verapamil Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04388527 COVID-19 Convalescent Plasma for Mechanically Ventilated Population United States N N Cell/Blood based ND:Convalescent plasma Safety Severe Cases
NCT04340544 Hydroxychloroquine for the Treatment of Mild COVID-19 Disease Germany Y N Drug Repurposing Hydroxychloroquine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04487444 Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection United States Y N Drug Repurposing Thymalfasin Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04338828 Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED United States Y N Drug Repurposing Nitric Oxide Efficacy - Other efficacy Mild/Moderate Cases
NCT04480424 Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19) United States Y N Cell/Blood based ND:Immunoglobulin Efficacy - Mortality Severe Cases
NCT04468087 Antiviral Agents Against COVID-19 Infection Brazil Y Y Drug Repurposing Atazanavir, Daclatasvir, Sofusbuvir Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04338958 Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation Germany N N Drug Repurposing Ruxolitinib Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04356690 Etoposide in Patients With COVID-19 Infection United States N N Drug Repurposing Etoposide Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04472494 Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise United States Y N Drug Repurposing Abatacept Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04415151 Tofacitinib for Treatment of Moderate COVID-19 United States Y N Drug Repurposing Tofacitinib Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04375124 Treatment of Angiotensin Peptide (1-7) for COVID-19 Turkey N N Drug Repurposing Angiotensin 1-7 Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04371952 DYNAMIC Study (DoxycYcliNe AMbulatoIre COVID-19) France Y N Drug Repurposing Doxycycline Efficacy - Oxygen parameters Mild/Moderate Cases
NCT04371822 Efficacy of Sunlight Activated Synthetic Porphyrin in COVID-19 Infected Patients Egypt Y Y Shelved drug or NME SnPP Protoporphyrin, Sulfonatoporphyrin Efficacy - Infection rate (prevention) Mild/Moderate Cases, Severe Cases
NCT04427098 Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients Iceland N N Drug Repurposing Enoxaparin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04438694 Use of Convalescent Plasma for Treatment of Patients With COVID-19 Infection Egypt N N Cell/Blood based ND:Convalescent plasma Efficacy - Other efficacy Severe Cases
NCT04443725 Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19 Egypt Y N Drug Repurposing Hydroxychloroquine, Sofosbuvir, Daclatasvir Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04366115 Evaluating AVM0703 for Treatment of COVID-19 United States Y N Drug Repurposing, Shelved drug or NME AVM0703 Safety Severe Cases
NCT04383002 High Dose Inhaled Nitric Oxide for COVID-19 (ICU Patients) Canada Y N Drug Repurposing Nitric Oxide Efficacy - Viral load Severe Cases
NCT04410328 Aggrenox To Treat Acute Covid-19 United States Y N Drug Repurposing Aspirin/dipyridamole Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04445935 Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial Qatar Y N Drug Repurposing Bivalirudin Efficacy - Oxygen parameters Severe Cases
NCT04343092 Efficacy of Ivermectin as Add on Therapy in COVID19 Patients Iraq Y N Drug Repurposing Ivermectin Efficacy - Other efficacy Severe Cases
NCT04338074 TXA and Corona Virus 2019 (COVID19) in Outpatients United States Y N Drug Repurposing Tranexamic acid Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04494724 Clazakizumab vs. Placebo - COVID-19 Infection United States Y N Shelved drug or NME Clazakizumab Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04366050 Ramipril for the Treatment of COVID-19 United States Y N Drug Repurposing Ramipril Efficacy - Mortality Severe Cases
NCT04438850 COVidIVERmectin: Ivermectin for Treatment of Covid-19 Italy Y N Drug Repurposing Ivermectin Safety Mild/Moderate Cases
NCT04338126 Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients United States Y N Drug Repurposing Tranexamic acid Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04355026 Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia Slovenia Y N Drug Repurposing Bromhexine Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04341675 Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia United States Y N Drug Repurposing Sirolimus Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04444271 Mesenchymal Stem Cell Infusion for COVID-19 Infection Pakistan Y N Cell/Blood based ND:Stem cells Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04469114 Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia Brazil Y N Drug Repurposing Tofacitinib Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04446104 A Preventive Treatment for Migrant Workers at High-risk of Covid-19 Singapore Y Y Drug Repurposing Hydroxychloroquine, Ivermectin, Zinc, Povidone-Iodine Efficacy - Oxygen parameters Exposed individuals (family members, HCP)
NCT04329923 The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine) United States Y Y Drug Repurposing Hydroxychloroquine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04394416 Trial of Imatinib for Hospitalized Adults With COVID-19 United States Y N Drug Repurposing Imatinib Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04374461 A Study of N-acetylcysteine in Patients With COVID-19 Infection United States N N Drug Repurposing N-acetylcysteine Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04397757 COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2. United States Y N Cell/Blood based ND:Convalescent plasma Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04361643 Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial Spain Y N Drug Repurposing Lenalidomide Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04455243 Inflammatory Regulation Effect of NAC on COVID-19 Treatment Saudi Arabia Y N Drug Repurposing N-acetylcysteine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04333628 Chloroquine for Mild Symptomatic and Asymptomatic COVID-19 Israel Y Y Drug Repurposing Chloroquine Efficacy - Viral load Mild/Moderate Cases
NCT04463602 Desidustat in the Management of COVID-19 Patients Mexico Y N Shelved drug or NME Desidustat Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04372628 Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19 United States Y N Drug Repurposing Lopinavir/ritonavir Efficacy - WHO scale Mild/Moderate Cases
NCT04429763 Safety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19 Pneumonia Colombia Y N Cell/Blood based ND:Stem cells Efficacy - Other efficacy Severe Cases
NCT04304053 Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention Spain Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP), Mild/Moderate Cases
NCT04421027 A Study of Baricitinib (LY3009104) in Participants With COVID-19 United States Y N Drug Repurposing Baricitinib Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04355143 Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19) United States Y N Drug Repurposing Colchicine Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04451174 Early Use of Corticosteroids in Hospitalized Patients With Moderate COVID19 Pneumonia Chile Y N Drug Repurposing Prednisone Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04362085 Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care Canada Y N Drug Repurposing Enoxaparin, Dalteparin, Tinzaparin, Heparin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04351620 High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19 United States N N Drug Repurposing Hydroxychloroquine Safety Mild/Moderate Cases
NCT04390464 mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R) United Kingdom Y Y Drug Repurposing Ravulizumab, Baricitinib Efficacy - Other efficacy Mild/Moderate Cases
NCT04480138 Pegylated Interferon - a2b With SARSCoV- 2 (COVID-19) Mexico Y N Drug Repurposing Interferon alpha-2b Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04363216 Pharmacologic Ascorbic Acid as an Activator of Lymphocyte Signaling for COVID-19 Treatment United States Y N Drug Repurposing Ascorbic Acid Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04339426 Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection United States N N Drug Repurposing Atovaquone, Azithromycin Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04334382 Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19 United States Y N Drug Repurposing Hydroxychloroquine Efficacy - Other efficacy Mild/Moderate Cases
NCT04437693 Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 Patients Qatar Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04438057 Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19 United States Y N Cell/Blood based ND:Convalescent plasma Efficacy - Other efficacy Mild/Moderate Cases
NCT04350320 Trial to Study the Benefit of Colchicine in Patients With COVID-19 Spain Y N Drug Repurposing Colchicine Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04342182 Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study) Netherlands Y N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Severe Cases
NCT04343001 Coronavirus Response - Active Support for Hospitalised Covid-19 Patients United Kingdom Y Y Drug Repurposing Aspirin, Losartan, Simvastatin Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04463420 Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19 Iran Y N Shelved drug or NME PHR160 Spray Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04410159 Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients Malaysia Y Y Shelved drug or NME Povidone-Iodine Efficacy - Viral load Mild/Moderate Cases
NCT04357990 Kerecis Oral and Nasal Spray for Treating the Symptoms of COVID-19 Iceland Y N Shelved drug or NME Omega3 Viruxide Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04356534 Convalescent Plasma Trial in COVID -19 Patients Bahrain Y N Cell/Blood based ND:Covalescent plasma Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04393311 Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients United States Y N Shelved drug or NME Ulinastatin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04348500 Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease United States Y N Shelved drug or NME Clazakizumab Efficacy - Oxygen parameters Severe Cases
NCT04392414 Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease Russian Federation Y N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04442191 Convalescent Plasma as a Possible Treatment for COVID-19 United States Y N Cell/Blood based ND:Convalescent plasma Efficacy - Oxygen parameters Mild/Moderate Cases
NCT04362189 Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19 United States Y Y Cell/Blood based ND:Stem cells Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04409522 Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients Iran Y N Drug Repurposing Melatonin Other Mild/Moderate Cases, Severe Cases
NCT04360980 The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection Iran Y N Drug Repurposing Colchicine Other Mild/Moderate Cases
NCT04335136 Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 Denmark Y N Shelved drug or NME Recombinant Human Angiotensin-converting Enzyme 2 Efficacy - Other efficacy Severe Cases
NCT04391127 Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection Mexico Y N Drug Repurposing Ivermectin, Hydroxychloroquine Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04359537 Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19 Pakistan Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04457726 Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19 Singapore N N Cell/Blood based ND:T-cells Safety Severe Cases
NCT04492254 Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients United Kingdom Y N Drug Repurposing Enoxaparin Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04276896 Immunity and Safety of Covid-19 Synthetic Minigene Vaccine China N N Cell/Blood based ND:T-cells Efficacy - WHO scale Mild/Moderate Cases
NCT04370236 XPro1595 for the Treatment of Pulmonary Complications From COVID-19 United States Y N Drug Repurposing XPro1595 Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04359511 Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia France Y N Drug Repurposing Prednisone, Hydrocortisone Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04331795 Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis United States N Y Drug Repurposing Tocilizumab Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04456452 Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation United States Y N Drug Repurposing Ampion Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04333225 Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers United States Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04405843 Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19 Colombia Y N Drug Repurposing Ivermectin Efficacy - WHO scale Mild/Moderate Cases
NCT04351724 Austrian CoronaVirus Adaptive Clinical Trial (COVID-19) Austria Y Y Drug Repurposing, Shelved drug or NME Hydroxychloroquine, Chloroquine, Lopinavir/ritonavir, Rivaroxaban, Candesartan, Clazakizumab Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04393246 mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms United Kingdom Y N Shelved drug or NME EDP1815, Dapagliflozin, Ambrisentan Efficacy - Other efficacy Mild/Moderate Cases
NCT04344444 Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease United States Y Y Drug Repurposing Hydroxychloroquine, Azithromycin Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04429867 Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease United States Y N Drug Repurposing Hydroxychloroquine Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04377659 Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection United States Y N Drug Repurposing Tocilizumab Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04425772 A Clinical Trial for Azvudine in the Treatment of Novel Coronavirus Pneumonia (COVID-19) United States Y N Drug Repurposing Azvudine Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04352465 Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients Brazil N N Shelved drug or NME Methotrexate nano-formulation Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04435314 Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19 Brazil Y N Drug Repurposing Nitazoxanide Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04352751 Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020 Pakistan N N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04389801 Use of Desferal for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection Egypt Y N Drug Repurposing Deferoxamine Efficacy - Mortality Mild/Moderate Cases
NCT04427501 A Study of LY3819253 (LY-CoV555) in Participants With Mild to Moderate COVID-19 Illness United States Y N Shelved drug or NME LY3819253 Efficacy - Viral load Mild/Moderate Cases
NCT04486313 Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19 United States Y N Drug Repurposing Nitazoxanide, ND:Dietary supplement Efficacy - Other efficacy Mild/Moderate Cases
NCT04374487 Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications India Y N Cell/Blood based ND:Convalescent plasma Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04328441 Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine Netherlands Y N Drug Repurposing, Vaccine BCG Vaccine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04432766 A Phase 1 Study to Assess BAT2020 in Hospitalized Patients Infected With SARS-CoV-2 (COVID-19) China Y N Shelved drug or NME BAT2020 Safety Mild/Moderate Cases, Severe Cases
NCT04429711 Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19 Israel Y N Drug Repurposing Ivermectin Efficacy - Viral load Mild/Moderate Cases
NCT04307693 Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19) Korea, Republic of Y Y Drug Repurposing Hydroxychloroquine, Lopinavir/ritonavir Efficacy - Viral load Mild/Moderate Cases
NCT04329650 Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia Spain Y N Drug Repurposing Siltuximab, Methylprednisolone Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04468139 The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19 Saudi Arabia N N Drug Repurposing, Other Ascorbic acid, ND:Quercetin/bromelain, Zinc Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04385849 Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19 United States Y N Shelved drug or NME N-803 Safety Mild/Moderate Cases, Severe Cases
NCT04454398 Study to Evaluate STI-1499 (COVI-GUARD) in Hospitalized Patients With COVID-19 United States Y N Cell/Blood based STI-1499 Safety Mild/Moderate Cases, Severe Cases
NCT04363814 Clinical Impact of BACTEK-R in Subject With Mild Pneumonia Due to COVID-19 Infection United States Y N Shelved drug or NME Bactek-R Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04345692 A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients United States Y N Drug Repurposing Hydroxychloroquine Efficacy - WHO scale Severe Cases
NCT04364763 A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study) United States N N Shelved drug or NME RBT-9 Efficacy - WHO scale Mild/Moderate Cases
NCT04397562 A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19 Russian Federation Y N Shelved drug or NME Levilimab Efficacy - Mortality Severe Cases
NCT04331899 Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19 United States Y N Shelved drug or NME Peg-Interferon lambda-1a Efficacy - Viral load Mild/Moderate Cases
NCT04397718 Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization United States Y N Drug Repurposing Degarelix Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04362332 Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19 Netherlands Y Y Drug Repurposing Chloroquine, Hydroxychloroquine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04441398 Efficacy and Safety of Nitazoxanide 600 mg to Treat Mild Ambulatory COVID-19 Patients Brazil Y N Drug Repurposing Nitazoxanide Efficacy - WHO scale Mild/Moderate Cases
NCT04486508 Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19 Iran Y Y Drug Repurposing Enoxaparin, Atorvastatin Efficacy - Other efficacy Severe Cases
NCT04434131 Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19 United States N N Cell/Blood based ND:Convalescent plasma Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04331834 Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic Spain Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04331470 Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19 Iran Y N Drug Repurposing Levamisole, Budesonide/formoterol Efficacy - Other efficacy Mild/Moderate Cases
NCT04440007 Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With SOC Versus SOC in Subjects With COVID-19 United States Y N Shelved drug or NME Abivertinib Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04423861 Efficacy and Safety of Nitazoxanide 600 mg TID for the Treatment of Hospitalized Patients With COVID-19 Brazil Y N Drug Repurposing Nitazoxanide Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04386252 Phase Ib-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults United States Y N Vaccine ND:Vaccine Safety Exposed individuals (family members, HCP)
NCT04356677 Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19 United States N N Drug Repurposing Ribavirin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04313023 The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2 United States Y N Shelved drug or NME PUL-042 Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04409327 Phase 3 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes United States Y N Shelved drug or NME RTB101 Efficacy - Other efficacy Other
NCT04336254 Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients China Y N Cell/Blood based ND:Stem cells Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04292899 Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) United States N N Shelved drug or NME Remdesivir Efficacy - Oxygen parameters Severe Cases
NCT04416139 Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19 Mexico N N Cell/Blood based ND:Stem cells Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04332094 Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19 Brazil Y N Drug Repurposing Tocilizumab Efficacy - Mortality Mild/Moderate Cases
NCT04456595 Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals Brazil Y N Vaccine ND:Vaccine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04466280 Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19 Iran Y N Drug Repurposing, Shelved drug or NME Hydroxychloroquine, Mucodentol Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04312997 The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection United States Y N Shelved drug or NME PUL-042 Efficacy - WHO scale Mild/Moderate Cases
NCT04385264 #StayHome: Early Hydroxychloroquine to Reduce Secondary Hospitalisation and Household Transmission in COVID-19 Switzerland Y N Drug Repurposing Hydroxychloroquine Efficacy - Other efficacy Mild/Moderate Cases
NCT04425460 A Multi-center,Randomized,Double-blind,Placebo-controlled,Phase 3 Study Evaluating Favipiravir in Treatment of COVID19 China Y N Drug Repurposing Favipiravir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04370782 Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting United States Y N Drug Repurposing Hydroxychloroquine, Azithromycin, Zinc, Doxycycline Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04334980 Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19 Canada Y Y Vaccine bacTRL-Spike vaccine Safety Other
NCT04478019 SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding United States Y N Shelved drug or NME Povidone-Iodine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04348409 Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19 Brazil Y N Drug Repurposing Nitazoxanide Efficacy - Viral load Mild/Moderate Cases
NCT04377711 A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients Switzerland Y N Drug Repurposing Ciclesonide Efficacy - Other efficacy Mild/Moderate Cases
NCT04353518 Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19 India Y N Shelved drug or NME ND:Mycobacterium Efficacy - Infection rate (prevention) General population
NCT04429334 Safety, Tolerability and Efficacy of Nangibotide in Mechanically Ventilated Patients With COVID-19 and Features of Systemic Inflammation France Y N Shelved drug or NME Nangibotide Safety Severe Cases
NCT04328493 The Vietnam Chloroquine Treatment on COVID-19 Viet Nam Y N Drug Repurposing Chloroquine Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04360551 Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients United States Y N Drug Repurposing Telmisartan Efficacy - WHO scale Mild/Moderate Cases
NCT04343989 A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection United States Y Y Shelved drug or NME Clazakizumab Safety Severe Cases
NCT04348474 Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19 Brazil N N Drug Repurposing Hydroxychloroquine, Azithromycin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04470531 Role of Co-trimoxazole in Severe COVID-19 Patients Bangladesh Y N Drug Repurposing Trimethoprim/sulfamethoxazole Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04488575 Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection United States Y N Shelved drug or NME EDP1815 Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04358809 Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill India Y N Vaccine ND:Mycobacterium Efficacy - Other efficacy Mild/Moderate Cases
NCT04492358 Treatment for Moderate/Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center Spain Y N Drug Repurposing Colchicine, Prednisone Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04348435 A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19 United States Y Y Cell/Blood based ND:Stem cells Efficacy - Other efficacy Exposed individuals (family members, HCP)
NCT04329572 Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19 Brazil N N Drug Repurposing Hydroxychloroquine, Azithromycin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT03348670 Follow NCT03305341 - Proof-of-Concept - COVID-19 AP TP Vaccine United States N N Vaccine ND:Vaccine Other Mild/Moderate Cases
NCT04292730 Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment United States Y Y Shelved drug or NME Remdesivir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04431453 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years of Age With Coronavirus Disease 2019 (COVID-19) United States N N Shelved drug or NME Remdesivir Safety Other
NCT04358549 Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19 United States Y N Drug Repurposing Favipiravir Efficacy - Viral load Mild/Moderate Cases
NCT04482699 RAPA-501-Allo Off-the-Shelf Therapy of COVID-19 United States Y Y Cell/Blood based ND:MSC Safety Mild/Moderate Cases, Severe Cases
NCT04481685 A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19) United States Y N Shelved drug or NME ATI-450 Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT03305341 Discovery Stage (Proof-of-concept) COVID-19 Antigen Presentation Therapeutic Vaccine United States N N Vaccine ND:Vaccine Other Mild/Moderate Cases
NCT04428021 Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure Italy Y N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04346615 Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen United States Y N Shelved drug or NME Vazegepant Safety Severe Cases
NCT04428268 Chloroquine + Losartan Compared to Chloroquine Alone for the Treatment of COVID-19 Pneumonia Mexico Y N Drug Repurposing Losartan Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04360824 Covid-19 Associated Coagulopathy United States Y N Drug Repurposing Enoxaparin Efficacy - Mortality General population, Mild/Moderate Cases
NCT04463264 Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoV-2 Virus Infection (COVID-19) Argentina Y N Drug Repurposing Nitazoxanide Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04368728 Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults United States Y Y Shelved drug or NME BNT162b1, BNT162b2 Safety General population
NCT04415060 SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival Canada Y N Drug Repurposing Isoflurane, Sevoflurane Efficacy - Mortality Severe Cases
NCT04349410 The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol United States Y Y Drug Repurposing, Shelved drug or NME, Cell/Blood based Hydroxychloroquine, Azithromycin, Doxycycline, Clindamycin, Primaquine, Remdesivir, Tocilizumab, Methylprednisolone, Losartan, ND:Convalescent plasma, Interferon alpha-2b Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04387760 Favipiravir vs Hydroxychloroquine in COVID -19 Bahrain Y Y Drug Repurposing Hydroxychloroquine, Favipiravir Efficacy - Viral load Mild/Moderate Cases
NCT04460651 PREPARE-IT. Prevention of COVID19 With EPA in Healthcare Providers at Risk - Intervention Trial Argentina Y N Drug Repurposing Icosapent ethyl Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04364802 COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients United States N N Shelved drug or NME Povidone-Iodine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04315896 Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial) Mexico Y N Drug Repurposing Hydroxychloroquine Efficacy - Mortality Severe Cases
NCT04408209 Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection Greece N N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Severe Cases
NCT04323514 Use of Ascorbic Acid in Patients With COVID 19 Italy N N Drug Repurposing Ascorbic acid Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04273646 Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19 China N N Cell/Blood based ND:Stem cells Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04381858 Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia Mexico Y N Cell/Blood based ND:Convalescent plasma Efficacy - Other efficacy Severe Cases
NCT04494646 BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) United States Y N Shelved drug or NME Bardoxolone Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04461925 Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs Ukraine N N Cell/Blood based ND:MSC Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04477083 Development and Validation of "Ready-to-Use" Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19 Egypt Y N Drug Repurposing Hydroxychloroquine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04362137 Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID) United States Y N Drug Repurposing Ruxolitinib Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04305106 Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT China Y N Drug Repurposing Bevacizumab Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04315987 NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia Brazil N N Cell/Blood based ND:Stem cells Efficacy - Other efficacy Severe Cases
NCT04460105 Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia United States Y N Drug Repurposing Lanadelumab Safety Mild/Moderate Cases, Severe Cases
NCT04354870 COVID-19 PrEP HCW HCQ Study United States N N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04244591 Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure China Y N Drug Repurposing Methylprednisolone Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04342663 A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection United States Y N Drug Repurposing Fluvoxamine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04325061 Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19 Spain Y N Drug Repurposing Dexamethasone Efficacy - Mortality Severe Cases
NCT04320615 A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia United States Y N Drug Repurposing Tocilizumab Efficacy - WHO scale Severe Cases
NCT04344730 Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia France Y Y Drug Repurposing, Other Dexamethasone, ND:Procedure Efficacy - Mortality Severe Cases
NCT04372186 A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia United States Y N Drug Repurposing Tocilizumab Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04407130 Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection. Bangladesh Y Y Drug Repurposing Ivermectin, Doxycycline Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04386616 A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia United States Y N Shelved drug or NME Astegolimab Efficacy - WHO scale Severe Cases
NCT04332107 Azithromycin for COVID-19 Treatment in Outpatients Nationwide United States Y N Drug Repurposing Azithromycin Efficacy - Other efficacy Mild/Moderate Cases
NCT04363736 A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia United States Y N Drug Repurposing Tocilizumab Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04363060 Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit France Y N Drug Repurposing Azithromycin, Amoxicillin/clavulanate Efficacy - Viral load Mild/Moderate Cases
NCT04371640 Sirolimus in COVID-19 Phase 1 United States Y N Drug Repurposing Sirolimus Efficacy - Viral load Severe Cases
NCT04455815 A Trial Looking at the Use of Camostat to Reduce Progression of Symptoms of Coronavirus (COVID-19) in People Who Have Tested Positive But Are Able to Stay at Home United Kingdom Y N Drug Repurposing Camostat Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04417257 Study of LAU-7b for the Treatment of COVID-19 Disease in Adults Canada Y N Shelved drug or NME LAU-7b Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04273529 The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia China Y N Drug Repurposing Thalidomide Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04273581 The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19 China Y N Drug Repurposing Thalidomide Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04409262 A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia United States Y N Drug Repurposing Tocilizumab Efficacy - WHO scale Severe Cases
NCT04335201 Defibrotide in COVID-19 Pneumonia Italy N N Drug Repurposing Defibrotide Efficacy - Other efficacy Severe Cases
NCT04379336 BCG Vaccination for Healthcare Workers in COVID-19 Pandemic South Africa Y N Drug Repurposing BCG Vaccine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04283461 Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19) United States N Y Vaccine ND:Vaccine Safety General population
NCT04374032 Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection Bosnia and Herzegovina Y N Drug Repurposing Metenkefalin, Tridecactide Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04359680 Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers United States Y N Drug Repurposing Nitazoxanide Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04334044 Treatment of SARS Caused by COVID-19 With Ruxolitinib Mexico N N Drug Repurposing Ruxolitinib Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04342221 Hydroxychloroquine for COVID-19 Germany Y N Drug Repurposing Hydroxychloroquine Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04362124 Performance Evaluation of BCG Vaccination in Healthcare Personnel to Reduce the Severity of SARS-COV-2 Infection Colombia Y N Drug Repurposing BCG Vaccine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04365127 Progesterone for the Treatment of COVID-19 in Hospitalized Men United States Y N Drug Repurposing Progesterone Efficacy - WHO scale Severe Cases, Other
NCT04382053 Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia United States Y N Shelved drug or NME DFV890 Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04353271 Trial of Hydroxychloroquine In Covid-19 Kinetics United States Y N Drug Repurposing Hydroxychloroquine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04343248 Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF) United States Y N Drug Repurposing Nitazoxanide Efficacy - Infection rate (prevention) Other
NCT04372017 Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection United States Y Y Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04449380 Clinical Study for the Treatment With Interferon-ß-1a (IFNß-1a) of COVID-19 Patients Italy Y N Drug Repurposing Interferon beta-1a Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04363203 VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL) United States Y Y Drug Repurposing Hydroxychloroquine, Azithromycin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Other
NCT04341207 Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients France N N Drug Repurposing Hydroxychloroquine, Azithromycin Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04469179 Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19 United States Y Y Shelved drug or NME SAB-185 Safety Mild/Moderate Cases, Severe Cases
NCT04252664 A Trial of Remdesivir in Adults With Mild and Moderate COVID-19 China Y N Shelved drug or NME Remdesivir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04413838 Efficiency and Security of NIVOLUMAB Therapy in Obese Individuals With COVID-19(COrona VIrus Disease) Infection France Y N Drug Repurposing Nivolumab Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases, Other
NCT04446065 Protection of Health Workers Against COVID-19 Chile Y N Shelved drug or NME Previfenon Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04405921 Hydroxychloroquine, Azithromycin in the Treatment of Covid-19 Tunisia N N Drug Repurposing Azithromycin, Hydroxychloroquine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04346628 Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19 United States Y N Drug Repurposing Favipiravir Efficacy - Viral load Mild/Moderate Cases
NCT04377646 A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers Tunisia Y N Drug Repurposing Hydroxychloroquine, Zinc Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP), Other
NCT04382651 Study of Efficacy and Safety of MAS825 in Patients With COVID-19 United States Y N Shelved drug or NME MAS825 Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04362813 Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia United States Y N Drug Repurposing Canakinumab Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04452643 Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to COVID-19 Infection in Healthcare Personnel Mexico Y N Shelved drug or NME MV130 Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04494984 A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19. Argentina Y N Shelved drug or NME INM005 Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04470297 Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19 Brazil Y N Drug Repurposing Ramelteon Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04358068 Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19 United States Y N Drug Repurposing Hydroxychloroquine, Azithromycin Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04437875 An Open Study of the Safety, Tolerability and Immunogenicity of "Gam-COVID-Vac Lyo" Vaccine Against COVID-19 Russian Federation N N Vaccine ND:Gam-COVID-Vac Lyo Vaccine Efficacy - Other efficacy General population
NCT04470609 Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged ?60 Years China Y Y Vaccine Inactivated SARS-CoV-2 vaccine Safety General population
NCT04435808 Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19 United States N N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04400032 Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome - Vanguard Canada N N Cell/Blood based ND:MSC Safety Severe Cases
NCT04354259 Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19 Canada Y Y Shelved drug or NME Interferon lambda Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04352608 Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19) China Y Y Vaccine ND:Vaccine Safety General population
NCT04383574 Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19) China Y N Vaccine ND:Vaccine Safety General population
NCT04280588 Fingolimod in COVID-19 China Y N Drug Repurposing Fingolimod Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04344457 Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19 United States N N Drug Repurposing Hydroxychloroquine, Indomethacin, Azithromycin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04351919 Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+) Tunisia N N Drug Repurposing Hydroxychloroquine, Azithromycin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04336332 Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19 United States Y Y Drug Repurposing Hydroxychloroquine, Azithromycin Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04368988 Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant Australia Y N Shelved drug or NME SARS-CoV-2 rS Vaccine, Matrix-M Adjuvant Safety General population
NCT04486482 A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function United States Y N Shelved drug or NME KB109 Safety Mild/Moderate Cases
NCT04366271 Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19 Spain Y N Cell/Blood based ND:Stem cells Efficacy - Mortality Severe Cases
NCT04422678 The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia Egypt Y N Drug Repurposing Imatinib Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04333472 Piclidenoson for Treatment of COVID-19 Israel Y N Shelved drug or NME Piclidenoson Efficacy - Viral load Mild/Moderate Cases
NCT04392128 Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE) France Y N Drug Repurposing Hydroxychloroquine, Azithromycin Efficacy - Viral load Other
NCT04414124 A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19 United States Y N Shelved drug or NME KB109 Safety Mild/Moderate Cases
NCT04389944 Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19 Switzerland N N Cell/Blood based ND:Convalescent plasma Safety Mild/Moderate Cases, Severe Cases
NCT03891420 A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19 Brazil Y N Shelved drug or NME Galidesivir Safety Mild/Moderate Cases, Severe Cases
NCT04397523 Efficacy and Safety of COVID-19 Convalescent Plasma Macedonia, the former Yugoslav Republic of N N Cell/Blood based ND:Convalescent plasma Efficacy - Other efficacy Severe Cases
NCT04351152 Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19 United States Y N Shelved drug or NME Lenzilumab Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04394208 Silymarin in COVID-19 Pneumonia Egypt Y N Drug Repurposing Silymarin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04303299 Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID-19 : A Randomized Control Trial Thailand Y Y Drug Repurposing, Shelved drug or NME Oseltamivir, Hydroxychloroquine, Darunavir, Lopinavir/ritonavir, Favipiravir Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04334005 Vitamin D on Prevention and Treatment of COVID-19 Spain Y N Drug Repurposing Vitamin D3 Efficacy - Mortality Mild/Moderate Cases
NCT04346446 Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients India Y N Cell/Blood based ND:Convalescent plasma Efficacy - Other efficacy Severe Cases
NCT04357457 Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia France Y N Drug Repurposing Almitrine Efficacy - Other efficacy Severe Cases
NCT04456049 Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-19 Switzerland Y N Drug Repurposing Enzalutamide Efficacy - Clinical improvement (except WHO scale) Other
NCT04405271 TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study) Argentina Y N Drug Repurposing Emtricitabine/Tenofovir Alafenamide Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04348877 Plasma Rich Antibodies From Recovered Patients From COVID19 Egypt N N Cell/Blood based ND:Convalescent plasma Efficacy - Viral load Severe Cases
NCT04344951 Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial Greece N N Drug Repurposing Chloroquine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04487574 A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19 Russian Federation Y N Shelved drug or NME XC221 Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04349241 Efficacy and Safety of Favipiravir in Management of COVID-19 Egypt Y N Drug Repurposing Favipiravir Efficacy - Viral load Mild/Moderate Cases
NCT04360876 Targeted Steroids for ARDS Due to COVID-19 Pneumonia: A Pilot Randomized Clinical Trial United States Y N Drug Repurposing Dexamethasone Efficacy - Other efficacy Severe Cases
NCT04452812 Statistical and Epidemiological Study Based on the Use of Convalescent Plasma for the Management of Patients With COVID-19 Mexico Y N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04362176 Passive Immunity Trial of Nashville II for COVID-19 United States Y N Cell/Blood based ND:Convalescent plasma Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04331600 Chloroquine as Antiviral Treatment in Coronavirus Infection 2020 Poland Y N Drug Repurposing Chloroquine Efficacy - Other efficacy Mild/Moderate Cases
NCT04409925 DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1) Canada N N Drug Repurposing Dornase alfa Safety Mild/Moderate Cases, Severe Cases
NCT04342897 A Study of LY3127804 in Participants With COVID-19 United States Y N Shelved drug or NME LY3127804 Efficacy - Oxygen parameters Severe Cases
NCT04487886 Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19) United States Y N Drug Repurposing Duvelisib Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04377308 Fluoxetine to Reduce Intubation and Death After COVID19 Infection United States N N Drug Repurposing Fluoxetine Efficacy - Infection rate (prevention) Mild/Moderate Cases, Severe Cases
NCT04360122 Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19 Egypt Y N Drug Repurposing Levamisole, Isoprinosine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04354428 Treatment for COVID-19 in High-Risk Adult Outpatients United States Y Y Drug Repurposing Hydroxychloroquine, Ascorbic acid, Folic acid, Azithromycin Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04350736 First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19 United Kingdom Y N Shelved drug or NME TD-0903 Safety General population
NCT04347681 Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19 Saudi Arabia N N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04348513 Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection Greece Y N Drug Repurposing Triiodothyronine Efficacy - Other efficacy Severe Cases
NCT04341116 Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19) United States Y Y Shelved drug or NME TJ003234 (Anti-GM-CSF Monoclonal Antibody) Efficacy - WHO scale Mild/Moderate Cases
NCT04377568 Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children Canada Y N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Other
NCT04373460 Convalescent Plasma to Limit SARS-CoV-2 Associated Complications United States Y N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Mild/Moderate Cases
NCT04350931 Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19 Egypt Y N Drug Repurposing BCG Vaccine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04458363 Convalescent Plasma in Pediatric COVID-19 United States N N Cell/Blood based ND:Convalescent plasma Safety Other
NCT04373044 Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19 United States N N Drug Repurposing, Shelved drug or NME Baricitinib, Hydroxychloroquine Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04389840 Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure United States Y N Shelved drug or NME Dociparastat Efficacy - Other efficacy Severe Cases
NCT04447469 Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation United States Y N Shelved drug or NME Mavrilimumab Efficacy - Oxygen parameters Severe Cases
NCT04341389 A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) China Y Y Vaccine ND:Vaccine Safety General population
NCT04359654 Nebulised Dornase Alfa for Treatment of COVID-19 United Kingdom Y N Drug Repurposing Dornase alfa Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04468971 REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia United States Y Y Shelved drug or NME CK0802 Safety Severe Cases
NCT04491994 Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression Pakistan Y N Drug Repurposing Hydoxychloroquine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04413864 Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19 France N N Drug Repurposing Dexmedetomidine Efficacy - Other efficacy Severe Cases
NCT04374526 Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression. Italy Y N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04375098 Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection Chile Y N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04317040 CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment United States Y N Shelved drug or NME CD24Fc Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04409509 Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19) United States Y N Shelved drug or NME Garadacimab Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04326790 The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention Greece Y N Drug Repurposing Colchicine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04339816 Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial Czech Republic Y N Drug Repurposing Azithromycin, Hydroxychloroquine Efficacy - Other efficacy Severe Cases
NCT04453488 Clinical Trial to Evaluate the Efficacy of RUTI® Against SARS-COV-2 Infection (COVID-19) in Healthcare Workers Spain Y N Vaccine ND:RUTI Vaccine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04349371 Saved From COVID-19 United States Y N Drug Repurposing Chloroquine Efficacy - Other efficacy Exposed individuals (family members, HCP)
NCT04364893 Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19 Brazil Y N Drug Repurposing Angiotensin Receptor Blockers, Angiotensin-converting Enzyme Inhibitors Efficacy - Other efficacy Severe Cases
NCT04351516 Test and Treat COVID 65plus+ Germany Y N Drug Repurposing Hydroxychloroquine Efficacy - Other efficacy Mild/Moderate Cases
NCT04451291 Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure Canada N N Cell/Blood based ND:Decidual Stromal Cells Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04345653 Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers United States N N Drug Repurposing Hydroxychloroquine Other Exposed individuals (family members, HCP)
NCT04468646 To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients Pakistan Y N Drug Repurposing Aprepitant Efficacy - WHO scale Severe Cases
NCT04331054 Protective Role of Inhaled Steroids for Covid-19 Infection France Y N Drug Repurposing Budesonide/formoterol Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04358406 Rhu-pGSN for Severe Covid-19 Pneumonia United States Y N Shelved drug or NME Recombinant human plasma gelsolin Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04346368 Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19) China Y N Cell/Blood based ND:Stem cells Efficacy - Oxygen parameters Severe Cases
NCT04392973 FAvipiravir and HydroxyChloroquine Combination Therapy Saudi Arabia Y N Drug Repurposing Favipiravir, Hydroxychloroquine Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04396067 Combination With Inhibitor of Neutrophil Elastase (All-trans Retinoic Acid ) and Isotretinoin May Enhances Neutralizing Antibodies in COVID -19 Infected Patients Better Than COVID-19 Inactivated Vaccines Egypt Y N Drug Repurposing Alvelestat, Isotretinoin Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04335071 Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19) Switzerland Y N Drug Repurposing Tocilizumab Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04395170 Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19. Colombia Y Y Cell/Blood based ND:Convalescent plasma, ND:Human Immunoglobulin Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04459676 Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia Brazil Y N Shelved drug or NME ANG-3777 Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04345276 Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection China N N Drug Repurposing, Shelved drug or NME Danoprevir, Ritonavir Efficacy - Oxygen parameters Mild/Moderate Cases
NCT04291729 Evaluation of Ganovo (Danoprevir ) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection China N N Drug Repurposing, Shelved drug or NME Danoprevir, Ritonavir, Interferon(NOS) Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04338906 Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19 Germany Y N Drug Repurposing Camostat Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04386447 Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19 Italy Y Y Drug Repurposing Oxytocin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04286503 The Clinical Study of Carrimycin on Treatment Patients With COVID-19 China Y N Shelved drug or NME Carrimycin Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04380376 Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia Russian Federation N N Drug Repurposing Melphalan Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04288102 Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19) China Y N Cell/Blood based ND:Stem cells Efficacy - Other efficacy Mild/Moderate Cases
NCT04352803 Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease United States N N Cell/Blood based ND:MSCs Safety Mild/Moderate Cases, Severe Cases
NCT04350580 Polyvalent Immunoglobulin in COVID-19 Related ARds France Y N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04487990 CoV-Hep Study: Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19 Brazil Y N Drug Repurposing Heparin Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04466241 Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial Ivory Coast Y Y Drug Repurposing Telmisartan, Atorvastatin Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04428073 Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection United States Y Y Vaccine ND:Vaccine Safety Mild/Moderate Cases
NCT04365582 OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome France Y N Drug Repurposing Azithromycin, Hydroxychloroquine, Lopinavir/ritonavir Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04353674 Modulation of Hyperinflammation in COVID-19 United States Y N Cell/Blood based ND:Neutrophil modulation Efficacy - Other efficacy Severe Cases
NCT04473261 Efficacy of Iodine Complex Against COVID-19 Patients Pakistan Y Y Shelved drug or NME Iodine complex Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04348305 Hydrocortisone for COVID-19 and Severe Hypoxia Denmark Y N Drug Repurposing Hydrocortisone Efficacy - Other efficacy Severe Cases
NCT04407286 Vitamin D Testing and Treatment for COVID 19 United States N N Drug Repurposing Vitamin D3 Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04401410 Anti-SARS Cov-2 T Cell Infusions for COVID 19 United States N N Cell/Blood based ND:T-cells Safety Mild/Moderate Cases, Severe Cases
NCT04344600 Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection United States Y N Shelved drug or NME Peg-Interferon lambda-1a Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04377503 Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19 Brazil Y N Drug Repurposing Tocilizumab Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04395456 A Phase 2 Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE) Greece Y N Shelved drug or NME AMY-101 Efficacy - Mortality Severe Cases
NCT04335305 Checkpoint Blockade in COVID-19 Pandemic Spain Y N Drug Repurposing Pembrolizumab, Tocilizumab Efficacy - Oxygen parameters Severe Cases
NCT04372589 Antithrombotic Therapy to Ameliorate Complications of COVID-19 ( ATTACC ) Canada Y N Drug Repurposing Heparin Efficacy - Other efficacy Severe Cases
NCT04273321 Efficacy and Safety of Corticosteroids in COVID-19 China Y N Drug Repurposing Methylprednisolone Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04474340 COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients Kuwait Y N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04403477 Convalescent Plasma Therapy in Severe COVID-19 Infection Bangladesh Y N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Severe Cases
NCT04351490 Impact of Zinc and Vitamin D3 Supplementation on the Survival of Aged Patients Infected With COVID-19 France Y N Drug Repurposing Zinc, Vitamin D3 Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04375735 London's Exogenous Surfactant Study for COVID19 United States Y N Drug Repurposing Bovine Lipid Extract Surfactant Safety Mild/Moderate Cases
NCT04353336 Efficacay of Chloroquine or Hydroxychloroquine in COVID-19 Treatment Egypt Y N Drug Repurposing Chloroquine, Hydroxychloroquine Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04397796 Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation United States Y N Cell/Blood based ND:Stem cells Safety Severe Cases
NCT04399889 hCT-MSCs for COVID19 ARDS United States Y N Cell/Blood based ND:MSC Safety Severe Cases
NCT04331665 Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia Canada N N Drug Repurposing Ruxolitinib Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04362111 Early Identification and Treatment of Cytokine Storm Syndrome in Covid-19 United States Y N Drug Repurposing Anakinra Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04378920 A Study of Trans Crocetin in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Disease (LEAF-4L7520/4L6715) France N N Shelved drug or NME LEAF-4L7520, LEAF-4L6715 Efficacy - Oxygen parameters Severe Cases
NCT04318444 Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19) United States Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04389671 The Safety and Preliminary Efficacy of Lucinactant in Adults With COVID-19 United States N N Drug Repurposing Lucinactant Efficacy - Oxygen parameters Severe Cases
NCT04395105 Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial Argentina Y N Drug Repurposing Dexamethasone Efficacy - Other efficacy Severe Cases
NCT04402203 Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh Bangladesh Y N Drug Repurposing Favipiravir Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04438837 Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers Israel Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04467840 Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia United States Y N Shelved drug or NME Opaganib Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04402944 Pulmozyme to Improve COVID-19 ARDS Outcomes United States Y N Drug Repurposing Dornase alfa Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04407390 Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly Denmark Y N Shelved drug or NME Nicotinamide Riboside Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04318015 Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial) Mexico Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04341038 Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury Spain Y N Drug Repurposing Methylprednisolone, Tacrolimus Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04381988 A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy United States Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Other
NCT04456361 Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19 Mexico N N Cell/Blood based ND:Stem cells Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04330144 Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial) Korea, Republic of Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) Mild/Moderate Cases, Severe Cases
NCT04392713 Efficacy of Ivermectin in COVID-19 Pakistan Y N Drug Repurposing Ivermectin Efficacy - Viral load Mild/Moderate Cases
NCT04407689 InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort France Y N Shelved drug or NME CYT107 Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04379076 InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort United Kingdom Y N Shelved drug or NME Interleukin-7 (CYT107) Other Mild/Moderate Cases
NCT04445311 Ivermectin in Treatment of COVID-19 Egypt Y N Drug Repurposing Ivermectin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04377997 Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19 United States Y N Drug Repurposing Enoxaparin Efficacy - Other efficacy Mild/Moderate Cases
NCT04345848 Preventing COVID-19 Complications With Low- and High-dose Anticoagulation Switzerland Y N Drug Repurposing Enoxaparin Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04335552 Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection United States Y Y Drug Repurposing Hydroxychloroquine, Azithromycin Efficacy - WHO scale Severe Cases
NCT04436458 Niclosamide In Moderate COVID-19 United States Y N Drug Repurposing Niclosamide Efficacy - Viral load Mild/Moderate Cases
NCT04343963 Pyridostigmine in Severe SARS-CoV-2 Infection Mexico Y N Drug Repurposing Pyridostigmine Efficacy - Mortality Severe Cases
NCT04374149 Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS United States Y N Drug Repurposing, Other Ruxolitinib, ND:Procedure Efficacy - Other efficacy Mild/Moderate Cases
NCT04419610 RAS and Coagulopathy in COVID19 United Kingdom Y N Shelved drug or NME TRV027 Efficacy - Other efficacy Other
NCT04401475 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With Moderate to Severe COVID-19 United States Y N Shelved drug or NME EB05 Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04390061 TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial Pneumonia Italy Y N Drug Repurposing Tofacitinib Efficacy - Other efficacy Mild/Moderate Cases
NCT04359329 Estrogen Patch for COVID-19 Symptoms United States Y N Drug Repurposing Estrogen patch Efficacy - Other efficacy Mild/Moderate Cases
NCT04422561 Prophylactic Ivermectin in COVID-19 Contacts Egypt N N Drug Repurposing Ivermectin Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04403555 Ivermectin and Doxycycine in COVID-19 Treatment Egypt Y N Drug Repurposing Doxycycline, Ivermectin Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04351295 Efficacy of Faviprevir in COVID-19 Treatment Egypt Y N Drug Repurposing Favipiravir Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04401293 Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients United States Y N Drug Repurposing Enoxaparin Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04387240 Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19 Saudi Arabia Y N Drug Repurposing Artesunate Efficacy - Other efficacy Mild/Moderate Cases
NCT04426201 InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-O ) United States Y N Shelved drug or NME CYT107 Efficacy - Other efficacy Other
NCT04345406 Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19 Egypt Y N Drug Repurposing Captopril, Enalapril Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04388709 Interferon Lambda Therapy for COVID-19 United States Y N Drug Repurposing Peginterferon lambda-1a Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04433988 Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients Egypt Y N Drug Repurposing Pentoxifylline Efficacy - Other efficacy Mild/Moderate Cases
NCT04374019 Novel Agents for Treatment of High-risk COVID-19 Positive Patients United States Y Y Drug Repurposing Hydroxychloroquine, Azithromycin, Ivermectin, Camostat, Artemisinin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04460443 Sofosbuvir With and Without Ribavirin in Treatment of COVID 19 Egypt Y Y Drug Repurposing Sofosbuvir, Ribavirin, Daclatasvir Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04363853 Tocilizumab Treatment in Patients With COVID-19 Mexico N N Drug Repurposing Tocilizumab Efficacy - Other efficacy Severe Cases
NCT04361032 Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia Tunisia Y N Drug Repurposing Tocilizumab, Deferoxamine Efficacy - Mortality Severe Cases
NCT04424901 Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19 United States Y N Drug Repurposing Dipyridamole Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04374552 Asymptomatic COVID-19 Trial United States Y N Drug Repurposing Hydroxychloroquine, Azithromycin Efficacy - Viral load Mild/Moderate Cases
NCT04408040 Use of Convalescent Plasma for COVID-19 United States N Y Cell/Blood based ND:Convalescent plasma Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04359901 Sarilumab for Patients With Moderate COVID-19 Disease United States Y N Drug Repurposing Sarilumab Efficacy - Other efficacy Mild/Moderate Cases
NCT04371107 Proactive Care of Ambulatory COVID19 Patients France Y N Drug Repurposing Azithromycin Efficacy - Other efficacy Mild/Moderate Cases
NCT04459247 Short Term, High Dose Vitamin D Supplementation for COVID-19 India Y N Drug Repurposing Vitamin D3 Efficacy - Viral load Mild/Moderate Cases
NCT04425915 Efficacy of Convalescent Plasma Therapy in Patients With COVID-19 India Y N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04351347 The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment Egypt Y N Drug Repurposing Ivermectin, Nitazoxanide, Chloroquine Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04313127 Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults China N N Vaccine ND:Vaccine Safety General population
NCT04447534 Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19 Egypt N N Drug Repurposing Zinc Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04469491 Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study France Y N Drug Repurposing Interferon-1-beta Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04399746 Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19 Mexico N N Drug Repurposing Ivermectin, Azithromycin, Cholecalciferol Efficacy - Viral load Mild/Moderate Cases
NCT04445467 An Adaptive Randomised Placebo Controlled Phase II Trial of Antivirals for COVID-19 Infection United States Y N Drug Repurposing Favipiravir Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04393051 Baricitinib Compared to Standard Therapy in Patients With COVID-19 Italy Y N Drug Repurposing Baricitinib Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04391101 Convalescent Plasma for the Treatment of Severe SARS-CoV-2 (COVID-19) Colombia Y N Cell/Blood based ND:Convalescent plasma Safety Severe Cases
NCT04479163 Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2 Cuba Y N Cell/Blood based ND:Convalescent plasma Efficacy - Oxygen parameters Other
NCT04472611 Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial United States Y N Drug Repurposing Colchicine, Rosuvastatin Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04343261 Convalescent Plasma in the Treatment of COVID 19 United States N N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Severe Cases
NCT04356937 Efficacy of Tocilizumab on Patients With COVID-19 United States Y N Drug Repurposing Tocilizumab Efficacy - Other efficacy Severe Cases
NCT04475302 BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots India Y N Drug Repurposing BCG Vaccine Efficacy - Mortality Other
NCT04344535 Convalescent Plasma vs. Standard Plasma for COVID-19 United States Y N Cell/Blood based ND:Convalescent plasma Efficacy - Oxygen parameters Severe Cases
NCT04371367 Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE ) France Y N Shelved drug or NME Avdoralimab Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04359862 Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection Spain Y N Drug Repurposing Sevoflurane Efficacy - Oxygen parameters Severe Cases
NCT04372082 Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19 France Y Y Drug Repurposing Diltiazem, Niclosamide, Hydroxychloroquine Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04442048 Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure Canada Y N Shelved drug or NME IMM-101 Efficacy - Infection rate (prevention) Other
NCT04363502 Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection United States Y N Shelved drug or NME Clazakizumab Efficacy - Other efficacy Severe Cases
NCT04392427 New Antiviral Drugs for Treatment of COVID-19 Egypt Y N Drug Repurposing Nitazoxanide, Ribavirin, Ivermectin Efficacy - Viral load Mild/Moderate Cases
NCT04404361 PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer United States Y N Shelved drug or NME Pacritinib Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04382924 Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease Australia Y N Shelved drug or NME Ifenprodil Efficacy - WHO scale Severe Cases
NCT04398290 iNOPulse for COVID-19 United States Y N Drug Repurposing Nitric oxide Safety Mild/Moderate Cases
NCT04445623 Prasugrel in Severe COVID-19 Pneumonia Italy Y N Drug Repurposing Prasugrel Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04344548 Phase I / II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia Colombia N N Cell/Blood based ND:NK-cells Safety Mild/Moderate Cases, Severe Cases
NCT04408183 GLS-1200Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) in Health Care Personnel United States Y N Shelved drug or NME GLS-1200 Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04482673 Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection United States Y N Drug Repurposing Vitamin D3 Other Other
NCT04334460 Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects United States Y N Shelved drug or NME BLD-2660 Efficacy - Viral load Mild/Moderate Cases
NCT04328012 COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 United States Y Y Drug Repurposing Lopinavir/ritonavir, Hydroxychloroquine, Losartan Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04445389 Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults Korea, Republic of Y N Vaccine GX-19 Safety Other
NCT04468009 Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma Argentina Y N Cell/Blood based ND:Convalescent plasma Efficacy - Mortality Severe Cases
NCT04261517 Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19 China Y N Drug Repurposing Hydroxychloroquine Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04405570 A Safety, Tolerability and Efficacy of EIDD-2801 to Eliminate Infectious Virus Detection in Persons With COVID-19 United States Y N Shelved drug or NME EIDD-2801 Efficacy - Viral load Mild/Moderate Cases
NCT04382950 Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2 Israel Y N Drug Repurposing, Shelved drug or NME rbACE2, Isotretinoin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04450004 Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years. United States Y N Vaccine ND:Vaccine Safety Other
NCT04366245 Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection Spain Y N Cell/Blood based ND:Convalescent plasma Safety Mild/Moderate Cases
NCT04367831 Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19 United States Y N Drug Repurposing Heparin, Enoxaparin/Lovenox Efficacy - Other efficacy Severe Cases
NCT04373824 Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study India Y N Drug Repurposing Ivermectin Efficacy - Viral load Mild/Moderate Cases
NCT04319731 A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure United States N N Cell/Blood based ND:Amniotic fluid Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04493242 Extracellular Vesicle Infusion Therapy for Severe COVID-19 United States Y N Shelved drug or NME DB-001 Efficacy - Mortality Severe Cases
NCT04385199 Convalescent Plasma for Patients With COVID-19 United States Y N Cell/Blood based ND:Convalescent plasma Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04366323 Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19 Spain Y N Cell/Blood based ND:Stem cells Safety Severe Cases
NCT04257656 A Trial of Remdesivir in Adults With Severe COVID-19 China Y N Shelved drug or NME Remdesivir Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04492514 Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation United States Y N Shelved drug or NME Mavrilimumab Efficacy - Mortality Severe Cases
NCT04477993 Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19 Brazil Y N Drug Repurposing Ruxolitinib Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04338698 Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT Pakistan Y Y Drug Repurposing Hydroxychloroquine, Oseltamivir, Azithromycin Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04375397 Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury United States Y N Drug Repurposing Ibrutinib Efficacy - Other efficacy Severe Cases
NCT04439045 Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity United States Y N Vaccine ND:VPM1002 vaccine Efficacy - Infection rate (prevention) Other
NCT04463004 Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation United States Y N Shelved drug or NME Mavrilimumab Efficacy - Mortality Severe Cases
NCT04399980 Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation United States Y N Shelved drug or NME Mavrilimumab Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04397510 Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury United States Y N Drug Repurposing Heparin Efficacy - Oxygen parameters Severe Cases
NCT04457609 Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients Indonesia Y N Drug Repurposing, Cell/Blood based Oseltamivir, Azithromycin, ND:Stem cells Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04470427 A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 United States Y N Vaccine mRNA-1273 vaccine Efficacy - Infection rate (prevention) General population
NCT04364737 CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients United States Y N Cell/Blood based ND:Convalescent plasma Efficacy - WHO scale Severe Cases
NCT04405076 Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older United States Y N Vaccine ND:Vaccine Safety General population
NCT04349631 A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19 United States N N Cell/Blood based ND:Stem cells Efficacy - Other efficacy Exposed individuals (family members, HCP)
NCT04379271 A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19) United States Y N Shelved drug or NME IMU-838 Efficacy - Other efficacy Mild/Moderate Cases
NCT04414241 Hydroxychloroquine to Prevent SARS-CoV-2 Infection Peru Y N Drug Repurposing Hydroxychloroquine Efficacy - Infection rate (prevention) General population
NCT04345601 Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) United States N N Cell/Blood based ND:MSC Safety Severe Cases
NCT04399356 Niclosamide for Mild to Moderate COVID-19 United States Y N Drug Repurposing Niclosamide Efficacy - Viral load Mild/Moderate Cases
NCT04351191 PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds Pakistan Y Y Drug Repurposing Hydroxychloroquine, Chloroquine Efficacy - Viral load Mild/Moderate Cases
NCT04377334 Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS) Germany Y N Cell/Blood based ND:Stem cells Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
ACTRN12620
000557932		 Therapies to prevent progression of COVID-19, including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 with or without Vitamin C, a multi-centre, international, randomized trial: The International ALLIANCE Study Australia Y Y Drug Repurposing Hydroxychloroquine, Azithromycin, Zinc Citrate, Vitamin D3, Vitamin B12, Ascorbic acid Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
ACTRN12620
000788976		 Safety and efficacy of intranasal delivery of BromAc® (Bromelain & Acetylcysteine) in swab positive SARS-CoV-2 patients – inactivating the COVID-19 virus by cleavage of the spike and other glycoproteins Australia N N Drug Repurposing, Other N-acetylcysteine, Bromelain Safety Mild/Moderate Cases
ChiCTR2000
030259		 Evaluation Danoprevir sodium tablets combined with ritonavir in the treatment of novel coronavirus infection (COVID-19): a randomized, open and controlled trial China Y N Drug Repurposing, Shelved drug or NME Danoprevir, Ritonavir Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
DRKS000224
84		 Clinical pilot study on the effects of a hydrogen peroxide mouthrinse on the intraoral viral load of SARS-CoV-2 (COVID-19) Germany N N Drug Repurposing Hydrogen peroxide Efficacy - Viral load Mild/Moderate Cases
JPRN-jRCT2
071200023		 Evaluation of Nelfinavir for asymptomatic and mild COVID-19: A multicenter open-label, blinded outcome, randomized controlled trial - NFV trial for asymptomatic and mild COVID-19 Japan Y N Drug Repurposing Nelfinavir Efficacy - Viral load Mild/Moderate Cases
JPRN-jRCTs
051200036		 Efficacy and safety of nintedanib on lung fibrosis in severe pneumonia induced by coronavirus disease 2019: Historical control study. Japan N N Drug Repurposing Nintedanib Efficacy - Mortality Severe Cases
2020-00203
9-31		 COVIDSTORM - study protocol COVID-19: Slavage TOcilizumab as a Rescue Measure Finland N N Drug Repurposing Tocilizumab Efficacy - Clinical improvement (except WHO scale) Severe Cases
2020-00203
8-33		 Controlled clinical trial of hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting Finland Y N Drug Repurposing Hydoxychloroquine Efficacy - Other efficacy Mild/Moderate Cases
2020-00210
2-58		 Mesenchymal stromal cell therapy for severe COVID-19 infection Belgium N N Cell/Blood based ND:MSC Safety Severe Cases
2020-00245
8-25		 Randomized, controlled, open label, phase 2 clinical trial of Interferon-ß-1a (IFNß-1a) in COVID-19 patients. Italy Y N Drug Repurposing Interferon beta 1a Efficacy - Viral load Mild/Moderate Cases, Severe Cases
2020-00232
2-85		 KAND567 Versus Placebo in Subjects Hospitalized with COVID-19. A Phase II, Randomized, 2-Arm Parallel-Group, Double-blind Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics. Sweden Y N Shelved drug or NME Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
2020-00148
3-28		 A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26COVS1 in Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older Belgium Y N Shelved drug or NME ND: Ad26COVS1 vaccine Safety General population
2020-00257
4-27		 A randomized, double-blind, placebo-controlled phase 2a and 2b study to evaluate the safety and efficacy of XAV-19 in patients with COVID-19 induced moderate pneumonia France Y N Shelved drug or NME XAV-19 Efficacy - Viral load Mild/Moderate Cases
NCT04510233 Ivermectin Nasal Spray for COVID19 Patients Egypt Y N Drug Repurposing Ivermectin Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04501796 A Trial of NT-I7 in COVID-19 (SPESELPIS) United States Y N Shelved drug or NME NT-17 Safety Mild/Moderate Cases
NCT04513158 Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection United States N N Cell/Blood based ND:Convalescent plasma Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04514302 Safety and Efficacy of Anti-SARS-CoV-2 Equine Antibody Fragments (INOSARS) for Hospitalized Patients With COVID-19 Mexico Y Y Shelved drug or NME INOSARS Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04504240 Role of Famotidine in the Symptomatic Improvement of COVID-19 Patients Bangladesh Y N Drug Repurposing Famotidine Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04500418 Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients Germany Y N Shelved drug or NME Cenicriviroc Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04516746 Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults United States Y N Vaccine AZD1222 Efficacy - Infection rate (prevention) General population
NCT04333732 CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION United States Y Y Vaccine MR Vaccine, MMRII Vaccine Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP), General population
NCT04497948 Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19 United States N N Drug Repurposing Acalabrutinib Other Severe Cases
NCT04513184 Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19 Mexico Y N Drug Repurposing Dexamethasone Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04497298 Clinical Trial to Evaluate the Safety and Immunogenicitiy of the COVID-19 Vaccine France Y Y Vaccine TMV-083 Vaccine Safety General population
NCT04501978 Therapeutics for Inpatients With COVID-19 United States Y N Drug Repurposing, Shelved drug or NME LY3819253, Remdesivir Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04511819 Losmapimod Safety and Efficacy in COVID-19 United States Y N Shelved drug or NME Losmapimod Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04390594 Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal Senegal Y N Drug Repurposing Nafamostat Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04501783 Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19 Russian Federation Y N Drug Repurposing Favipiravir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases
NCT04498325 Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19) United States Y Y Shelved drug or NME NT-I7 Safety Mild/Moderate Cases, Severe Cases
NCT04513470 Allocetra-OTS in COVID-19 Israel N N Cell/Blood based ND:Allocetra-OTS Safety Severe Cases
NCT04516954 Convalescent Plasma for COVID-19 Patients Viet Nam N N Cell/Blood based ND:Convalescent plasma Safety Mild/Moderate Cases, Severe Cases
NCT04498273 COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-79 United States Y Y Drug Repurposing Aspirin, Apixaban Efficacy - Other efficacy Mild/Moderate Cases, Other
NCT04504734 Bucillamine in Treatment of Patients With COVID-19 Canada Y N Drug Repurposing Bucillamine Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04497649 Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients Egypt Y N Drug Repurposing Ledipasvir, Ribavirin, Daclatasvir, Sofosbuvir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04509999 Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection United States Y N Drug Repurposing Bicalutamide Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases, Other
NCT04505774 Anti-thrombotics for Adults Hospitalized With COVID-19 United States Y N Drug Repurposing Heparin Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04500132 To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia Korea, Republic of Y N Shelved drug or NME EC-18 Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04498377 Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19 China Y N Shelved drug or NME F-652 Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04502472 Open-label Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma United States N N Cell/Blood based ND:Convelescent plasma Efficacy - Clinical improvement (except WHO scale) Severe Cases
NCT04501965 Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Azythromycin in Asymptomatic Covid-19 Patients Guinea Y N Drug Repurposing, Other Hydroxychloroquine, Azithromycine, ND:Phytomedicine Efficacy - Viral load Mild/Moderate Cases
NCT04502342 Add on to Azythromycine, Phytomedicine and/or Antimalarial Drug vs Hydroxychloroquine in Uncomplicated COVID-19 Patients Guinea Y Y Drug Repurposing, Other Hydroxycloroquine, Azythromycine, Cospherunate, ND;Phytomedicine Efficacy - Viral load Mild/Moderate Cases
NCT04501952 Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting United States Y N Shelved drug or NME Remdesivir Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04510207 A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above United Arab Emirates Y N Vaccine ND:Vaccine Efficacy - Infection rate (prevention) General population, Other
NCT04484493 Corticosteroid Nasal Spray in COVID-19 Anosmia Egypt Y N Drug Repurposing Mometasone furoate Other Other
NCT04497987 A Study of LY3819253 (LY-CoV555) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff United States Y N Shelved drug or NME LY3819253 Efficacy - Infection rate (prevention) Exposed individuals (family members, HCP)
NCT04511650 A Study to Evaluate the Safety and Efficacy of Razuprotafib, a Novel Tie 2 Activator, in Hospitalized Subjects With Moderate to Severe Coronavirus Disease 2019 (COVID-19) United States Y N Shelved drug or NME Razuprotafib Safety Mild/Moderate Cases, Severe Cases
NCT04512079 FREEDOM COVID-19 Anticoagulation Strategy United States Y N Drug Repurposing Apixaban Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04497389 Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients United States Y N Cell/Blood based ND:Amniotic Fluid Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04509973 Higher vs. Lower Doses of Dexamethasone for COVID-19 and Severe Hypoxia Denmark Y N Drug Repurposing Dexamethasone Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04499313 Dexamethasone Vs Methylprednisolone for the Treatment of Patients With ARDS Caused by COVID-19 Bangladesh Y N Drug Repurposing Dexamethasone, Methylprednisolone Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04517188 Halodine Nasal Antiseptic in Patients With COVID-19 United States N N Shelved drug or NME Povidone-Iodine Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04498247 A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001) United States Y N Vaccine ND:Vaccine Safety Other
NCT04500067 Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment Ukraine Y N Cell/Blood based ND:Immunoglobulin Efficacy - Clinical improvement (except WHO scale) Mild/Moderate Cases, Severe Cases
NCT04508023 A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection United States Y N Drug Repurposing Rivaroxaban Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases
NCT04510194 MET-Covid Trial - METformin for Prevention and Outpatient Treatment of COVID-19 United States Y N Drug Repurposing Metformin Efficacy - Mortality Mild/Moderate Cases, Severe Cases
NCT04510038 Colchicine vs Current Standard of Care in Hospitalized Patients With COVID-19 and Cardiac Injury United States Y N Drug Repurposing Colchicine Efficacy - Mortality Other
NCT04510402 Phase I/II Trial of Povidone-iodine (PVP-I) Nasal Swab For Preventing COVID-19 Spread in Healthy Subjects United Kingdom N Y Shelved drug or NME Povidone-Iodine Safety General population, Other
NCT04345419 Remdesivir vs Chloroquine in Covid 19 Egypt Y Y Drug Repurposing Chloroquine, Remdesivir Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04445220 A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy United States Y N Shelved drug or NME SBI-101 Safety Other
NCT04498936 Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19 Egypt Y N Drug Repurposing Ledipasvir/sofosbuvir, Nitazoxanide Efficacy - Viral load Mild/Moderate Cases, Severe Cases
NCT04517396 Fenofibrate Intervention as COVID-19 Therapy United States Y N Drug Repurposing Fenofibrate Efficacy - WHO scale Mild/Moderate Cases, Severe Cases
NCT04504032 A Randomized, Controlled, Phase 2b Trial to Evaluate Safety and Efficacy of Rivaroxaban United States Y N Drug Repurposing Rivaroxaban Safety Mild/Moderate Cases, Severe Cases
NCT04505592 Tenecteplase in Patients With COVID-19 United States Y N Drug Repurposing Tenecteplase Efficacy - Oxygen parameters Mild/Moderate Cases, Severe Cases
NCT04516941 CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19 Switzerland Y Y Drug Repurposing Colchicine, Edoxaban Efficacy - Other efficacy Mild/Moderate Cases, Severe Cases